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Part I: A General Method for Establishing the Global 
Epidemiology of Congenital Disorders 
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Article 1: Introduction: scope and general overview 
Abstract 
Congenital disorders (birth defects), are pathological conditions arising before birth, whether 
evident at birth or manifesting later in life. They fall into two main groups: those with 
environmental causes (maternal infection or illness, or exposure to teratogens) and those 
with mainly endogenous causes (chromosomal disorders, single gene disorders, most 
congenital malformations, disorders due to genetic risk factors) here called constitutional 
congenital disorders.  
Congenital disorders are important causes of early death and disability. However their 
contribution to the global burden of disease is seriously under-estimated because of difficulty 
in obtaining local observational data in many countries. The Modell Global Database of 
Congenital Disorders – MGDb – is an instrument designed to overcome this problem. This 
series of articles describes the methods used in the Database to generate the country-
specific estimates for the birth prevalence and outcomes of constitutional congenital 
disorders published online in the appendices. 
Estimates are based on the following evidence-based assumptions on baseline birth 
prevalence, i.e. the prevalence that would apply in the absence of any intervention. (a) 
Chromosomal disorders: birth prevalence of Down syndrome and other trisomies varies with 
maternal age while that of other disorders is relatively constant. (b) Congenital 
malformations: when environmentally-determined malformations are excluded, there is little 
evidence for country differences in birth prevalences with the exception of neural tube 
defects and oro-facial clefts. (c) The baseline birth prevalence of most single gene disorders 
is determined by a balance between new mutation and loss of harmful variants by natural 
selection: therefore their collective birth prevalence varies little between populations. (d) 
Global data is available on the prevalence of parental consanguinity, the principal factor 
affecting the birth prevalence of recessively-inherited disorders. (e) Some genetically 
determined disorders are common because the responsible gene variant also confers a 
selective advantage: available data on gene frequencies permits country-specific calculation 
of the birth prevalence of haemoglobin disorders, rhesus haemolytic disease and neonatal 
jaundice due to glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
Once baseline birth prevalence is known, it can be combined with demographic and other 
data to reach country-specific estimates of annual affected births, and to quantify the effects 
of interventions. This approach is used in the current version of the Global Database to 
generate country-specific estimates for severe, early-onset constitutional congenital 
disorders, specifically designed to meet the information needs of policy-makers. 
This introduction focuses on two main points. 
 The need for an agreed terminology for use in community genetics. Lack of clear, 
agreed definitions causes confusion and undermines consensus. For example, the 
term congenital anomalies (which covers only chromosomal disorders and congenital 
malformations) is widely thought to apply for the totality of congenital disorders, and 
this contributes to the current misperception of their public health importance. As a 
first step towards consensus, this Introduction includes a set of proposed definitions 
of terms for use in Community Genetic epidemiology. 
 Contrasting estimates for under-5 deaths due to congenital disorders. For congenital 
anomalies alone, the Global Burden of Disease (GBD) estimate for 2000 was 3.3 
under-5 deaths /1,000 births: WHO and GBD estimates for 2010 are 2.02 and 
3.7/1,000 respectively. These contrast a March of Dimes estimate of 9-10/1,000 for 
2000, and Global Database estimate of 8/1,000 for 2010. The Global Database 
estimate for total congenital disorders is 15 under-5 deaths /1,000 births. 
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The remaining articles describe the methods used in the Global Database in sufficient detail 
to allow critical review and enable the interested reader to replicate and apply the method 
locally. 
The articles, and the current Global Database, are the product of an international 
collaboration intended to improve the quality and availability of evidence on the birth 
prevalence and outcomes of congenital disorders. 
1.1 Introduction 
Congenital disorders (also called birth defects) are defined as “any potential pathological 
conditions arising before birth --- whether they are evident at birth or become manifest later 
in life” (WHO (1985a), (2000) and (2006)). They cover a wide range of severity, can affect 
any aspect of structure or function, and are an important cause of early death and life-long 
disability. They fall into five main groups (Figure 1.1). 
 
Figure 1.1. The main groups of congenital disorders. Some have known environmental causes, some have genetic 
causes (chromosomal disorders, single gene (Mendelian) disorders, disorders due to genetic risk 
factors), and some (including many congenital malformations) have no known cause and could occur in 
any pregnancy. However there is considerable overlap between groups. The image is notional: there is 
no relation between size of the circles and frequency or actual degree of overlap. (The outline of 
environmental causes is indicated differently because of uncertain and changing birth prevalence.) 
The burden of congenital disorders can be greatly reduced by appropriate interventions. 
However accurate diagnosis can require specialist clinical and laboratory facilities: under-
estimation is inevitable when these resources are not available. Consequently, in large parts 
of the world the absence of reliable epidemiological data leads to serious under-estimation of 
the public health importance of congenital disorders, and impedes policy development.  
We propose that this problem can, in large part, be overcome because four major groups - 
chromosomal disorders, congenital malformations, single gene disorders, and disorders due 
to common genetic risk factors - have (mainly) endogenous causes. Consequently their birth 
prevalence1 in the absence of any intervention (their baseline birth prevalence) is relatively 
stable in any given population, and is largely independent of environmental change. In 
practice sufficient observational data exists to support evidence-based estimates of the 
baseline birth prevalence of these congenital disorders for any country. This (possibly) 
unique characteristic offers an extraordinary advantage to the epidemiologist, because it 
provides a relatively stable baseline against which to assess all estimates of outcomes and 
effects of interventions. 
                                               
1 Throughout this series the term “birth prevalence” is used instead of “incidence” to describe the frequency of new 
cases as they present to health services (see definitions in terminology section below). 
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Furthermore, outcomes in the absence of intervention and with available interventions are 
known for most groups of congenital disorder. 
It is possible, in principle, to relate these rates to demographic and other available data, and 
so reach evidence-based, country-specific estimates of actual affected births, and to quantify 
the effects of interventions, for almost any country. 
In view of this important common characteristic, these groups are here collectively called 
constitutional congenital disorders. 
We have tested the above proposal by creating a system that generates country-specific 
epidemiological estimates of severe2, early-onset3 constitutional congenital disorders 
specifically designed to meet the information needs of policy-makers – the Modell Global 
Database of Constitutional Congenital Disorders (MGDb or “the Global Database” for short). 
This series of articles aims to describe the methods used in sufficient detail to enable 
criticism, improvement, and their wider application. 
Background of the Global Database 
The need for epidemiological data on congenital disorders was recognised in the 1950s, 
partly in order to be able to assess effects of exposure to atomic radiation. This led on to 
development of some population-specific registries (e.g. the British Columbia Health 
Surveillance Registry in 1952 (Baird 1987) and the Hungarian Congenital Abnormality 
Registry in 1962 (Czeizel 1997)), and some large-scale surveys in the USA (e.g. Trimble and 
Doughty (1974), Myrianthopoulos and Chung (1974)). The observations on congenital 
anomalies were broadly consistent (Czeizel and Sankaranarayanan 1984) and were thought 
to apply generally for populations of Northern European origin. A WHO comparative study of 
the birth prevalence of selected congenital malformations in 24 centres representing all 
WHO regions again gave broadly consistent results (Stevenson, Johnston et al. 1966). 
In the 1980s the WHO Hereditary Diseases programme continued to develop the global 
picture, starting with the global epidemiology of haemoglobin disorders (Gross 1983) and 
preliminary estimates for the full range of congenital disorders (WHO 1985a). The initiative 
was continued by the WHO European and Eastern Mediterranean Regional offices (Modell, 
Kuliev et al. (1991), Alwan, Modell et al. (1997)4. It provided a quantitative basis for the 
March of Dimes Global Report on Birth Defects (Christianson, Howson et al. 2006), which in 
turn led to inclusion of congenital disorders in the Global Burden of Disease study, and 
development of the Born Healthy needs assessment toolkit (Nacul, Stewart et al. (2014) and 
www.bornhealthy.org). These in turn prompted development of the database to cover 
outcomes as well as birth prevalences, and to ensure rigorous review by international 
experts. 
                                               
2 That cause early death or disability in the absence of intervention. 
3 That present before 20 years of age. 
4 The WHO initiative began with creation of a database of haemoglobin disorders (see Modell, B. and M. Darlison 
(2008). "Global epidemiology of haemoglobin disorders and derived service indicators." Bull World Health Organ 86(6): 
480-487. and www.modell-almanac.net), was progressively extended to include other disorder groups, and provided 
input for several reports (WHO (1985a). Community approaches to the control of hereditary diseases. Report of a WHO 
Advisory Group on Hereditary Diseases. Geneva 3‑5 October 1985. Unpublished WHO document., WHO (2000). 
Primary health care approaches for prevention and control of congenital and genetic disorders : report of a WHO 
meeting, Cairo, Egypt, 6-8 December 1999. Geneva, World Health Organization: 43 p. + annexes., WHO and March of 
Dimes (2006). Management of birth defects and haemoglobin disorders : report of a joint WHO-March of Dimes 
meeting, Geneva, Switzerland, 17-19 May 2006. Geneva, World Health Organization: 27 p.) and reviews (Christianson, 
A. and B. Modell (2004). "Medical genetics in developing countries." Annu Rev Genomics Hum Genet 5: 219-
265.,Christianson, A., C. P. Howson and B. Modell (2006). "March of Dimes: global report on birth defects, the hidden 
toll of dying and disabled children." March of Dimes: global report on birth defects, the hidden toll of dying and disabled 
children.). 
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Limitations of the Global Database 
Currently the Database includes only early-onset congenital disorders (i.e. those that usually 
present before 20 years of age5). It does not (yet) include congenital disorders caused by 
environmental risk factors such as maternal exposure to infection6, malnutrition, or 
teratogens, because their epidemiology is not susceptible to the form of modelling currently 
used. Conventional methods such as local ongoing surveillance or periodic surveys are 
required to map their epidemiology, because exposure to risk, and hence birth prevalence, 
varies with place, time, and deployment of interventions including immunisation, nutritional 
supplementation, restriction of exposure to teratogens and diagnosis and treatment for the 
mother before or during pregnancy. 
We emphasise here that the Global Database does not pretend to provide accurate figures. 
Rather, it aims to provide a framework for objective assessment of the global, regional and 
national burden of congenital disorders, and to generate provisional estimates that are 
sufficiently evidence-based to fill the void caused by the absence of observational data, and 
so remove the impasse to policy and service development that often results. 
The general argument 
Policymakers need information in order to make decisions. They prefer clear, unambiguous, 
agreed evidence that covers, in this case: 
 The scale of the problem before them – baseline birth prevalence (incidence). 7 
 Outcomes in the absence of intervention. 
 Available interventions and their potential effects. 
 The current country (or regional) situation with respect to deployment of 
interventions, and current outcomes. 
 Future projections (a) with current policies, (b) with policy changes. 
 For each potential intervention, an objective appraisal of the difference that 
deployment might make in terms of human and financial costs and benefits. 
Figure 1.2 shows the life-time trajectory of any constitutional congenital disorder. Outcomes 
in the absence of care are shown in blue, interventions and additional outcomes are shown 
in red. 
                                               
5 This is the upper limit for the source data published by Baird, P. A., T. W. Anderson, H. B. Newcombe and R. B. Lowry 
(1988). "Genetic disorders in children and young adults: a population study." Am J Hum Genet 42(5): 677-693. 
6 For a brief discussion of congenital disorders due to maternal infection see Annex A2: Environmental disorders. 
European registry data indicate that congenital infections account for around 1% of congenital anomalies in high income 
settings. Obviously the rate is far higher in most lower-income settings. 
7 This is the essential starting point for assessing service needs and the potential and actual effect of interventions. 
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Figure 1.2. Chart showing the sequence of events covered in the Global Database. Boxes represent data points, of 
which those linked to rounded lozenges representing possible interventions enumerate their main 
outcome types. 
We propose that sufficient demographic and disorder-specific data exist or can be inferred to 
quantify each step in the trajectory for each group of constitutional congenital disorders, and 
so to meet many of the information needs of policy-makers at the country level. 
 Country-specific global demographic estimates including annual births are available 
from UN World Population Prospects (WPP)8. 
 The birth prevalence in the absence of any intervention (baseline birth prevalence) of 
the main groups of constitutional congenital disorder is known or can be estimated. 
 The effects of implementing available interventions have been recorded. 
 Birth outcomes, and outcomes for live-born children with no care and with optimal 
care are known or can be estimated. 
 The proportion of a population with access to optimal services can be estimated 
using infant mortality as an indicator. 
 By integrating these data, it is possible to generate comprehensive epidemiological 
estimates at the country level that are – in the broadest sense – evidence-based. 
These can then be aggregated in a variety of ways to yield regional and global 
estimates.9 
 
                                               
8 http://esa.un.org/unpd/wpp  
9 Possible application of the method at the sub-country (e.g. administrative) level is being investigated. 
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Outputs from the Global Database 
The following outputs are selected to inform service planning. 
Baseline birth prevalence (prevalence in the absence of any intervention) 
This is the foundation of the Global Database, because 
 It is the most strongly evidence-based of all inputs 
 It provides an envelope that must be filled by all estimated outcomes. 
Outcomes to age 5 
Estimated outcomes are particularly reliable to age 5, for the following reasons. 
 Birth outcomes (termination of pregnancy, fetal death, live birth) are recorded in 
many congenital anomaly registries. 
 The literature contains substantial data on survival to age 5, but observational data 
on full long-term survival is limited. 
 Since mortality due to congenital disorders is highest in the early years, survival with 
disability to age 5 may be taken as an indicator of long term service needs.  
 Disability is arguably of even greater significance than early mortality in terms of 
service needs. 
The table shows key outputs to age 5, selected for publication on the Web. 
Table 1.1 Key outputs to age 5 from the Global Database, for each disorder group. 
BASELINE birth 
prevalence,  
i.e. if no 
intervention. 
Estimated NO-CARE outcomes at age 5 
 (outcomes in the absence of any 
intervention) 
Estimated ACTUAL outcomes at age 5, 
2010-14 
(outcomes with current interventions). 
1. Total affected 





This is the 
BASELINE RATE: 
all outcomes must 
fit within this 
envelope. 
2. Fetal deaths 
6. Reduction due to pre-pregnancy 
intervention 
3. Under-5 deaths attributable to the 
disorder 
7. Reduction due to termination of pregnancy 
(TOP) 
4. Under-5 deaths due to other causes 8. Actual fetal deaths 
5. Survivors at 5 years living with disability 
9. Actual under-5 deaths attributable to the 
disorder 
 
10. Actual under-5 deaths due to other 
causes 
 
11. Actual survivors at 5 years living with 
disability 
 
12. Actual survivors at 5 years effectively 
cured 
The sum of 2-5 above equals the 
BASELINE. 
The sum of 6-12 above equals the 
BASELINE 
There are inevitably many inaccuracies in the numerous inputs used to achieve these 
estimates. However the rule remains that all outcomes must fill the envelope of baseline 
birth prevalence. Thus for example, under-estimation of termination of pregnancy will lead to 
over-estimation of early mortality; over-estimation of early mortality will lead to under-
estimation of disability or cure. Despite such variation, all the outcomes listed are important 
for health services, and cannot be discounted or ignored. 
Long-term outcomes 
These estimates are based on projected long-term survival, for which the evidence is often 
weaker. They include: 
 disorder-specific mean life expectancy by country  
 estimated months (or years) of life lost, or lived with disability, due to each disorder. 
 estimated current patient numbers with each disorder, and their age distribution 
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Purpose and organisation of this series of articles 
This set of thirteen articles describes how input data are obtained and handled, in sufficient 
detail to enable the development of similar country or regional databases. Since the method 
requires integration of data from many different sources, some articles are unavoidably 
weighty. The first five articles cover methods that are common for all disorder groups and the 
remainder address aspects specific for individual disorder groups, as follows. 
 Part I. General Method 
o Article 1: Introduction: scope and general overview (this article). 
o Article 2: Core methods for estimates to five years of age. 
o Article 3: Methods for generating long-term estimates. 
o Article 4: Uses of demographic and geographic data 
o Article 5: Estimating access to services 
 Part II. Congenital anomalies 
o Chromosomal disorders. Estimating birth prevalence and outcomes 
o Congenital malformations 1. Estimating birth prevalence and birth outcomes 
o Congenital malformations 2. Estimating outcomes of live births 
 Part III. Genetic disorders 
o Haemoglobin disorders. A model for single gene disorders 
o Rare single gene disorders10. Estimating collective birth prevalence and 
outcomes 
o Consanguinity-associated disorders. Estimating collective birth prevalence 
and outcomes 
o Rhesus haemolytic disease. Estimating birth prevalence and outcomes 
o G6PD deficiency neonatal jaundice. Estimating numbers at risk 
These articles together with their Annexes give full details of the method used, plus 
examples of outputs, chosen to illustrate the potential of the method and summarised by 
WHO Region. Further data including selected country-specific estimates are available online 
at www.mgdb.info. 
The need for an agreed terminology 
Evidence supporting policy-making should be presented using clear, unambiguous and 
uncontroversial terms that are suitable for a multidisciplinary audience. For effective handling 
at the public health level congenital disorders must be bundled into manageable and clearly 
defined groups. The construction of a quantitative database requires clear definition of each 
item included, but we encountered many examples of ill-defined terminology while building 
the Global Database. To enable the work to go forward, it proved necessary to create a set 
of terms and definitions appropriate for use in Community Genetic epidemiology. These 
terms are used throughout this series of articles, and they are defined at first use either in 
the text or in a footnote. They are listed fully below with the aim of stimulating discussion, 
and initiating an agreed terminology suitable for use in Community Genetics. 
                                               
10 A collective term used in the Global Database for dominant, recessive and X-linked single gene disorders whose 
prevalence is determined by a balance between new mutation and natural selection, and so are expected to have 
similar collective birth prevalence world-wide. 
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The lack of agreed terminology arises because the diversity of congenital disorders has led 
to the development of disparate - often disease-specific - clinical services.11 Clinical service 
fragmentation in turn leads to fragmentation of concepts, promotes competition rather than 
collaboration to achieve a consensus, and creates intellectual and practical problems in 
handling congenital disorders as a group. To take just one example, the fact that the terms 
congenital anomaly and congenital disorder are often, mistakenly, treated as equivalent has 
contributed to widely divergent estimates of the global burden of congenital disorders, and 
can cause confusion and paralysis for policy-makers. 
Figure 1.3 shows the main disorder groups covered by the WHO definition of congenital 
disorders, and the different ways in which they are bundled by different professional 
groups.12 
 
Figure 1.3. Bundling of the main groups of congenital disorder used for different professional purposes. The WHO 
definition is shown on the left. The ICD10 definition of congenital anomalies includes only disorders with 
structural effects and excludes the majority of genetic disorders. Genetic disorders include 
chromosomal disorders but exclude environmental disorders and most congenital malformations. The 
bundling used here into environmental and constitutional congenital disorders is shown on the right. 
The bundling used by Rare Diseases organisations (e.g. globalgenes.org) includes some disorders in 
all groups. 
The term congenital anomaly applies for congenital disorders with structural effects, 
regardless of cause, and so includes cases in all major groups though malformations and 
chromosomal disorders predominate. They are sufficiently clearly delineated at a practical 
clinical level to be recorded in formal congenital anomaly registries and to have their own 
chapter in ICD10 - Chapter XVII “congenital malformations, deformations and chromosomal 
abnormalities” (formerly the Q chapter). The ICD10 classification greatly facilitates collective 
recording and tracking and, together with the availability of quantitative data from registries, 
gives congenital anomalies a relatively high profile in a public health context. This has the 
advantage that high quality prevalence data are readily available, but the disadvantage that 
these data may be interpreted as describing the totality of congenital disorders. 
In contrast, the scattering of single gene disorders13 throughout the ICD system makes them 
difficult to grasp collectively, and they are often seen as too diverse and individually rare to 
be worthy of consideration at a public health level. However single gene disorders are 
estimated to account for over 30% of congenital disorders world-wide (Christianson and 
Modell 2004) so this omission is unacceptable. The Global Database uses a collective 
quantitative approach for single gene disorders derived from the fundamental principles of 
                                               
11 For example there is usually little contact between specialist services for haemophilia, phenylketonuria, cystic fibrosis 
and haemoglobin disorders though all are common single gene disorders. 
12 Confusion is sometimes avoided by calling the entire group “congenital and genetic disorders”. However cumbersome 
usage is best avoided, especially when addressing a non-specialist audience. 
13 Disorders caused by DNA variants with strong effect. They follow Mendelian inheritance patterns (dominant, 



















population genetics (see Article 10: Single gene disorders). In addition, as a place-holder for 
the large but still diffuse category of disorders due to genetic risk factors,14 it includes three 
well-understood risk factors – rhesus negativity, G6PD deficiency and alpha plus 
thalassaemia. 
The distinction between environmental and constitutional congenital disorders on the right of 
Figure 1.3 and used here cuts across the traditional bundling on the left. Clearly the 
distinction is not absolute: some disorders classed as constitutional may also be strongly 
influenced by environmental factors, and environmental influences often interact strongly 
with genetic predisposition15. Rather, as is common in medicine, the distinction is a 
pragmatic one enforced by the fact that the current Global Database method can be used 
only for disorders with a predictable baseline birth prevalence. 
Divergent estimates of under-5 deaths due to congenital disorders 
Terminological confusion is partly responsible for a wide discrepancy between estimates of 
global early mortality due to congenital disorders.  
It is widely recognised that the average baseline birth prevalence of constitutional congenital 
anomalies is at least 20/1,000 (Czeizel and Sankaranarayanan (1984), WHO (1985a), Baird, 
Anderson et al. (1988)), while the baseline birth prevalence of congenital disorders (including 
single gene disorders and early-onset disorders due to genetic risk factors) is over 37/1,000 
(Christianson, Howson et al. 2006). Their contribution to early death and disability is masked 
by high early mortality from other causes in lower-income settings, but it is estimated that 
infant mortality can fall below 10/1,000 only when interventions for prevention and care are 
in place (WHO (1985a), Christianson, Howson et al. (2006). Consequently congenital 
disorders would be expected to hold a significant place in global health policy-making16, but 
they are not mentioned at all in recent reviews of global early mortality such as Mathers and 
Loncar (2006) and (Black, Cousens et al. 2010). 
Estimates of global under-5 deaths due to congenital anomalies17 in 2000-2001 were 
3.3/1,000 births (4.1%) from the Global Burden of Disease (GBD) study (Lopez, Mathers et 
al. 2006), 2/1,000 from WHO (Liu, Johnson et al. 2012), and 9-10/1,000 (12-13%) from the 
March of Dimes (Christianson, Howson et al. 2006). 
Table 1.2 compares more recent estimates. The GBD estimate for congenital anomalies in 
2013 (www.healthdata.org) at 3.7/1,000 births is around half the Global Database estimate. 
Furthermore, GBD’s use of the term “congenital” to cover congenital anomalies gives the 
misleading impression that GBD estimates apply for all congenital disorders. Table 1.2 
shows GBD estimates for “congenital” under-5 deaths are only a quarter of the Global 
Database estimates for total congenital disorders (for details see Annex A1: Comparison of 
GBD and Global Database under-5 mortality estimates) . 
                                               
14 A DNA variant that is usually harmless but can interact with other genetic and environmental factors to cause a 
clinical disorder. Many common DNA polymorphisms with weak effects on health fall into this category. 
15 For example the birth prevalence of neural tube defects is strongly influenced by maternal vitamin intake, so many 
cases could be classed as due to genetic risk factors. Here they are classed as constitutional because (a) no normal 
diet contains enough natural folate to completely prevent them and (b) there is as yet insufficient evidence to split this 
clearly-defined malformation group by cause. 
16 For example the UN 4th Millennium Development Goal (to reduce the under-5 mortality rate by two-thirds, 
www.un.org/millenniumgoals) and WHO’s strategy for non-communicable diseases (www.WHO.int). 
17 It is only possible to compare estimates for congenital anomalies because, with the exception of haemoglobin 
disorders, single gene disorders are not included as a category in the GBD. 
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Table 1.2. Contrasting estimates of the contribution of congenital anomalies and congenital disorders to global 
under-5 deaths in 2013 
World rates for 2013 
GBD  
congenital anomalies 




Total births, 1,000s 136,110    
World under-5 deaths 8,001,839    
"Congenital" under-5 deaths /1,000 3.7 8.0 15.0 
Annual "congenital" under 5 deaths 503,609 1,088,883 2,041,656 
"Congenital" under-5 deaths % of total 6.3 13.6 25.5 
The Global Database is the product of an international collaboration aiming to improve the 
quality and availability of evidence on the birth prevalence and outcomes of congenital 
disorders. 
Reasons for divergent estimates  
The wide divergence between different authoritative estimates of the contribution of 
congenital disorders to the global burden of disease makes it necessary to consider possible 
reasons for over- or under-estimating their significance. 
Possible reasons for over-estimation 
In response to a letter in the Lancet (Modell, Berry et al. 2012), Liu, Cousens et al. (2012) 
listed six possible reasons for over-estimation of under-5 mortality due to congenital 
anomalies: 
 unrepresentatively high prevalences based on biased samples 
 effects of different fertility patterns or genetic and environmental contexts 
 inclusion or otherwise of stillbirths and terminations of pregnancy 
 risks of double-counting 
 shortage of population-based, cause-specific fatality rate data for varying care 
settings 
 inclusion of deaths of affected children due to other causes 
In revising the Global Database, great care has been taken to exclude these possible 
sources of error and they do not significantly affect current estimates of under-5 deaths due 
to congenital anomalies. However, the discrepancy between the revised Global Database 
and GBD estimates remains as wide as ever. 
Possible reasons for under-estimation 
There is good general agreement between Global Database and GBD estimates of under-5 
deaths due to congenital anomalies for high income countries. However GBD estimates are 
far below Global Database estimates for most middle and low income countries (see Annex 
A1: Comparison of GBD and Global Database under-5 mortality estimates). This is the 
explanation for the difference between the global estimates, and for our conclusion that the 
global burden of congenital disorders is grossly underestimated. Many different factors may 
contribute to this under-estimation. 
Requirements for correct diagnosis 
Only a minority of congenital disorders are obvious at birth, and accurate diagnosis 
frequently requires resources that are not available in lower-income settings. Therefore little 
reliable prevalence data are available for lower-income countries. In the absence of data it is 
easy to assume that the problem is not significant, or that there is no evidence to support 
service planning. 
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Difficulty in defining cause of death 
Reliable, medically-certified cause of death data can only be obtained in high income 
settings with low mortality due to congenital disorders because prevention and care are also 
available. In lower-income settings deaths due to congenital disorders are likely to be mis-
attributed to other causes, such as infection. Therefore if observed medically-certified death 
rates are applied globally, early deaths due to congenital disorders will be greatly under-
estimated.  
Perceived low prevalence in high income settings 
Congenital disorders are generally perceived to be rare in high income settings because (a) 
the present high income countries had the lowest baseline birth prevalence of congenital 
disorders to start with; (b) the birth prevalence of some groups has been greatly reduced by 
interventions such as anti-D for rhesus negative mothers, and prenatal diagnosis with the 
option of termination of pregnancy; (c) death and disability due to some groups has been 
greatly reduced by early diagnosis and successful treatment (e.g. paediatric surgery). 
Since it is death and disability that bring disorders to the attention of health services, their 
perceived prevalence in high income settings is now far below their actual birth prevalence. 
Because so many academic/medical policy-makers come from, or were trained in high 
income countries this biased perception tends to be extended globally. 
Reliance on the International Classification of Diseases (ICD) 
The fact that congenital disorders are collectively common but individually rare presents 
difficulties in grasping them collectively. ICD is a common starting- point for epidemiological 
undertakings, and the placing of conditions within it can affect their perceived importance. 
The fact that chromosomal disorders and congenital malformations are grouped together 
under the heading of congenital anomalies in ICD10 chapter XVII (the Q chapter) provides a 
convenient handle for addressing this group collectively at the public health level. By 
contrast single gene disorders, which contribute almost half of all congenital disorders, are 
scattered throughout the ICD system and are usually perceived as too diverse and 
individually rare to handle collectively.18 
Fragmentation of clinical services 
Because of their extreme clinical diversity, management of genetic diseases requires diverse 
interventions involving numerous different services. Fragmentation of clinical services 
exacerbates the problem of handling these disorders as a group. 
Failures in professional communication 
The specialist literature contains extensive information on the nature, prevalence and 
outcomes of congenital disorders, but this is inadequately reflected in the public health 
literature – the specialist community has failed to communicate with the public health 
community. 
The Global Database is designed to overcome the problems that lead to under-estimation of 
the collective public health importance of congenital disorders, by helping to bridge the gap 
between public health and existing specialist knowledge.  
                                               
18 In recent years this problem has led to the development of the Rare Diseases community, e.g. 
https://rarediseases.org, www.raredisease.org.uk 
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1.2 Notes on terminology and definitions of terms used in the Global 
Database 
General principles 
Progress in any discipline requires agreement between professionals on the meaning of the 
terms used. The first part of this Introduction clearly demonstrates the need for consideration 
and agreement on terminology. A first step could be to agree on standards for 
communication in community genetics. 
Standards for communication– initial suggestions 
Terms used must take account of the audience to be addressed. For example, the current 
enterprise aims to harmonise specialist medical genetic information with public health 
objectives. The target audience is therefore multidisciplinary, ranging from directors of public 
health to primary health care practitioners, politicians, the media and patient support 
associations. The same principle applies for the whole of Community Genetics, since the 
defined aim is to make genetic information and services available to all who may benefit. 
Therefore agreed, clear and simple terms must be used: (a) to enable communication 
among health professionals working in different disciplines; and (b) to support health 
professionals to provide correct and consistent information to others. Therefore - 
Each term used must be: 
 precise but comprehensible 
 transparent, and accurate in its clinical implications 
 sensitive to the preferences of users, especially patients 
Additionally 
 terms used should as far as possible apply across the full spectrum of congenital 
disorders 
 terminology should be harmonised internationally 
 consideration should be given to translation into the vernacular 
Selection of terms used in the Global Database 
In the course of developing the Global Database, it was necessary to find terms that 
precisely define each element included in the calculations. All such terms, as used in the 
Database, are listed below. 
We use existing specialist terminology as far as possible, but it sometimes proved necessary 
to find alternative terms to (a) meet the specific requirements of the database, (b) facilitate 
communication with public health practitioners and (c) take account of the general 
requirements for multi-disciplinary communication. In some instances the terms used to 
meet these requirements differ from those conventionally used by specialists.  
We therefore emphasise that: 
 The definitions listed here are presented exclusively in order to describe their use in 
building the Global Database, and in the accompanying documents. 
 There is no intention to alter existing specialist usage: we are not proposing the 
terms listed should be generally adopted. 
 Our experience of the need for agreed definitions does point to some inconsistencies 
in current usage: the terms listed could perhaps contribute to (hypothetical) future 
discussion aiming to harmonise current usage. 
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 We also offer this list of definitions in the hope of stimulating debate about terms for 
future use in the broad context of Community Genetics.  
Requirements for multidisciplinary communication 
Community genetics aims to support the incorporation of genetic approaches into medical 
practice. The target audience therefore includes everyone involved in developing policies for 
reproductive health and paediatric services – a wide range of health professionals, members 
of lay support groups, politicians, educators and journalists. However many terms relating to 
congenital disorders were designed for specialist use and may not be readily understood by 
a more general audience. Though it is not possible to avoid the use of technical terms, we 
consider it desirable to adjust some conventional specialist terms for use in the 
multidisciplinary context of Community Genetics.  
The technical terms used in these articles aim to comply with the following rules for 
multidisciplinary communication. 
 All technical terms should be as precise, simple and clear as possible, and free of 
unintended bias. 
 Abbreviations and acronyms should be avoided as far as possible. 
 Technical terms should be defined in the text and/or a footnote when first used. 
 A Glossary should be provided. 
The following list is intended to include all technical terms used in this series of articles, 
together with a discussion of the reasons for selecting them when this is indicated. Creation 
of the list and definition of terms is a work in progress. All terms are proposed with the aim of 
obtaining wide consultation. To facilitate review and consultation, terms are grouped under 




To what extent are these terms equivalent, and which should be chosen for use in 
Community Genetics? In the Global Database the term disorder is generally used in 
preference to disease to refer to a condition that can lead to death or disability, because this 
is the term that many patients prefer. Not all congenital heart defects cause death or 
disability: the Global Database identifies those that cause death or disability as congenital 
heart disease. The term condition is not used as it can cover almost any phenotype 
regardless of whether or not it causes death or disability. 
Congenital disorder (Birth defect) 
“Any potential pathological condition arising before birth --- whether it is evident at birth or 
becomes manifest later in life.” (WHO (1985a) and (2000), WHO and March of Dimes 
(2006)). This definition includes environmental congenital disorders, congenital 
malformations, single gene disorders, chromosomal disorders and disorders due to genetic 
risk factors (see definition below). The term congenital anomalies is often, mistakenly, used 
as equivalent to congenital disorders. 
Congenital anomaly 
A disorder included in Chapter XVII (formerly the Q chapter) of ICD 10 – “Congenital 
malformations, deformations and chromosomal abnormalities”. This chapter includes 
congenital disorders with structural effects regardless of cause. It does not include the 
majority of single gene disorders and disorders due to genetic risk factors. 
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The term congenital anomaly is often, mistakenly, understood to be equivalent to congenital 
disorder. (See e.g. Wikipedia article on congenital disorders; WHO short document on pre-
pregnancy care; British and Irish Network of Congenital Anomaly Researchers (BINOCAR) – 
“A congenital anomaly is defined as any defect present at delivery, probably originating 
before birth, and includes structural, chromosomal, genetic and biochemical defects and 
malformations.”  
Congenital anomaly registry 
A system for collecting data on the birth prevalence of congenital anomalies. Most registries 
also record birth outcomes. Conditions included are usually limited to those listed in the 
chapter XVII (the Q chapter) of ICD10, with some exclusions. Many, but not all congenital 
anomaly registries contribute to umbrella registries such as EUROCAT19 or ICBDSR20. The 
reports of the umbrella registries giving details of participating registries show wide 
differences in opportunities, and methods used, for collecting data. 
Umbrella registry 
A registry that collects data from a number of contributing registries in a standardised format. 
The two umbrella registries used in the Global Database are the European Surveillance of 
Congenital Anomalies network (EUROCAT) and the International Clearing House for Birth 
Defects and Research (ICBDSR). For UK, see The National Congenital Anomaly and Rare 
Disease Registration Service (NCARDRS). Public Health England 
Environmental congenital disorder 
A congenital disorder due to one or more external risk factors such as maternal exposure to 
infection, malnutrition, or teratogens. Any organ system, or multiple systems may be 
implicated. Their birth prevalence can be greatly reduced by conventional public health 
measures including immunisation, restriction of exposure to teratogens, nutritional 
supplementation, or diagnosis and treatment during pregnancy. The borderline between 
environmental and constitutional congenital disorders is not clear-cut, e.g. a proportion of 
neural tube defects (and oro-facial clefts, and possibly some other malformations) are 
avoided by folic acid food fortification. 
Constitutional congenital disorder 
A congenital disorder (mainly) due to an endogenous rather than an environmental cause. 
This definition includes most congenital malformations, chromosomal disorders, single gene 
disorders, and disorders due to common genetic risk factors. The borderline between 
environmental and constitutional congenital disorders is not clear-cut (see above). 
Sporadic congenital disorder 
A congenital disorder that can arise in any pregnancy, without known environmental or 
genetic cause. This definition applies to most congenital malformations and chromosomal 
disorders. It also includes disorders with functional rather than structural effects and no 
known cause (e.g. cerebral palsy arising before birth). 
Congenital disorders, age at onset 
Early onset = congenital disorders that usually present before puberty: disorders initially 
treated by paediatricians21. Later onset = congenital disorders that usually present in adult 
                                               
19 EUROCAT: European Surveillance of Congenital Anomalies. Eurocat-network.eu 
20 International Clearinghouse for Birth Defects. www.icbdsr.org 
21 The paediatric upper age limit is often defined as 12 years, but is often considerably higher, especially when a 
disorder involved delayed or absent puberty. For example Baird et al (1988) use an age limit of 20 years: the rates 
presented are used in the Global Database because the great majority of the disorders included present before 12 
years of age. Bittles, A. H. and J. V. Neel (1994). "The costs of human inbreeding and their implications for variations at 
the DNA level." Nat Genet 8(2): 117-121. and Bittles, A. H. and M. L. Black (2010a). "Evolution in health and medicine 
Sackler colloquium: Consanguinity, human evolution, and complex diseases." Proc Natl Acad Sci U S A 107 Suppl 1: 
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life, e.g. family cancer syndromes, genetically-determined neurodegenerative disorders, 
cardiovascular disease due to bicuspid aortic valve. 
Severe congenital disorder 
A congenital disorder that causes premature death or disability in the absence of 
intervention. (In genetic counselling, it is up to informed parents to assess the severity of a 
disorder in the context of their individual medical, social and economic situation.) 
Lethal congenital disorder 
Disorder for which treatment is ineffective, that almost always causes early death (e.g. 
anencephaly, bilateral renal agenesis, alpha thalassaemia hydrops fetalis). 
Potentially lethal congenital disorder 
Disorder that is highly likely to cause early death in the absence of care, but may be either 
corrected or greatly ameliorated by optimal care (e.g. many types of congenital 
malformation, haemoglobin disorders, phenylketonuria, cystic fibrosis). 
Usually sub-lethal congenital disorder 
Disorder that, untreated, causes disability but permits long-term survival (e.g. most 
malformations of the limbs or genitalia). 
Chromosomal disorders 
Naming of chromosomal disorders in the Global Database 
Trisomy 21: The professionally-agreed term is Down syndrome, and this is used in the 
Global Database. However it may also be called Down’s syndrome (perhaps in response to 
expressed preference of lay support groups). For example, official groups in the UK include 
the Down’s Syndrome Association, the UK Down Syndrome Cytogenetic Register (DSCR), 
and the National Down’s syndrome screening programme. 
Other trisomies: Trisomy 13: Patau syndrome, and Trisomy 18: Edwards syndrome. 
Other autosomal (also called “rare chromosomal disorders”): Includes other disorders of 
chromosome number (triploidy, other trisomies) and chromosomal rearrangements. The 
group is described quantitatively by Wellesley, Dolk et al. (2012). 
Sex chromosome disorders: XO: Turner syndrome, and XXY: Klinefelter syndrome. 
Congenital malformation 
A congenital physical anomaly that is deleterious, i.e. a structural defect perceived as a 
health problem. (Dictionary: irregular, anomalous, abnormal, or faulty formation or structure). 
Isolated congenital malformation 
One or more malformation(s) within one organ system (EUROCAT definition). The definition 
covers several different malformations affecting the same system, e.g. several different 
congenital heart defects. 
Single isolated congenital malformation  
A congenital malformation affecting only one part of an organ system. For example, many 
malformations of the heart involve more than one part of the organ – e.g. the ventricular 
septum plus one or more of the cardiac valves. EUROCAT defines malformations affecting 
one or more components of the heart but not associated with a defect in any other organ 
                                               
1779-1786. describe “pre-reproductive mortality” associated with parental consanguinity, without specifying an age limit: 
their rates are used in the Global Database to represent the consanguinity-associated increment in under-5 mortality in 
the absence of care, because in this situation most deaths due to recessive disorders occur before 5 years of age. 
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system as “isolated congenital heart defects”. By contrast, a defect in only one component of 
the heart is defined as a “single isolated congenital heart defect” (Garne 2013). 
Chromosomal-associated congenital malformations 
Congenital malformations that form part of a chromosomal syndrome e.g. over 30% of Down 
syndrome cases are associated with congenital malformations, mainly congenital heart 
disease. Patau and Edwards syndromes are always associated with malformation. Less 
severe congenital malformations are also common in Turner syndrome. 
Non-chromosomal congenital malformations 
Congenital disorders that remain when chromosomal-associated cases are subtracted.  
Non-syndromic congenital malformations 
Congenital malformations that are not associated with chromosomal disorders, single gene 
disorders or genetic syndromes, and not due to environmental factors – i.e. cases with no 
known cause. In reports on the epidemiology of congenital malformations affected birth 
prevalence is ideally described in terms of total and “non-syndromic” cases (e.g. birth 
prevalence of oro-facial clefts in China and Latin America). 
ICBDSR and EUROCAT (to 2015) provide data for total and non-chromosomal congenital 
malformations. Non-syndromic congenital malformations are calculated by subtracting cases 
due to environmental causes, single gene disorders and genetic syndromes. In 2015 
EUROCAT changed to reporting total and “non-genetic” malformations. To obtain non-
syndromic congenital malformations cases with environmental causes must be subtracted. 
Associated congenital malformations 
Malformations that occur in two or more organ systems in the same individual. Around 16% 
of non-syndromic malformations are associated, i.e. contribute to multiple malformations, so 
that for every 100 malformations reported there are around 84 affected individuals. In 
EUROCAT data, average association rates are 16% for total non-syndromic malformations, 
11% for malformations in live births, 44% in fetal deaths/ stillbirths and 37% in terminations 
of pregnancy for fetal impairment. 
Multiple malformations (Multiple congenital anomalies – MCAs) 
Two or more major (i.e. life threatening, severely disabling, or requiring substantial medical 
care) unrelated defects of unknown aetiology in the same fetus or infant22. 
Additional conditions 
A category included in the Global Database to accommodate non-genetic congenital 
disorders that are perceived as congenital disorders by paediatricians but are not included in 
congenital anomaly registries because: (a) they are classed elsewhere in ICD10 (e.g. 
congenital hypothyroidism due to thyroid aplasia or dysplasia); (b) they cause functional 
rather than structural abnormality (e.g. cerebral palsy); or (c) they have uncertain status (e.g. 
pyloric stenosis). 
The three disorders currently included in the Global Database (congenital hypothyroidism 
due to thyroid a/dysplasia, pyloric stenosis, prematurity-related persistent patent ductus 
arteriosus) may all be bundled with congenital malformations for summary purposes. 
Rare diseases 
(Wikipedia, March 2016) 
 In the United States, the Rare Diseases Act of 2002 defines rare disease strictly 
according to prevalence, specifically "any disease or condition that affects fewer than 
                                               
22 www.icbdsr.org 
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200,000 people in the United States," or about 1 in 1,500 people. (This definition is 
essentially like that of the Orphan Drug Act of 1983, a federal law that was written to 
encourage research into rare diseases and possible cures.) (Comment: a major 
shortcoming of this approach is that, as the total population increases, the 
denominator and hence the prevalence changes, e.g. the US population increased 
from 234m in 1983, to 321m in 2016. Over the same time period a similar but 
opposite effect has occurred in Japan, with a secular decline in population). 
 In Japan, the legal definition of a rare disease is one that affects fewer than 50,000 
patients in Japan, or about 1 in 2,500 people. 
 The European Commission on Public Health defines rare diseases as “life-
threatening or chronically debilitating diseases which are of such low prevalence that 
special combined efforts are needed to address them”. The term low prevalence is 
later defined as generally meaning fewer than 1 in 2,000 people. (Diseases that are 
statistically rare, but not also life-threatening, chronically debilitating, or inadequately 
treated, are excluded from their definition.) The European Organization for Rare 
Diseases (EURORDIS) also includes both rare diseases and neglected diseases into 
a larger category of “orphan diseases”. 
Comment. Almost all definitions of rare diseases are based on prevalence in the population 
rather than birth prevalence. Therefore when survival improves as a result of care, disorders 
may move out of the category – e.g. sickle cell anaemia might be classed as rare in some 
sub-Saharan African countries where birth prevalence is high, but not-rare in North America 
where birth prevalence is far lower.  
The effective mingling of rare genetic disorders and communicable diseases ranging across 
malaria, leprosy, TB etc. is understandable in promoting the care needs of people with all 
forms of rare diseases, and their families. But from diagnostic, genetic educational and 
genetic counselling perspectives it can create a major problem. The more so when the 
prevalence of communicable diseases in high and low income countries (even communities) 
varies greatly. Additional controversy exists as to whether all rare diseases should be 
bundled together, e.g. <1/2,000, or into ‘rare’ (<1/2,000) and ultra-rare (<1/100,000?).  
Genetic disorders 
Genetically-determined disorders 
Collective term for single gene disorders, chromosomal disorders and disorders due to 
genetic risk factors. This is an imprecise and potentially confusing term that groups disorders 
with a clear-cut genetic cause (chromosomal and single gene) with a potentially very large 
group of “disorders due to genetic risk factors” whose boundaries have not yet been defined 
(see definition of term). Therefore, this collective term is not used in the Global Database or 
the Methods articles. 
Single gene disorders 
Disorders caused by DNA variants with strong effect. They follow Mendelian inheritance 
patterns (dominant, recessive, X-linked): most individuals with the relevant variant (or 
combination of variants) develop the disorder. 
 Dominant single gene disorders. Most individuals with one copy of the gene variant 
develop the associated disorder. 
 Recessive single gene disorders. This term usually only applies for disorders caused 
by DNA variants of the autosomes. Individuals who inherit one gene variant for a 
recessive disorder are unaffected. Most individuals who inherit two gene variants for 
the same recessive disorder develop the disorder. 
 X-linked single gene disorders are due to DNA variants on the X chromosome. Most 
males whose single X chromosome carries the relevant gene variant develop the 
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disorder. Most females in whom only one X chromosome carries the relevant variant 
are unaffected. Females who inherit two copies of the relevant variant may develop 
the disorder. 
Autosomal dominant and autosomal recessive disorders 
The terms dominant and recessive are often pre-fixed with “autosomal” to distinguish them 
from X-linked dominant and recessive disorders. The autosomal prefix is not used in the 
Global database for three reasons that take account of the need to clearly define every term 
used for a multidisciplinary audience. (1) When grouping single gene disorders the priority 
focus is on inheritance pattern, independent of the arrangement of genes on chromosomes. 
The autosomal prefix should only be used when the intended audience already has a clear 
understanding of the relationship of genes and chromosomes. Otherwise the inclusion of 
chromosome-specific terms can cause confusion. (2) The terms dominant and recessive do 
not strictly apply for most X-linked disorders because random X-chromosome inactivation 
can lead to manifestation of the disorder in female heterozygotes. (3) Cumbersome 
terminology should be avoided as far as possible. 
Therefore the Global Database uses the simple terms dominant, recessive and X-linked 
disorders. 
Rare single gene disorders 
A collective term for dominant, recessive and X-linked single gene disorders that are 
disadvantageous without any compensating selective advantage. Such disorders are 
expected to have similar collective birth prevalence world-wide, because their gene 
frequency is determined by a balance between new mutation rate and natural selection, 
neither of which vary greatly between populations (see Article 10: Single gene disorders). 
Consanguinity 
The term consanguineous simply means related by blood. Consanguinity refers to the state 
of being related by blood. In medical genetics, the term refers to the relationship between 
people who are second cousins or closer. However in a health context the term 
“consanguinity” is often used to mean a consanguineous union. This usage should be 
avoided in the interest of clarity. We suggest the following terms. 
 Consanguineous union = the relationship between blood relatives who have children 
together, whether married or not. 
 Parental consanguinity = a general term for use when discussing the implications for an 
individual or group, of a consanguineous relationship between their parents. 
In populations where most couples marry, the term consanguineous marriage is often used 
to describe a union between blood relatives. The term cousin marriage is also used in 
populations where consanguineous unions involve cousins but e.g. uncle/niece marriage is 
excluded. We aim to avoid using these terms in the global context of Community Genetics. 
Consanguinity-associated disorders 
A collective term for the increment in congenital disorders associated with parental 
consanguinity. The increment is mainly due to increased birth prevalence of recessive single 
gene disorders. Consanguinity-associated disorders should not be called disorders due to 
parental consanguinity. They are due to the inheritance of two recessive gene variants that 
can cause the same disorder. Parental consanguinity increases the chance that a couple will 
both carry the same recessive gene variant. It does not in itself cause any medical problem. 
Haemoglobin disorders (haemoglobinopathies) 
Disorders caused by variants of the haemoglobin genes. These are called 
haemoglobinopathies by specialists, but most non-specialists find this term 
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unpronounceable. The English translation, haemoglobin disorder, is preferable for 
multidisciplinary use. 
Multifactorial disorder 
A term used for clinical categories of disorder with genetic, environmental and unknown 
causes, especially when these are obscure or ill-understood. Most “multifactorial disorders” 
include a relatively small group of single gene disorders, some with both genetic and 
environmental causes, and some with purely environmental causes. As an example, 
congenital malformations are often described as multifactorial disorders: the proportion due 
to environmental causes falls with improving public health; a handful are due to single gene 
disorders; some (vitamin-sensitive malformations) are due to both genetic and environmental 
causes; the majority are due to sporadic accidents in embryonic development. The term can 
be confusing, as it is often mistakenly understood to imply genetic/environmental interaction 
in most cases. It is not used in the Global Database because it tends to obscure rather than 
clarify understanding of cause. 
Genetic risk factor 
A DNA variant that can interact with other genetic and environmental factors to cause a 
clinical disorder. Many common DNA variants (genetic polymorphisms) may have weak 
effects on health and so fall into this category. Some such variants have very clear-cut 
effects in the sense that the disorder concerned can only arise if a specific risk factor is 
present (e.g. rhesus haemolytic disease of the newborn, the common forms of haemoglobin 
H disease). However most genetic risk factors increase the chance that a given clinical 
disorder will arise, e.g. G6PD deficiency increases the risk of severe neonatal jaundice, 
alpha-1-antitrypsin deficiency contributes to risk of early-onset liver disease and chronic lung 
disease in adult life. Many other common polymorphisms are genetic risk factors for 
common diseases of adult life. For example the common E4 polymorphism of the APOE 
gene is associated with increased risk of coronary heart disease, and the common C282Y 
allele in the HFE gene is associated with risk of haemochromatosis. 
Disorders due to genetic risk factors 
Disorders caused by the interaction of gene variants with weak effects on health with each 
other and with environmental factors. Rhesus negativity, G6PD deficiency and alpha plus 
thalassaemia are included in the Global Database because they are well-understood 
examples of genetic risk factors for early-onset congenital disorders. 
Genetic polymorphism 
“The occurrence of two or more alleles for a given locus in a population, where at least two 
alleles appear with frequencies of more than 1 percent” (Bodmer and Cavalli-Sforza 1976). 
Allele / Allele frequency 
Carrier / heterozygote 
A heterozygote is an individual in whom the two copies of a given gene differ. In a medical 
context the term is usually used for an individual who has one normal copy of a given gene, 
and one copy that can potentially cause a genetic disorder. 
Since only a minority of health professionals have a clear understanding of the specialist 
term heterozygous, we propose replacing it with the term “carrier” for communicating with a 
Community Genetic audience. With this usage- 
 Carriers of dominant disorders are at high risk of developing the disorder themselves 
at some point in life, and have a 50% reproductive risk (i.e. each child has a 50% risk 
of inheriting the responsible gene variant). 
 Carriers of recessive disorders have no personal risk of developing the disorders 
themselves. They have potential reproductive risk which only becomes an actual 
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reproductive risk if they have children with a partner who carries the same recessive 
disorder. They then have a 25% reproductive risk (i.e. each child has a 25% risk of 
developing the disease). Carriers of recessive disorders may be called healthy 
carriers, to emphasise that the carrier state does not predispose to any disorder. 
 Carriers of X-linked disorders have a 25% reproductive risk (i.e. each male child has 
a 50% risk of inheriting an X chromosome that carries a gene for the disorder and 
developing the disease). A proportion of female carriers of X-linked disorders may 
also develop the disorder (with varying degrees of severity) as a result of unequal X-
chromosome inactivation. 
Carrier prevalence 
The proportion of a population who are carriers of a specific single gene disorder. 
Gene variant 
Term used to describe a difference from the commonest DNA sequence of a gene. The 
commonest sequence may be called the canonical sequence. 
Genetic polymorphism 
When a variant affects more than 1% of genes it is viewed as a common variant and is 
called a genetic polymorphism. Most genetic polymorphisms are harmless or have weak 
effects on health. However polymorphisms that can cause disease but have a selective 
advantage, such as haemoglobin S, can reach high prevalence. 
Balanced polymorphism 
The situation where the frequency of a gene that gives a selective advantage but can also 
cause disease, stabilises because advantage and disadvantage are balanced. The best-
known examples are haemoglobin disorders and G6PD deficiency, in malaria endemic 
areas. 
Genetic fitness 
Ability of an individual or group to pass their genes on to subsequent generations, by 
comparison with the population norm. This specialist term has strong negative connotations 
for some populations. The equivalent and more transparent term reproductive success is 
therefore used in the Global Database. 
Reproductive success 
Ability of an individual or couple to have descendants, when compared with the population 
norm. This term may be used as equivalent to genetic fitness. The term descendants 
includes children and grandchildren. A couple at risk for a genetic disorder may have the 
same number of children as others, but if those with the genetic disorder are unable to 
reproduce, the couple’s ultimate reproductive success is reduced. Therefore the true 
measure of an individual’s genetic fitness is their ability to transmit their genes to 
grandchildren and subsequent generations. 
Reproductive disadvantage 
Anything that interferes with an individual or couple’s genetic fitness. 
Consanguinity 
The dictionary definition is “related by blood”. Since this term applies for any blood relative it 
should be qualified when applied to the relationship between a couple. 
Inbreeding 
When used for human beings this is a highly pejorative term that should be avoided. It can 
usually be replaced by more neutral and precise terms such as consanguineous marriage or 
parental consanguinity. 
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Consanguineous marriage /union 
A marriage between a individuals who are blood relatives. In medical genetics the term 
applies for a couple who are related as second cousins or closer. Strictly, the relevant 
relationship is a consanguineous union because not all parents are married. However most 
observational data actually applies for consanguineous marriage because surveys usually 
enquire into marriage relationships, and in many relevant populations marriage is virtually 
universal. In common parlance, consanguineous marriage is often called cousin marriage. 
Parental consanguinity 
In community genetics the main interest is in the implications for offspring of 
consanguineous parents, i.e. in the implications of parental consanguinity. This term is used 
as far as possible in the Global Database. 
Coefficient of consanguinity (Coefficient of inbreeding) 
A specialist term used for quantifying the genetic implications of parental consanguinity in 
terms of the additional proportion of gene pairs that are identical by descent (F). In the 
original specialist literature it was called the coefficient of inbreeding. However the term 
“inbreeding” is highly pejorative in popular usage and should be avoided with non-specialist 
audiences – indeed with any audience, since the borderline between specialists and the 
public is increasingly porous. 
Interventions/prevention 
Prevention 
The word prevention is derived from the Latin praevenire, meaning to arrive first or 
beforehand, and applies for any intervention undertaken to avoid any specified event. 
However it is a very weighted and potentially contentious term in the context of Community 
Genetics. The problem is that prevention is a main aim for public health, and public health 
professionals include termination of pregnancy for fetal impairment as a form of prevention. 
But the abortion issue is so highly politicised in some settings that it can be desirable (or 
even necessary) to preclude discussion to avoid side-tracking. In this situation other 
euphemistic terms must be found, e.g. avoidance (of birth) or secondary prevention (see 
below). For this reason the term prevention is used as little as possible in the Global 
Database. Since it depends on intervention, it is replaced when possible by specifying the 
timing of the relevant intervention – before or during pregnancy or after birth. 
Prevention of congenital disorders 
Interventions for congenital disorders are intended to prevent associated death and 
disability. Specialist publications often describe three levels of prevention: (1) primary 
prevention, when a disorder is stopped from arising in the first place (e.g. maternal 
immunisation against rubella, anti-D for rhesus negative mothers, folic acid food fortification); 
(2) Secondary prevention: an affected fetus is prevented from reaching birth – a euphemism 
for termination of pregnancy; and (3) Tertiary prevention: an existing disorder is prevented 
from causing clinical problems (e.g. treatment of congenital hypothyroidism, cure of a 
congenital malformation by paediatric surgery). However, when the terms primary, 
secondary and tertiary prevention are used the general reader usually has to pause to check 
their meaning23. Therefore in the Global Database interventions are described according to 
their timing in relation to pregnancy. 
 Interventions before pregnancy. This term covers pre-conception interventions that 
prevent disorders arising in the first place (e.g. anti-D, folic acid food fortification, 
                                               
23 Also, it can be hard to place some interventions in the hierarchy. For example, preventing virilisation of a female fetus 
with congenital adrenal hyperplasia, by treating the mother with dexamethasone throughout pregnancy - ?primary or 
secondary prevention. 
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genetic risk identification with information and counselling, polar body-based pre-
pregnancy genetic diagnosis): it also includes intervention between conception and 
implantation (genetic diagnosis based on blastomere sampling). 
 Interventions during pregnancy. This term covers identification of increased risk of 
congenital disorder with information and counselling, and prenatal diagnosis with or 
without the option of termination of an affected pregnancy. Benefits of prenatal 
diagnosis include informed choice of pregnancy outcome for the parents, intra-
uterine treatment when this is possible, optimal neonatal care for an affected infant, 
and the option of termination of pregnancy if the fetus has a severe disorder (when 
this is legal). 
 Early diagnosis and care. Optimal care often depends on early diagnosis. Early 
diagnosis includes prenatal diagnosis, neonatal diagnosis by physical examination or 
other investigation, and clinical paediatric diagnosis by trained professionals. 
Birth outcomes 
Miscarriage 
The definition of miscarriage depends on the country definition of stillbirth, and this is highly 
variable. In the Global Database the term miscarriage is used for fetal loss before 20 weeks 
of pregnancy (measured from the last menstrual period). 
Birth 
This term covers all pregnancy outcomes after 20 weeks’ gestation (measured from the last 
menstrual period). However, some pregnancies terminated for fetal impairment would have 
ended in miscarriage before 20 weeks. It may therefore be necessary to adjust terminations 
of pregnancy reported by congenital anomaly registries for estimated losses before 20 
weeks, before including them in total births. 
Stillbirth 
The definition of stillbirth ranges by country from pregnancy loss after 20 weeks to loss after 
28 weeks’ gestation (measured from the last menstrual period), and weight is also usually 
taken into account. This naturally leads to difficulties in obtaining reliable data, and in 
comparing rates between countries and over time. 
Fetal death 
EUROCAT defines fetal death as death in utero after 20 weeks from the last menstrual 
period. In EUROCAT, and hence in the Global Database, fetal death is used as an indicator 
of prevalence of stillbirth. In theory this use might inflate stillbirth estimates (e.g. the WHO 
definition of stillbirth for global use is death in utero after 28 weeks’ gestation). However 
there is good evidence that the prevalence of fetal death due to congenital disorders is 
under-estimated in many settings. Therefore it is reasonable to use observed fetal death 
rates as an indicator of stillbirth rates, in the absence of other reliable data. 
Abortion 
This is an ambiguous term that may be used both for miscarriage and for medically-induced 
abortion. Abortion is a highly politicised topic. Therefore the term abortion is best avoided 
when the aim is to give an objective description of birth outcomes. 
Medically-induced abortion 
The United Nations report on legality of medical abortion includes seven indications for 
medical abortion: (1) to save the life of the woman; (2) to preserve physical health; (3) to 
preserve mental health; (4) rape or incest; (5) fetal impairment; (6) economic or social 
reasons; (7) available on request. 
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Abortion for fetal impairment is included in the Global Database, under the heading 
termination of pregnancy (TOP) for fetal impairment. 
Termination of pregnancy for fetal impairment 
EUROCAT uses the term “termination of pregnancy for fetal anomaly” (TOPFA). However 
this term might be understood as applying only for congenital anomalies. The term used in 
the Global Database is termination of pregnancy (TOP) for fetal impairment, because the 
term impairment covers all severe congenital disorders and is consistent with UN usage. 
Termination of pregnancy for fetal impairment is sometimes (often) counted as a solution to 
the problem presented by a congenital disorder. However in reality termination of a wanted 
pregnancy is a heavy cost for parents and so for societies. In the Global Database 
termination of pregnancy for fetal impairment it is included with fetal death, premature death 
and life-long disability, as a cost of congenital disorders. 
Measures of frequency 
Ascertainment 
The proportion of actual cases that are recorded. It corresponds to sensitivity (true positive 
rate), defined as the proportion of actual positive cases correctly identified. 
Incidence 
The frequency with which new cases of a disorder arise. For public health purposes 
incidence is often expressed as new cases per 100,000 population per year. However the 
incidence of congenital disorders is best described in terms of birth prevalence, i.e. affected 
births/1,000 births (live births, or total births). 
Prevalence 
A measure of the number of cases of a disorder present in a given population at a given 
time, e.g. cases/100,000 population. Because of high early mortality, the birth prevalence of 
congenital disorders (rate/1,000 births) is far higher than their population prevalence 
(rate/1,000, 10,000 or 100,000 total population). When effective cure is possible, the 
population prevalence rises at a rate proportional to access to care, until it stabilises at the 
same level as birth prevalence. This equalisation can occur at 80 years from the start of 
effective intervention, at the earliest. 
Birth prevalence 
Throughout this series the term “birth prevalence” is used in place of “incidence” to describe 
the frequency of new cases as they present to health services. Strictly, incidence applies for 
the frequency with which new cases arise: many congenital disorders that arise at or soon 
after conception miscarry leading to wide differences between true incidence and frequency 
at birth. Therefore when the aim is to assess service needs, prevalence at birth is taken for 
practical purposes as equivalent to incidence. The distinction is not only theoretical: it 
matters practically – e.g. the difference between prevalence in the second trimester of 
pregnancy and at term must be taken into account when calculating the impact of prenatal 
diagnosis on the birth prevalence of congenital disorders. 
 In this series birth prevalence is usually expressed in terms of affected births per 
1,000 live births, because World Population Prospects (WPP) data provide the 
denominator, and in WPP the term “births” applies only for live births. 
 In most congenital anomaly registries, including EUROCAT, birth prevalence is 
usually expressed in terms of affected births per 10,000 total births. (For Rare 
Diseases Orphanet uses cases/100,000). 
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Baseline birth prevalence (potential birth prevalence) 
The birth prevalence that would obtain in the absence of any intervention. In congenital 
anomaly registries birth prevalence is usually expressed as rate/10,000 or /1,000 total births 
(stillbirths and live births). This is because: (a) congenital disorders make an important 
contribution to stillbirths; and (b) reliable data on stillbirth rates are available in most settings 
with congenital anomaly registries. However, at a global level, birth prevalence is usually 
expressed as rate/1,000 live births. This is because the most reliable and consistent source 
of global demographic data (UN World Population Prospects, WPP) only publishes 
estimates for live births (due to the difficulty of collecting reliable stillbirth data in many lower-
income settings.) This difference leads to modest under-estimation when actual annual 
affected births are calculated by applying rates from congenital anomaly registries to WPP 
birth data. 
Baseline birth prevalence provides the starting-point for assessing service need and the 
impact of different interventions. 
Actual birth prevalence 
Actual births /1,000 live births, allowing for the effects of interventions before or during 
pregnancy. (The denominator is live births because of the use of WPP birth data.) 
Total birth prevalence 
Includes all outcomes of affected pregnancies after 20 weeks' gestation (termination of 
pregnancy, fetal death/stillbirth, live birth). Expressed as total affected births /1,000 live 
births. 
Live birth prevalence 
Affected live births /1,000 live births 
Reference rate 
A rate that can be used as a yardstick for comparisons between countries or over time (e.g. 
baseline birth prevalence = reference rate for congenital disorders). 
Live birth outcomes 
Effective cure, e.g. for congenital malformations corrected by paediatric surgery. It does not 
mean complete correction with no residual problems. Rather it means that the problem has 
been sufficiently corrected to allow affected individuals to live their lives free from continuing 
medical care, and to achieve life goals such as independent living, finding a partner, 
reproductive success, even with some persisting problems. 
Severe disability. Disability likely to cause premature death and/or prevent independent 
living and attainment of other life goals. 
Mild/moderate disability. Disability that does not usually lead to premature death, may allow 
independent living, but may diminish reproductive success. 
Residual disability. Disability that persists despite best possible care. May be severe, e.g. 
Down syndrome or spina bifida, or mild/moderate, e.g. some cases of oro-facial clefts. 
Well on treatment. The condition of people born with a congenital disorder who are able to 
lead an effectively normal life including reproductive success, providing they have ongoing 
treatment (e.g. treated congenital hypothyroidism, phenylketonuria (PKU), thalassaemia 
major). 
Demography 
Level of economic development 
The terms comparing developed/developing or industrialised/industrialising etc. are 
outdated. The World Bank classification of high, middle and low income countries is currently 
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used by the Global Burden of Disease study. In the Global Database the key distinction is 
between high income countries capable of providing optimal care equitably to their 
population, and countries that have not yet reached this level of economic development. 
Non-high income countries are often collectively described as "low and middle income 
countries" (LMIC). The collective term used in the Global Database is “lower-income 
countries (or settings)” because: (a) the crucial difference is between high income countries 
and the rest; and (b) it is desirable to avoid cumbersome usages and abbreviations. 
However our principal indicator of level of economic development is estimated access to 
services, based on infant mortality. That is, we really use a continuous rather than a stepped 
indicator. 
Ethnic group 
Ethnic minority. A population group that is distinguished genetically or culturally from the 
majority population of a country. 
Sex ratio 
The relationship between numbers of males and females in a group, usually expressed as 
males/females. Sex ratio at birth is similar worldwide in the absence of prenatal sex 
selection. When used in relation to population age distribution it gives a measure of excess 
of one sex or the other in any age group, and so may cast light on the history of the 
population. 
Sex ratio at birth. The usual (male/female) sex ratio at birth is 1.05 +/- 0.01 (51.2% males, 
48.8% females) with little geographical or ethnic variation.  
Total fertility rate (TFR) (final family size) 
The total fertility rate (TFR) of a population is the average number of children that would be 
born to each woman over her lifetime if: (a) She were to experience the exact current age-
specific fertility rates through her lifetime; and (b) She were to survive from birth through the 
end of her reproductive life. It is obtained by summing the single-year age-specific rates at a 
given time. The estimate is for total births per woman, including stillbirths and live births. 
TFR is used in the Global Database in estimates for disorders whose prevalence is related 
to birth number (e.g. rhesus haemolytic disease of the newborn), and in estimates of the 
potential maximum effect of genetic risk information on reproductive behaviour. 
World Population Prospects (WPP) annual births 
WPP estimates for births apply for live births only. 
Reference region 
A region chosen for comparison with other countries or regions because it demonstrates the 
maximum potential effect of available interventions. Data for this region can therefore be 
used as a yardstick for assessing the extent to which interventions are implemented in other 
regions, and for projecting the likely effects of future choices concerning available 
interventions at regional and global levels. Western Europe is chosen as the reference 
region for WHO regions. 
Survival and mortality 
Causes of death24 
“In 1967, the Twentieth World Health Assembly defined the causes of death to be entered on 
the medical certificate of cause of death as “all those diseases, morbid conditions or injuries 
                                               
24 From Volume 2: Instruction manual, page 31. (4. Rules and guidelines for mortality and morbidity coding.) in World 
Health Organization. (2004). International statistical classification of diseases and related health problems. Geneva, 
World Health Organization. www.who.int 
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which either resulted in or contributed to death and the circumstances of the accident or 
violence which produced any such injuries”. ---. When only one cause of death is recorded, 
this cause is selected for tabulation. When more than one cause of death is recorded, 
selection should be made in accordance with -- the concept of the underlying cause of 
death.” 
Underlying cause of death 
“It was agreed by the Sixth Decennial International Revision Conference that the cause of 
death for primary tabulation should be designated the underlying cause of death. --- For this 
purpose, the underlying cause has been defined as: “(a) the disease or injury which initiated 
the train of morbid events leading directly to death; or (b) the circumstances of the accident 
or violence which produced the fatal injury”. 
Two examples: The sequence when a child with untreated Down syndrome dies may be: (a) 
pneumonia, due to (b) congenital heart disease, due to (c) Down syndrome: the underlying 
cause of death is Down syndrome. When a child with sickle cell disease dies in rural Africa 
the sequence may be: (a) infection, due to (b) functional asplenia, due to (c) sickle cell 
disorder: the underlying cause of death is sickle cell disorder. 
Survival 
For congenital disorders, the proportion of affected individuals born and still alive at given 
age intervals (usually 5-year intervals). Visually presented as a survival curve. In the Global 
Database, survival curves with optimal care and in the absence of care are needed for each 
disorder group. Availability of a full survival curve permits calculation of mean life expectancy 
(mean age at death) and so of years of life lost or lived with disability. 
Prospective survival curve 
A survival curve that describes the anticipated survival of affected individuals born today, 
assuming no new treatments become available. Survival curves with optimal care, based on 
the most recent available data, are in fact prospective survival curves. 
Retrospective survival curve 
A survival curve showing estimated survival of people living at a given time by age group, 
looking back over the previous 80 years. Retrospective survival curves take account of the 
history of the introduction of new therapeutic interventions. For example, routine closure of 
all open spina bifida only became policy in the early 1970s. Therefore although long-term 
survival is now expected for 70% of people with spina bifida, the retrospective survival curve 
predicts that in 2010 there would be relatively few survivors with spina bifida over 45 years 
old. 
Mortality 
The proportion of affected individuals who have died by given age intervals. The converse of 
survival. 
Early mortality 
Neonatal, infant, under-5 deaths/1,000 births. 
Attributable mortality 
The proportion of affected individuals who have died due to their diagnosis, rather than from 
any other cause. In calculating mortality attributable to congenital disorders, the relevant 
proportion of affected individuals who may have died from other causes before they would 
have died due to their condition, is subtracted from deaths calculated using survival curves. 
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Optimal care 
In principle, optimal care should mean care including all the interventions available at the 
relevant time. In the Global Database it means the level of care typically available when 
infant mortality is 10/1,000 or lower. 
No-care situation 
A situation in which there is no access to health services of any kind, even basic primary 
care. (The baseline condition for human populations.) 
Mean age at death 
This term can be ambiguous because it may be used in two ways: (a) the mean age of death 
of all individuals with a given disorder; or (b) the mean age of recorded deaths. Czeizel used 
it in the second sense, so that in his data only 30% of Down syndrome cases died by the 
age of 20 but mean age at death was only 2.5 years. The sense in which the term is used 
must be clearly defined. In the Global Database, to avoid confusion and use a more 
optimistic tone, the equivalent term mean life expectancy is used. 
Mean life expectancy 
Mean life expectancy of all individuals with a given disorder. Equivalent to mean age at 
death for all individuals born with the disorder. 
Access to care 
As used in the Global Database, access to care means access to the typical range of 
services available when infant mortality is 10/1,000 or lower. Access to care is estimated 
using a formula based on infant mortality, taken as the single simplest indicator of level of 
health care development. 
Specialist services 
Costs and benefits 
Unfavourable outcome / Favourable outcome 
Costs / Benefits 
To include discussion of years of life lost etc., and expression of costs and benefits in terms 
of rates per individual in the relevant birth cohort. 
The “normal range” – a point for discussion in the context of the effect of vitamin 




Article 2: Core methods for estimates to five years of age 
Abstract 
This article specifies the congenital disorder groups included in the Modell Global Database 
of Congenital Disorders, and describes methods used to obtain country-specific 
epidemiological estimates from birth to five years of age. 
The estimates are based on data from the following sources. (1) Country-specific estimates 
of birth prevalence are available for neural tube defects, oro-facial clefts, haemoglobin 
disorders, parental consanguinity, rhesus negativity and G6PD deficiency. (2) Birth 
prevalences and birth outcomes for congenital anomalies are available from “umbrella” 
registries of congenital anomalies (EUROCAT and ICBDSR); (3) Country specific 
demographic estimates are from UN World Population Prospects; (4) disorder-specific 
survival data obtained from the literature, supplemented by expert opinion. 
Data from these sources are processed to create the following sets of country-specific 
inputs. (1) baseline birth prevalence (i.e. prevalence that would obtain in the absence of any 
intervention); (2) effects of pre-pregnancy interventions and termination of pregnancy on 
birth prevalence; (3) disorder-specific survival and disability (a) in a baseline no-care 
situation and (b) with optimal care. 
Country-specific estimates of actual annual affected births, birth outcomes and survival to 
age five are then obtained by relating rates for birth prevalence and outcomes in the 
absence of care and with optimal care, to the estimated proportion of each population with 
access to optimal care. In the absence of a readily-available global source of information on 
access to optimal care, we use a method based on infant mortality rate.  
We emphasise the central importance of baseline birth prevalence for all further calculations. 
(a) The evidence base for these estimates is particularly strong. (b) Baseline birth 
prevalence provides a quantitative envelope which must be filled by the sum of all outcomes. 
The method is illustrated by charting selected outcomes by WHO region. Tables and charts 
also includes estimates for Western Europe, as a region which broadly represent outcomes 
with optimal care. 
Calculations for 2010-14 indicate that current interventions, when fully deployed at the 
population level, can reduce pathological outcomes by over 60%, and under-5 deaths by 
around 80%. Currently, congenital disorders are estimated to cause over 20% of global 
under-five deaths, while in high income settings where general under-5 mortality is very low 
they may account for around 70% of under-5 deaths. 
Introduction 
A full description of the general method used in building the Global Database is unavoidably 
lengthy, and so is presented in two parts. This article describes the methods used for 
calculating outcomes up to at five years of age, while the next describes methods used for 
calculating long-term outcomes. The articles also include summaries of selected outputs by 
WHO Region. 
The five-year break-point is chosen (a) because most deaths due to early-onset congenital 
disorders occur in the first few years of life; (b) reliable survival data is available up to five 
years of age for most of the disorders included; (c) under-5 mortality was the key indicator of 
access to appropriate services for the fourth UN Millennium Development Goal (MDG4), and 
(d) the calculations used for estimating long-term outcomes are more complex and results 
are more tentative. 
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Scope - conditions included 
The Global Database provides country estimates of birth prevalence, mortality and disability 
for the 32 clinical diagnostic groups listed in Table 2.1. The table also indicates the principal 
sources for the birth prevalences currently used in the database, and the intermediate 
groupings used to “bundle” data for different purposes. 
 The chromosomal disorder group includes all disorders that cause serious disability 
for the affected person25. 
 The congenital malformation group includes the ICD 10 system groups used in most 
congenital anomaly registries. 
 The additional conditions group accommodates disorders that would be classed as 
congenital by paediatricians but are not included in congenital anomaly registries 
because either they are placed elsewhere in ICD 10, or cause functional rather than 
structural abnormality, or have uncertain status. At present only three examples are 
included as “place-holders” for this group.  
Two groups of genetic disorders are included, but there is no sharp boundary between them. 
 Single gene disorders are caused by DNA variants with strong effect and so follow 
Mendelian inheritance patterns (dominant, X-linked, recessive). Most individuals with 
the relevant variant (or combination of variants) develop the disorder. At present, only 
disorders that present before 20 years of age are included. 
 Disorders due to genetic risk factors are caused by interaction of (often very 
common) DNA variants with other genetic and environmental factors26. The Global 
Database includes two early-onset examples (rhesus haemolytic disease of the 
newborn and neonatal jaundice due to G6PD deficiency) because (a) the underlying 
mechanisms are exceptionally well understood, and (b) they are potentially lethal but 
can be effectively prevented and/or treated. 
                                               
25 Chromosomal anomalies whose only effect is to increase reproductive risk (e.g. balanced structural rearrangements) 
are not currently included. 
26 This group may also be called “multifactorial disorders”. However this broad term is not used in the Global Database 
because (a) it includes common disorders of adult life where gene/environment interaction is involved and (b) it is often 
mistakenly understood to mean that all cases have a genetic component. In fact most “multifactorial disorders” include a 
relatively small group of single gene disorders, some with both genetic and environmental causes, and some with purely 
environmental causes. 
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Table 2.1. Groups of early-onset constitutional congenital disorders included in the Global Database, with 





Principal sources for reference baseline 






Down syndrome (+21) Hook and Hamerton (1977) 
Morris, Mutton et al. (2002); 
calculation based on maternal age 
Other trisomies (+13, +18) 




Turner syndrome (XO) EUROCAT data 
Klinefelter syndrome (XXY) 
Visootsak and Graham (2006), 





Anencephaly Elwood, Little et al. (1992) 
Systematic review 2010.  
Literature.  
Personal communications. 
Spina bifida & encephalocele 
Oro-facial clefts 
Cleft lip +/- cleft palate (CL(P) Mossey and Little (2002) 
Kadir, Mossey et al. (2016) Cleft palate (CP) 
Congenital heart 
disease (CHD) 
Very severe CHD 






CNS not neural tube defect 
EUROCAT data 
Eye 
Ear, face, neck 
Respiratory system 
Digestive system 












Congenital hypothyroidism1 Modell and Modell (1992) 
Prem-assoc. persistent PDA  EUROCAT data 
Pyloric stenosis 
Pedersen, Garne et al. (2008) 
Modell and Modell (1992) 
Single gene 
disorders 
Rare single gene 
disorders 
Dominant 
Classical studies (see Table 2.8 below) X-linked 






Bundey and Alam (1993) 
Bittles and Neel (1994) 
Haemoglobin 
disorders  
Sickle cell disorders 




Rhesus haemolytic disease 
Mourant, Kopeć et al. (1976) 
Bhutani, Zipursky et al. (2013) 
G6PD deficiency (G6PDd) neonatal jaundice 
(NNJ) 
WHO 1985c, 
Howes, Piel et al. (2012) 
1. Hypothyroidism due to thyroid agenesis or dysgenesis. Hypothyroidism due to iodine deficiency is 
excluded. 
2. Rare recessives = recessive disorders that would occur in the absence of parental consanguinity. 
Conditions not included 
A comprehensive database of congenital disorders would include all conditions regardless of 
cause or age at onset. However the following groups are not currently included. 
1. Environmental congenital disorders, for the reasons given above. 
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2. Non-genetic congenital disorders with functional rather than anatomical effects that 
are not included in congenital anomaly registries, e.g. cerebral palsy with intra-
uterine onset27.  
3. Later-onset constitutional congenital disorders such as family cancer syndromes, 
genetically-determined neurodegenerative disorders, or cardiac disease due to 
bicuspid aortic valve. 
4. Disorders due to genetic risk factors other than rhesus negativity, G6PD deficiency or 
alpha plus thalassaemia. 
If, in the future, the concept of a Global Database of Congenital Disorders gains wider 
support, of these disorder groups may be progressively added. 
Bundling disorder groups for presentation 
All calculations in the Global Database are made separately for the 32 disorder groups in 
Table 2.1. However for clarity in presentation they must be aggregated into fewer, 
meaningful groups. There are relatively small inter-country differences in baseline birth 
prevalence of the first three groups - chromosomal disorders, congenital malformations and 
rare single gene disorders, but there are wide inter-country differences in the birth 
prevalence of consanguinity-associated disorders, haemoglobin disorders, rhesus 
haemolytic disease and G6PD deficiency. Table 2.2 shows the seven resulting “main 
disorder groups” and for each group the range of baseline birth prevalence and estimated 
under-5 mortality with no care. 
Table 2.2. Main groups of congenital disorder as used in this report. 
Main disorder group 
Births /1,000 World average Estimated % under-5 
death if no care Min Max Births /1,000 % of total 
Chromosomal disorders 3.4 5.8 4.0 10.1 57-65 
Congenital malformations 20.7 30.9 21.2 53.4 52-63 
Rare single gene disorders 3.6 4.5 11.4 11.4 
Consanguinity-associated 0 21.6 4.3 10.8 72 
Haemoglobin disorders 0 25.5 3.2 8.2 5-95 
Rhesus haemolytic disease 0.05 6.4 2.2 5.6 50-82 
G6PDd neonatal jaundice 0 2.45 0.2 0.5 77 
Desired outputs 
The first step is to define the desired outputs, since they determine the inputs that are 
needed. To meet the information needs of policy-makers, the Global Database can generate 
the following outputs for each disorder group. 
 Affected birth prevalence in the absence of any intervention (baseline birth 
prevalence). This is the starting point for quantifying the scale of the problem. 
 Outcomes in the absence of any intervention - stillbirth, death, disability at 5 years of 
age28 and lifetime. These are starting points for assessing the effects of interventions. 
 Available interventions. Table 2.3 lists available interventions before pregnancy, 
during pregnancy or after birth, and their potential benefits, and shows those that are 
quantifiable in the Global Database. 
                                               
27 Neurological damage leading to cerebral palsy may occur in utero, at birth, or later e.g. due to cerebral malaria. In 
high income settings, the first predominates and birth prevalence is approximately known. 
28 Five years of age is chosen as a critical “end-point” because the present database includes only early-onset 
disorders, which have their greatest impact in terms of mortality within the first five years. In addition, under-5 mortality 
was the chosen outcome point for Millennium Development Goal 4. 
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Table 2.3. Interventions that can affect the birth prevalence and outcomes of congenital disorders29 
Timing of 
intervention 





Anti-D for rhesus negative mothers 
Conversion of potential affected 
pregnancy to unaffected pregnancy  
Yes 
Multi-vitamin supplementation.  No 
Folic acid food fortification Yes 
Identification of genetic risk, 
information, genetic counselling 
Informed reproductive choice Yes 
During  
pregnancy 
Identification of increased risk, 
information, counselling. 
Prenatal diagnosis  
Informed choice of intervention Yes 
Intra-uterine treatment No 
Option of termination of pregnancy Yes 
Appropriate, timely neonatal care No 
After birth Early diagnosis and care 
Effective cure, or well on treatment Yes 
Improved survival Yes 
Reduced disability Partly 
 Effect of interventions before birth. Actual birth outcomes (termination of pregnancy, 
stillbirth, live birth) 
 Effect of interventions after birth. Actual outcomes to age 5 (neonatal, infant, under-5 
mortality, disability, cure). 
 Current number and age distribution of living affected individuals, untreated or 
treated, in the population. 
 Potential future effects of present policies, and of possible changes in policies, on 
numbers of affected individuals and outcomes. 
Policy-makers also seek an assessment of costs and benefits. It is not possible to give an 
assessment of financial costs, as these vary widely depending on country. In addition, many 
of the human costs associated with congenital disorders are difficult to quantify. 
Nevertheless, the above outputs go a long way to providing a basis for formal economic 
analysis at the country level. 
Inputs required 
Evidence-based estimates for most of the desired outputs can be generated from the 
following inputs. 
For every country 
 Basic demographic data. Most of the necessary date is available from the UN World 
Population Prospects (WPP) (http://esa.un.org/unpd/wpp). WPP provides country 
estimates from 1950 to 2015, with projections to 2100 using different assumptions. 
Rates for stillbirths, neonatal mortality and parental consanguinity are obtained from 
other sources (see Article 4: Uses of demographic and geographic data). 
 Estimated access to services. This is calculated on the basis of infant mortality (see 
Article 5: Estimating access to services.) 
For each disorder group 
 Baseline birth prevalence (the prevalence that would apply in the absence of any 
intervention): total affected births, stillbirths, live births per 1,000 live births. 
 Available interventions before pregnancy, during pregnancy, and after birth. 
o Historical evolution of each intervention over time. 
                                               
29 Obviously, these interventions form part of a comprehensive package including interventions for both 
environmentally- determined and constitutional congenital disorders. 
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o Effects of interventions in terms of the quantifiable benefits listed in Table 2.3. 
 Survival of live-born affected individuals (a) in the absence of care and (b) with 
optimal care, by five-year intervals. 
 Proportion of adult survivors expected to achieve universal life objectives such as 
living independently, building a family. 
Demographic input data 
Table 2.4 shows the range of demographic data used in the Global Database. Most are used 
in standard calculations for all disorder groups. The lower three rows show items used for 
specific purposes. 
Table 2.4. Range of demographic data used in the Global Database, by topic 
























Population 1000s • • • • • • • 
Population age distribution • • • • • • • 
Annual births 1,000s • • • • • • • 
Stillbirth rate • • • • • • • 
Neonatal mortality • • • • • • • 
Infant mortality • • • • • • • 
Under 5 mortality • • • • • • • 
Average life expectancy (M & F) • • • • • • • 
Total fertility rate (TFR)   • •  •  
% of mothers 35 plus •       
Coefficient of consanguinity (F)   •  • •  
Access to services is calculated from infant mortality, with adjustment for the effects of parental consanguinity 
and AIDS- related infant deaths, as described in Article 5: Estimating access to services. 
UN World Population Prospects (2015 revision) provides reference data for most items. 
Other data sources are: stillbirths: Blencowe, Vos et al. (2013); neonatal mortality: 
www.childmortality.org, Cousens, Blencowe et al. (2011); coefficient of consanguinity: Bittles 
and Black (2010b), Bittles and Black (2010a), Bittles’ www.consang.net and personal 
communications. 
Aggregating country data for regional and global comparison 
National policymakers are, of course, primarily interested in data for their own country. 
Detailed tabular country data is best published online to enable rapid access, and to allow 
for updating to reflect changes with time. For more general purposes and to aid comparisons 
and benchmarking, countries must be bundled into regions that are appropriate for the 
relevant audience. WPP 2015 bundles 233 UN countries/territories geographically into six 
continental regions and 24 sub-regions, but other organisations bundle them differently 
depending on their objectives (see Article 4: Uses of demographic and geographic data). 
The WHO bundles them administratively and pragmatically into six regions each served by a 
regional office - the African Region (AFR), American Region (AMR), Eastern Mediterranean 
Region (EMR), European Region (EUR), South East Asian Region (SEAR), and Western 
Pacific Region (WPR). The Global Burden of Disease (GBD) study30 bundles them into 
seven super-regions and 21 sub-regions: GBD bundling has the advantage that it also takes 
account of income level, a key determinant of health service development. 
                                               
30 www.healthdata.org/gbd 
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Because this project is designed to support policy-making at the national level, facilitated by 
the relevant WHO Regional Office, it is appropriately illustrated using the WHO regions31. 
However their large size and the wide range of countries/territories covered by each region 
obscures important differences. To enable more fine-grained presentation of estimates we 
therefore created a set of provisional sub-regional country groups intended to reflect the 
approximate level of health services development, and so based on GBD sub-regions as far 
as possible. 
Table 2.5 lists the countries/territories included in each WHO region and provisional sub-
region generated in this way. Table 2.6 shows average annual births and infant mortality by 
WHO region and sub-region in 1990-94, and 2010-14, i.e. spanning the operational period of 
Millennium Development Goal 4 (MDG4) “to reduce by two-thirds, between 1990 and 2015, 
the under-five mortality rate”. 
Interventions are most fully deployed at the population level in high income settings, though 
local policies may limit e.g. folic acid food fortification or access to termination of pregnancy. 
Thus when a WHO region includes a high income sub-region this may be seen as a local 
reference region that demonstrates the potential effects of available interventions throughout 
that WHO region. 
The use of reference populations 
Western Europe is used as a global reference region because it includes a large population 
(currently 4.5 million births annually) in which available interventions (apart from folic acid 
food fortification) are near-equitably deployed at the population level, and their actual impact 
is recorded (e.g. by registries) or can be assessed by other means. Data for Western Europe 
can therefore be used to assess the maximum achievable effect (the “power”) of the 
interventions when fully deployed, and results can be used to project the likely effects of 
future choices to deploy these interventions elsewhere.32  
Other high income sub-regions that could be used as regional reference populations include: 
the North American and South America High Income regions for AMR, the Gulf States for 
EMR, and Asia Pacific High Income for WPR. However for these, most rates are calculated 
using the Database rather than directly observed as in Western Europe. There are no 
corresponding high income reference regions for AFR and SEAR. 
For these reasons, observed rates for Western Europe are included for comparison in most 
charts and tables. 
                                               
31 In addition, the present project is supported by the WHO Office for the Eastern Mediterranean Region. 
32 This should not be taken to imply that all interventions should be deployed as in Western Europe – e.g. termination of 
pregnancy for fetal impairment is politically and socially accepted in most of Europe but this may not be the case 
elsewhere.  
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Table 2.5. Bundling of countries/territories by WHO Region, and the provisional sub-regions used for more fine-
grained presentation of data from the Modell Global Database 
WHO African Region (AFR) 
North Africa. Algeria, Western Sahara. 
Sub-Saharan Africa. Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, 
Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, 
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, 
Mauritius, Mayotte, Mozambique, Niger, Nigeria, Réunion, Rwanda, Saint Helena, Sao Tome and Principe, 
Senegal, Seychelles, Sierra Leone, South Sudan, Togo, Uganda, United Republic of Tanzania, Zambia. 
Southern Africa. Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe. 
WHO American Region (AMR) 
North America. Canada, Greenland, Saint Pierre and Miquelon, United States of America. 
Caribbean. Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Belize, Bermuda, British Virgin Islands, 
Caribbean Netherlands, Cayman Islands, Cuba, Curaçao, Dominica, Dominican Republic, French Guiana, 
Grenada, Guadeloupe, Guyana, Haiti, Jamaica, Martinique, Montserrat, Puerto Rico, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines, Sint Maarten (Dutch part), Suriname, Trinidad and Tobago, Turks and 
Caicos Islands, United States Virgin Islands.  
Central America. Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, 
Venezuela (Bolivarian Republic of). 
South America. Bolivia (Plurinational State of), Brazil, Ecuador, Paraguay, Peru. 
South America High Income. Argentina, Chile, Falkland Islands (Malvinas), Uruguay. 
WHO Eastern Mediterranean Region (EMR) 
Gulf States. Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates. 
North Africa /Middle East. Egypt, Iran (Islamic Republic of), Iraq, Jordan, Lebanon, Libya, Morocco, State of 
Palestine, Sudan, Syrian Arab Republic, Tunisia, Yemen. 
South Asia. Afghanistan, Pakistan. 
East Africa. Djibouti, Somalia, South Sudan. 
WHO European Region (EUR) 
Western Europe. Andorra, Austria, Belgium, Channel Islands, Cyprus, Denmark, Faeroe Islands, Finland, 
France, Germany, Gibraltar, Greece, Holy See, Iceland, Ireland, Isle of Man, Israel, Italy, Liechtenstein, 
Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, United 
Kingdom. 
Central Europe. Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, 
Poland, Romania, Serbia, Slovakia, Slovenia, TFYR Macedonia. 
Eastern Europe. Belarus, Estonia, Latvia, Lithuania, Republic of Moldova, Russian Federation, Ukraine. 
Middle East. Turkey. 
Central Asia. Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan. 
WHO South East Asian Region (SEAR) 
South Asia. Bangladesh, Bhutan, India, Nepal. 
Southeast Asia. Indonesia, Maldives, Myanmar, Sri Lanka, Thailand, Timor-Leste,  
East Asia. Dem. People's Republic of Korea 
WHO Western Pacific Region (WPR) 
East Asia. China, Mongolia. 
Southeast Asia. Cambodia, Lao People's Democratic Republic, Malaysia, Philippines, Viet Nam. 
Asia Pacific High Income. Brunei Darussalam, China, Hong Kong SAR, China, Macao SAR, Japan, Other non-
specified areas (Taiwan), Republic of Korea, Singapore. 
Oceania. American Samoa, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Micronesia 
(Fed. States of), Nauru, New Caledonia, Niue, Northern Mariana Islands, Palau, Papua New Guinea, Samoa, 
Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna Islands. 
Australasia. Australia, New Zealand. 
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Table 2.6. WHO regions and proposed sub-regions, with average infant mortality and annual births, 1990-2014 
(WPP 2015 revision) 
WHO sub-region 
Infant deaths /1,000 live births Annual births 
1990-94 2010-14 1990-94 2010-14 
North Africa (Algeria, Western Sahara) 47.9 30.4 798 960 
Sub-Saharan Africa 115.1 64.8 20,615 31,399 
Southern Africa 52.6 42.1 1,664 1,871 
AFR Total 108.3 62.6 23,077 34,230 
North America 8.6 5.9 4,429 4,365 
Caribbean 45.3 26.9 882 791 
Central America 33.3 18.5 4,981 4,710 
South America 46.6 21.7 4,908 4,414 
South America High Income (Argentina, Chile) 22.9 12.2 1,058 1,039 
AMR Total 30.6 15.8 16,257 15,319 
Gulf region 28.2 12.7 759 913 
EMR middle income 103 21.0 5,099 6,982 
EMR low income 127.6 66.6 597 9,011 
EMR Total 73.1 44.8 13,951 16,906 
Western Europe 6.8 3.3 4,429 4,424 
Central Europe 17.1 6.3 1,567 1,173 
Eastern Europe 20.5 8.2 2,464 2,530 
Middle East (Turkey) 56.2 12.6 1,381 1,304 
Central Asia 63.6 33.4 1,822 1,865 
EUR Total 25.8 10.7 11,662 11,296 
South Asia 83 40.3 31,967 29,722 
Southeast Asia 52.9 25.7 7,174 7,224 
East Asia (North Korea) 42.1 22 436 358 
SEAR Total 77.1 37.3 39,577 37,304 
East Asia 40.5 11.7 22,699 16,938 
Southeast Asia 38.5 21.6 5,118 4,941 
Asia Pacific High Income 6.2 2.6 2,397 1,838 
Oceania 58.7 41.9 227 279 
Australasia 6.9 4 318 372 
WPR Total 37.3 13.3 30,759 24,368 
World 63 35.8 135,284 139,840 
Note 1. Sub-regions for five of the WHO regions are based on GBD sub-regions. This was not possible for the 
EMR as the GBD uses a single North Africa/Middle East/Central Asia region (even though the countries included 
range from the Gulf States at one extreme of economic development to Somalia and Djibouti at the other). 
Therefore for the purposes of the Global Database EMR countries are bundled into four sub-regions based on 
infant mortality. 
Note 2. Naming can be confusing when one GBD sub-region spans more than one WHO region, especially when 
only one or two countries are involved. In such cases the names of the countries concerned are also shown in 
the table. For the sake of clarity these country names are then used in relevant tables throughout this series. 
Estimating access to services 
Outcomes at the extremes – those in the absence of diagnosis and care, and with optimal 
care (i.e. when all interventions are fully and equitably available) - can be characterised for 
most groups of congenital disorders. In the highest income countries, average outcomes will 
be close to those for optimal care, while in the lowest income countries outcomes will be 
closer to those in the absence of care. However, the majority of countries lie somewhere 
between these two extremes. Estimates for these countries can be obtained by combining 
estimates for the two extremes in proportions that reflect an estimate of access to optimal 
services. 
However no readily-accessible source for assessments of access to services exists. To fill 
this gap when estimating the global burden of neonatal morbidity the WHO Child Health 
Epidemiology Reference Group (CHERG) estimated access in relation to five neonatal 
mortality groups (Blencowe, Vos et al. 2013) and considered that neonatal mortality of less 
than 6/1,000 (equivalent to an infant mortality of around 10/1,000) indicates that a population 
has near 100% access to optimal care. This is consistent with an earlier WHO estimate that 
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infant mortality can only fall below 10/1,000 when services for congenital disorders are 
available (WHO 1985a). The term optimal care as used here therefore applies to the range 
of services typically available when infant mortality is 10/1,000 or lower. 
Using the CHERG estimates as a starting-point, we developed an equation based on infant 
mortality for estimating the proportion of each population with access to optimal services 
(see Article 5: Estimating access to services for details). 
Using the BETA.DIST function in Microsoft Excel the equation is: 
Proportion with access = (1-BETADIST(LN(IMR-10),2.5,5.5,0,LN(1000))) 
Figure 2.1 shows the proportion of the population of each WHO region estimated to have 
access to optimal care from 1950 to 2015, using this equation. 
 
Figure 2.1. Chart showing increasing proportion of the population with access to optimal services by WHO region, 
1950-2015, calculated from infant mortality using the equation described in Article 5: Estimating access 
to services. In the Western European reference region average infant mortality in 1950 was over 
40/1,000. It fell below 10/1,000 in the 1980s, coinciding with the development of key services for care 
and prevention of congenital disorders, summarised in Table 2.11.  
The estimate that the Western European population only obtained access to optimal 
services in the 1980s, which seems surprising at first sight, reflects the fact that infant 
mortality in the region was over 40/1,000 in 1950, and many services now considered 
routine were developed during the 1970s and 1980s (see Table 2.11).  
Baseline birth prevalences 
The level of a disorder in a population is usually described in terms of incidence (number of 
new cases arising in a defined time period) and prevalence (cases present in a given unit of 
population e.g. per thousand or per million). The true incidence of congenital disorders is the 
rate at which they arise - usually at or soon after conception. However so many affected 
embryos may fail to implant or miscarry that the true incidence is hard to establish and may 
bear little relationship to their prevalence at birth, the rate of greatest importance for health 
services. Therefore for practical purposes their birth prevalence is treated as their incidence, 
and expressed as affected births per /1,000 total births. 
Baseline, or potential, birth prevalence is the prevalence that would apply in the absence of 
any intervention. It provides the foundation of the Global Database because it is the estimate 
with the strongest evidence base. Since it is relatively constant for any given population it 
also provides an “envelope” into which all outcomes must “fit”. For this reason the sources 
used to derive baseline birth prevalences must be considered in some detail. Baseline birth 





























































































































The definition of miscarriage depends on the definition of stillbirth, which differs widely by 
country (see below). To solve this problem EUROCAT reports numbers of “fetal deaths” 
defined as death in utero after 20 weeks’ gestation33. By implication losses before 20 weeks’ 
gestation are viewed as miscarriages. The Global Database follows this convention. It does 
not include miscarriage, and uses fetal death as a proxy for stillbirth. 
Birth outcomes 
Following the EUROCAT convention, all pregnancy outcomes after 20 weeks’ gestation are 
counted as births. 
Terminations of affected pregnancies 
Since practitioners aim to achieve a definitive prenatal diagnosis as early in pregnancy as 
possible, many terminations for fetal impairment occur before 20 weeks’ gestation, but some 
of these pregnancies would have miscarried spontaneously in the absence of intervention. 
Total terminations must therefore be adjusted using known rates for fetal loss in relation to 
gestational age. Only cases where the pregnancy would otherwise have continued past 20 
weeks are included in the Global Database.  
Fetal death and stillbirth 
The legal definition of stillbirth ranges by country from death in utero after 20 weeks’ 
gestation to death after 28 weeks’ gestation, and may or may not also take account of 
weight. In addition, reporting varies with country, time and social attitudes. The ICD10 
definition of stillbirth is death in utero after 22 completed weeks’ gestation (WHO (2006), 
Stanton, Lawn et al. (2006)), but the current WHO definition is fetal death in the third 
trimester (≥1000 g birthweight or ≥28 completed weeks of gestation) (Cousens, Blencowe et 
al. 2011).  
EUROCAT manages the inconsistent definition of stillbirth by reporting all in utero deaths 
after 20 weeks’ gestation as “fetal deaths”, and uses this figure as a proxy for stillbirth, e.g. in 
estimating perinatal mortality associated with congenital anomalies. This convention is 
followed in the Global Database, and the term “fetal death/stillbirth” is used to ensure clarity. 
Live births 
For most disorder groups, the birth prevalences of congenital anomalies used to calculate 
annual affected births etc. in the Global Database are total birth prevalences (i.e. include 
terminations of pregnancy and fetal deaths). In these cases live births are estimated by 
subtracting termination and fetal death rates from total affected births. 
However the WPP birth data which provides the main denominator for calculating birth 
prevalence applies for live births only34. This leads to slight under-estimation of both total 
affected births and affected live-births. 
Premature births 
Though 7-8% of births are pre-term, 18% of congenital anomalies occur in pre-term infants. 
Honein, Kirby et al. (2009) found an average malformation rate of 80/1,000 among pre-term 
babies compared with 30/1,000 among term babies, the extent of association differing with 
degree of prematurity and malformation group (Table 2.7).  
                                               
33 See EUROCAT Guide 1.4 available at www.eurocat-network.eu 
34 This is not obvious on the WPP website, or in the associated glossary. However the UN Demographic Yearbook 
series (UNDY) specifies that births = live births: we assume this also applies for WPP birth data.  
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Table 2.7. Association of major malformation groups with prematurity in 8.88 million births: ranked in descending 











Very pre-term  
(24 to 31 wk) 
Moderately pre-term 
(32 to 36 wk) 
Population rate   7.7   
Abdominal wall 3,076 0.46 43 7.7 9.2 
Central Nervous System 16,215 2.40 34 16.2 4.3 
Respiratory tract 10,722 1.58 26 11.5 2.9 
Cardiovascular2 61,898 9.16 26 9.3 3.2 
Gastrointestinal3 27,338 4.05 21 5.0 2.8 
Eye, face, neck, ear 17,863 2.64 20 5.2 2.6 
Genito-urinary 50,056 7.41 18 4.1 2.3 
Musculo-skeletal 66,579 9.85 17 3.4 2.2 
Skin 11,885 1.76 15 2.1 2.0 
Orofacial 9,536 1.41 15 2.8 1.9 
1. The prevalence ratio is the prevalence in pre-term infants as a multiple of the rate in term infants. 
2. Includes patent ductus arteriosus 
3. Includes pyloric stenosis 1.59/1,000 
The causal relationship between congenital disorders and prematurity is unclear: some 
malformations may cause premature birth (e.g. CNS and lung malformations that affect 
formation or circulation of amniotic fluid), others may be caused by it (e.g. cardiac defects 
related to changing blood flow at birth). Congenital anomaly registries as a rule do not report 
on prematurity, except to exclude prematurity-related persistent patent ductus arteriosus. 
Therefore, because of lack of data, no allowance is currently made for this association in the 
Global Database.  
Classical studies of birth prevalence 
Extensive studies of the birth prevalence of congenital disorders were conducted in the 
aftermath of the second world war, in order to establish a baseline for assessing possible 
effects of exposure to atomic radiation, on the assumption that an increase in mutation rate 
would manifest as increased birth prevalence of affected children (United Nations. Scientific 
Committee on the Effects of Atomic Radiation. (1977), (1982) and (1986))35. Table 2.8 
shows the most important of these classical studies and the disorder groups surveyed. 
Although the range of diagnoses included differed between studies, the rates observed were 
broadly consistent, and were generally considered to apply world-wide (Baird, Anderson et 
al. 1988). 
These studies have the advantage that they predate the introduction of interventions that 
reduce affected birth prevalences (e.g. periconceptional vitamin supplementation, 
termination of pregnancy for fetal impairment), or increase detection rates (e.g. routine fetal 
anomaly scanning, sophisticated neonatal screening). The rates observed therefore 
represent uncomplicated baseline birth prevalences. 
                                               
35 The Hungarian registry enabled reassurance for the Hungarian population on after-effects of the Chernobyl disaster 
(). 
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Neel (1958)  +  
Stevenson (1959)  +   +   +  
Stevenson, Johnston et al. (1966)   +   
Trimble and Doughty (1974)  +   +   +  
Myrianthopoulos and Chung (1974)   +   
Carter (1977)    +  
Ash, Vennart et al. (1977)  +   +   +  
Hook and Hamerton (1977)  +    
Czeizel and Sankaranarayanan (1984)  +   +   
Baird, Anderson et al. (1988)  +   +   +  
Note. All studies included only disorders that cause early death or life-long disability in the absence of 
intervention. 
Concern about atomic radiation, proof of the effect of rubella infection during pregnancy, and 
the thalidomide disaster of the 1960s led to recognition of the need for ongoing surveillance 
of congenital anomalies, and ultimately to initiation of the International Clearing House for 
Birth Defect Surveillance and Research (ICBDSR, www.icbdsr.org) in 1974, and the linked 
European Surveillance of Congenital Anomalies (EUROCAT, www.eurocat-network.eu) 
network in 1979. These “umbrella registries” are a key source of reference data and have 
the outstanding advantage that in addition to reporting birth prevalences, most participating 
registries also record birth outcomes including termination of pregnancy for fetal impairment, 
fetal death/stillbirth, and live birth, and so enable the effect of prenatal diagnosis with the 
option of termination of pregnancy to be quantified. 
Sources for rates used in the Global Database 
Table 2.1 shows the sources for the total birth prevalences used in the Global Database. 
Table 2.10 shows rates for total affected births and fetal deaths/stillbirths. Sources for fetal 
death/stillbirth rates are: chromosomal disorders and congenital malformations, EUROCAT 
data adjusted for associations; multiple malformations, J Rankin, personal communication re 
Tennant, Pearce et al. (2010); consanguinity-related and recessive disorders, Bundey and 
Alam (1993) and Bittles and Black (2010b); Rhesus haemolytic disease, from the literature. 
Avoiding double counting when categories overlap 
To ensure scientific rigor, it is necessary that numbers be counted as accurately as possible, 
and to show how possible errors are avoided. The overlap between categories in Figure 1.1 
in the introductory article indicates that there can be a risk of double counting. 
Given the appropriate inputs, the precise outputs desired and the way in which they are 
calculated depend on the objective of the particular exercise. For example, the Born Healthy 
toolkit (Nacul, Stewart et al. (2014) and http://toolkit.bornhealthy.org) promotes assessment 
of service needs. For this purpose, the number of all conditions must be summed, that is, 
individuals who appear in overlapping categories must be counted more than once. Thus the 
need for paediatric cardiac surgery is assessed by summing all cases of congenital heart 
disease, whether isolated, associated with another type of malformation, or part of a 
chromosomal or genetic syndrome.  
The objective of the present exercise is to estimate numbers of individuals with one or more 
congenital disorders, and outcomes for those individuals in terms of survival, disability, and 
mortality. The existence of overlapping categories therefore causes a serious risk of inflating 
estimates by double counting. There are two sources of risk, both associated with congenital 
malformations. (1) Congenital anomaly registries include all cases with a detectable 
malformation independent of cause, while the other three categories are based on cause, 
creating overlap between groups. (2) Most congenital anomaly registries report numbers of 
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malformations rather than numbers of affected individuals, in the process counting 
individuals with more than one type of malformation multiple times. 
In the Global Database double counting is avoided as follows. 
1. A chromosomal disorder usually represents a complex syndrome, often including 
malformations. Fortunately the umbrella registries distinguish between chromosomal-
associated malformations and non-chromosomal malformations. Chromosomal-
associated malformations are treated as part of the relevant chromosomal syndrome. 
2. Malformations associated with single gene disorders (e.g. skeletal dysplasias) or 
other genetic syndromes, and consanguinity-associated congenital malformations36 
are included with single gene disorders. 
3. The two early-onset genetic risk factors included (rhesus negativity and G6PD 
deficiency) do not overlap with other groups of constitutional congenital disorders. 
These steps remove sub-groups of malformations, leaving a large group of non-syndromic 
congenital malformations. In order to obtain numbers of affected individuals, this group must 
be adjusted for double counting, i.e. it is necessary to distinguish individuals with isolated 
congenital malformations (affecting only one system) from those with multiple malformations. 
Table 2.7 shows that around 16% of non-syndromic malformations are associated, i.e. 
contribute to multiple malformations. It is particularly important to adjust for associations 
when assessing birth outcomes, because termination of pregnancy and fetal death are 
commonest in the multiple malformation group. Adjustment leads to the conclusion that (in 
Western Europe) 11% of malformations in live-borns are associated, compared with 37% in 
terminations and 44% in fetal deaths (Table 2.9). For details of the calculation see Article 7: 
Congenital malformations: birth prevalence and birth outcomes. 
With this approach, the number of individuals with a constitutional congenital disorder is the 
sum of those with a chromosomal disorder, an isolated congenital malformation, multiple 
malformations, a single gene disorder, or a disorder due to the effect of an early-onset 
genetic risk factor.  
Table 2.9. Non-syndromic congenital malformations: adjusting rates for double counting (based on average 
EUROCAT rates for 2005-09, for countries where termination of pregnancy is legal and reported 
  Total  
/1,000 
Birth Outcomes 




Non-syndromic malformations 23.6 20.2 0.4 2.96 
Individuals with 1 or more malformation 19.8 17.9 0.25 1.66 
Difference /1,000 3.8 2.3 0.15 1.30 
% difference 16.0 11.5 37.4 44.1 
% isolated 84 88.5 62.6 55.9 
Baseline birth prevalences used in the Global Database 
Table 2.10 shows the global average baseline prevalences for 2010-14 generated by the 
Global Database. Rates are shown for total birth prevalence, fetal death/stillbirth37 and live 
birth. The figures shown are global averages: actual input data differs by country. The table 
                                               
36 For discussion of malformations related to parental consanguinity, see Article 11: Gene clustering and parental 
consanguinity.  
37 Sources for fetal death/stillbirth rates are as follows. Chromosomal disorders and congenital malformations, 
EUROCAT data adjusted for associations. Multiple malformations, J Rankin, personal communication re Tennant et al. 
(2010). Consanguinity-associated and recessive disorders, Bundey, S. and H. Alam (1993). "A five-year prospective 
study of the health of children in different ethnic groups, with particular reference to the effect of inbreeding." Eur J Hum 
Genet 1(3): 206-219. and Bittles, A. H. and M. L. Black (2010b). "The impact of consanguinity on neonatal and infant 
health." Early Hum Dev 86(11): 737-741. Rhesus haemolytic disease, from the literature 
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indicates groups considered to have closely similar prevalence world-wide and those whose 
birth prevalence is known to differ by country.  
The total global estimate for total affected births of isolated congenital disorders is 40/1,000. 
Figure 2.2 shows the relative contributions of the main disorder groups to this total. 
 
Figure 2.2. Baseline constitutional congenital disorders: total births /1,000, world by WHO Region, ranked in 
descending order of total baseline birth prevalence. Estimates for the Western European reference 
population are included. There is relatively little inter-regional variation for chromosomal disorders and 
congenital malformations (congenital anomalies). Inter-regional differences are mainly due to inter-






































Table 2.10. Average global rates for baseline (potential) birth prevalences of the disorder groups included in the 
Global Database (2010-14) 





Estimated global average, 2010-14 
Potential 
total births 













Down syndrome Maternal age 
related 
1.67 0.08 1.59 4.8 
Other trisomies (+13, +18) 0.69 0.37 0.31 54.7 
Other autosomal Invariant 0.70 0.15 0.55 21.7 
Turner syndrome (XO) Invariant 0.22 0.05 0.18 21.1 




Anencephaly Country rate 1.03 0.51 0.51 50.0 
Spina bifida & encephalocele Country rate 1.12 0.10 1.02 9.0 
Oro-facial clefts Country rate 0.92 0.01 0.91 1.5 
Very severe CHD Invariant 0.39 0.01 0.38 2.9 
Severe CHD Invariant 2.94 0.02 2.92 0.7 
CNS not neural tube defect Invariant 0.87 0.03 0.84 3.8 
Eye Invariant 0.27 0.00 0.27 0.2 
Ear, face, neck Invariant 0.27 0.00 0.27 1.3 
Respiratory system Invariant 0.49 0.03 0.46 6.1 
Digestive system Invariant 0.96 0.01 0.95 1.2 
Abdominal wall defects Invariant 0.36 0.02 0.33 6.2 
Urinary system Invariant 2.59 0.03 2.56 1.3 
Multiple malformations Invariant 1.41 0.07 1.33 5.1 
Genital system Invariant 1.77 0.00 1.76 0.2 
Limb Invariant 3.42 0.03 3.39 0.9 
Additional 
conditions 
Congenital hypothyroidism Country rate 0.21 0.00 0.21 0.0 
PDA assoc w prematurity Invariant 0.30 0.00 0.30 0.0 
Pyloric stenosis Country rate 0.87 0.00 0.87 0.0 
Single gene 
disorders 
Dominant Invariant 1.40 0.00 1.40 0.0 
X-linked Invariant 0.05 0.00 0.05 0.0 
Recessive (baseline) Invariant 1.95 0.29 1.66 14.9 
Consangunity-related Country rate 6.50 0.97 5.53 14.9 
Sickle cell disorders Country rate 2.75 0.00 2.75 0.0 
Thalassaemias Country rate 0.42 0.00 0.42 0.2 
Genetic risk 
factors 
Rhesus haemolytic disease Country rate 1.20 0.30 0.90 25.0 
G6PDd kernicterus Country rate 1.30 0.00 1.30 0.0 
Estimated global total  39.8 3.1 36.6 7.9 
Available interventions 
There are only three possible outcomes for early-onset congenital disorders in the absence 
of intervention - fetal death, premature death, and life with some degree of disability. 
Table 2.11 summarises the evolution of the interventions listed in Table 2.3 by disorder 
group and decade. The timeline indicates introduction of the methods: this does not equate 
to their universal deployment, even in high income settings.  
With these interventions the number of possible outcomes increases to six: 
1. Affected birth converted into unaffected birth, or avoided, by pre-conception 
intervention 
2. Affected birth avoided by intervention during pregnancy 
3. Stillbirth/fetal death (pregnancy loss after 20 weeks’ gestation) 
4. Early death (neonatal, infant, under-5 death) 
5. Disability (classed here only as severe, mild/moderate, or well on treatment) 
6. Effective cure (enabling near-normal length and quality of life, even with residual 
problems) 
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Improvements in diagnosis and care not only reduce the birth prevalence of affected infants; 
they also prolong the survival and ameliorate the levels of disability of children with incurable 
disorders, and so cause a steady increase in the cumulative number living with these 
disorders and requiring appropriate care. The evolution of this effect needs to be quantified 
in order to assess service needs.  
Table 2.11. Evolution over time of the interventions available for congenital disorders 
 
Survival and early mortality with optimal care and with none 
Table 2.12 shows the main sources used in the Global Database for estimating survival in 
the absence of care, and with optimal care. The upper age limit of the observational data is 
also shown. 
Table 2.12. Principal sources of data on survival with congenital disorders 






Down syndrome  
Baird and Sadovnick (1987), 
(1988) 
Life time 
Penrose (1949);  
Carter (1958);  
Stevenson (1959) 
Frid, Drott et al. (2004). 1 yr  
Other trisomies Wu, Springett et al. (2013) 5 yr Lethal 
Other autosomal Est. 10% <Down    Est. 10% <Down syndrome 
Turner syndrome 
Price, Clayton et al. (1986) 
Stochholm, Juul et al. (2006) 
60 yr Mortality est. 2 × optimal care  
Klinefelter syndrome Bojesen, Juul et al. (2004) 
Assumed 
normal 
Bojesen, Juul et al. (2004) 
Congenital 
malformations 
Anencephaly Lethal  Lethal 
Spina bifida & 
encephalocele  
Hunt and Oakeshott (2003); 30 yr 
Lorber (1971); 
Laurence and Tew (1971) 
Bowman, McLone et al. (2001) 
Tennant, Pearce et al. (2010) 
20 yr 
Oro-facial clefts Christensen, Juel et al. (2004) Life time Smile Train data; Raju (2000) 





anti -D, Rh-ve mothers





Single gene disorders Counsel l ing on recurrence risk




Serum markers , 
1st trimester PND
US markers , 




Neural  tube defects Amnio & AFP
Maternal  serum 
AFP, ul trasound
Routine feta l  
anomaly scan
1st trimester US
Congen heart disease 4-chamber scan
Other congen malfns






CVS & DNA: 
1st trim PND
Other s ingle gene
Rhesus  disease Amnio, IU transfn
Chromosomal  disorders Mandatory care Repair of CHD
NTD (spina  bi fida) Selective closure routine closure
Oro-facia l  clefts Surgica l  repair
Pyloric s tenos is Surgica l  repair
Congen heart disease Repair PDA
Repair "mi ld" 
defs




Other congen malfns NN exam: surgica l  repair
Improved 
techniques
Congen hypothyroidism NN screen, Rx
Hb: tha lassaemia Transfus ion, parentera l  Fe chelation
Oral  i ron 
chelation
Hb : s ickle cel l NN screen & care
Some metabol ic disorders NN screen, Rx
Decade








Antenatal risk identification & prenatal diagnosis
Diagnosis & care, live-born affected
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Wren and O'Sullivan (2001) 
Tennant, Pearce et al. (2010); 
Wren, Irving et al. (2012) 
20 yr C Wren personal communication 
CNS not NTD 
Tennant, Pearce et al. (2010); 
Skjaerven, Wilcox et al. (1999); 
Lie, Wilcox et al. (2001) 
20 yr: 
Tennant, 




Wilcox et al. 
(1999) and 
Lie, Wilcox et 
al. (2001) 
Expert opinion (AC & BM) 
Eye 
Ear, face, neck 
Respiratory system 
Digestive system 













  PDA assoc w prem Campbell (1968) 
  Pyloric stenosis Lethal 
Rare single gene 
Dominant 
Costa, Scriver et al. (1985) 
Life time 
estimates  
Estimates based on Baird, 
Anderson et al. (1988) 
X-linked 
Rare recessives  
Consanguinity-
associated. 




Modell, Khan et al. (2000) and 
(2008) 
45 yr Modell and Berdoukas (1984) 
Hb sickle cell Platt, Brambilla et al. (1994) life time Fleming, Storey et al. (1979) 
Genetic risk 
factors 
Rhesus negativity Bhutani, Zipursky et al. (2013) Assumed 
normal 
Stevenson (1959) 
G6PD deficiency WHO (1985b) WHO (1985b) 
Survival is usually expressed as percentage of affected individuals born in a given year who 
are still alive by given age intervals, and charted as a survival curve. Age intervals used for 
congenital disorders are usually birth to 1 month, to 1 year, to 5 years and then by 5-year 
intervals. Mortality is the complement of survival. As an example, Figure 2.3 shows the 
survival curves used for oro-facial clefts with optimal care and no care.  
 
Figure 2.3. Survival with oro-facial clefts (OFCs) with no care (China, India) and optimal care (Denmark). 
(Calculations of P Mossey and B Modell, based on analysis of accounting data from the Smile Train 
NGO38, and Christensen, Juel et al. (2004)39). Mean life expectancies calculated from the curves are: 
OFC with no care, 4.4 years. OFC with optimal care 74.5 years, compared with average 79.5 years for 
the Danish population. Importantly, the curve also shows that residual problems can continue to affect 
people with corrected congenital malformations. For this reason cure is described as “effective cure” in 
the Global Database. 
                                               
38 www.smiletrain.org.uk 
39 Christensen found that people born with oro-facial clefts had a life time 1.4 relative risk of dying, with only minor 
differences related to sex, age or year of birth. This relative risk was applied to WPP survival data for the Danish 


































































































The ideal survival curve would cover the entire potential life span from birth, but Table 2.12 
shows that this data is not always available. However, for most congenital disorders mortality 
is highest within the first five years of life, the period for which survival data both with no care 
and with optimal care is most complete and most reliable. Therefore current data allows 
reasonably reliable estimation of early mortality in the Global Database. However it must be 
kept in mind that available survival data usually lags behind the current situation, especially 
when there are significant technical advances in care. 
Calculating early mortality – neonatal, infant and under-5 
Table 2.13 shows rates based on the literature for neonatal, infant and under-5 mortality with 
optimal care, and in the absence of care. Details of the way these estimates are obtained 
are given in the articles on different disorder groups. The rates in Table 2.13 are used in the 
Global Database to calculate annual neonatal, infant and under-5 deaths from annual 
affected births. However, most reports, including those of untreated disorders in the older 
literature, originate from high income settings where basic supportive care was available. 
Mortality estimates based on the rates in Table 2.13 are therefore likely to under-estimate 
mortality in lower-income settings. No allowance is made for this in the calculations. 
Total versus attributable deaths 
To avoid double-counting it is important to allow for the overlaps inherent in multiple causes 
of death40. For assessing total deaths of people with a given disorder, all deaths of affected 
individuals must be included, whatever the cause. However when the aim is to assess 
attributable deaths - deaths that are specifically due to a disorder – background mortality 
should also be considered, because some affected individuals who would have died of their 
disorder in fact die earlier from unrelated causes, and the proportion of such deaths varies 
with place and time. That is, mortality should be divided into deaths attributable to the 
disorder and deaths from other causes. No similar adjustment is needed for survival. 
Since the current aim is to estimate attributable deaths, background mortality in the relevant 
country at the time the data was collected (from WPP) is has already been allowed for in 
Table 2.13, which therefore represent mortality due to the disorder in the absence of any 
other cause to obtain disorder-specific attributable mortality41. In the Global Database, the 
resulting “baseline” mortality rates are adjusted for local background mortality, to obtain 
country-specific estimates of attributable mortality (See Annex A4: Calculation of attributable 
early mortality for a worked example). 
To obtain attributable early deaths, numbers are adjusted for deaths from other causes using 
country rates for neonatal, infant and under-5 deaths. The adjustment makes relatively little 
difference in countries where early background mortality is low, but when background 
mortality is high a sizeable difference is observed. Figure 2.4 shows estimated under-5 
mortality in 2010-14 calculated in this way, to illustrate differences between regions and 
disorder groups. 
                                               
40 When a single cause is given this should be the underlying cause of death defined as “the disease or injury which 
initiated the train of morbid events leading directly to death” (www.who.int). 
41 Since most survival data, including that for the no-care situation, was collected in high income settings with low early 
mortality, this adjustment makes relatively little difference for most disorder groups. 
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Figure 2.4. Estimated under-5 deaths due to congenital disorders, 2010-15, by main disorder group. World by WHO 
region, in descending order of total attributable under-5 mortality 
Table 2.13. Estimates of early mortality and mean life expectancy by disorder group, with no care and with 
optimal care 
Main group Disorder group 
No care: % mortality at: 
Optimal care: % mortality 
at: 
1 mo 1 yr 5 yrs 1 mo 1 yr 5 yrs 
Chromosomal 
disorders 
Down syndrome 35 45 69 1 2 6 
Other trisomies 92 100 100 64 92 100 
Other autosomal 42 51 72 11 12 15 
Turner syndr 0 0 0 0 0 0 
Klinefelter syndr 0 0 0 0 0 0 
Congenital  
malformations 
Anencephaly 100 100 100 100 100 100 
Spina bif & e'cele 80 90 93 17 25 33 
Oro-facial clefts 32 41 82 1 1 1 
Very severe CHD   96 97   63 70 
Severe CHD  64 65   9 10 
CNS not NTD 95 95 95 21 27 31 
Eye 28 33 36 0 1 3 
Ear, face, neck 2 7 8 6 6 6 
Respiratory 30 35 40 37 42 42 
Digestive system 65 70 75 14 16 17 
Abd. wall defects 95 100 100 16 19 19 
Urinary system 10 25 40 11 12 12 
Multiple malfns 54 59 61 40 50 53 
Genital system 0 0 0 0 0 0 
Limb 1 2 7 3 3 3 
Additional 
conditions 
Congenital hypothyroidism 0 25 55 0 0 0 
Prem-assoc PDA 15 30 32 0 0 0 
Pyloric stenosis 0 100 100 0 0 0 
Rare single gene 
Dominant   60 100   34 50 
X-linked   35 40   20 25 
Rare recessives   40 50   30 35 
Consanguinity Consanguinity-associated   40 50   30 35 
Haemoglobin 
disorders 
Sickle cell disease   20 80   4 5 
Beta thalassaemia   30 90   1 1 
Genetic risk factors 
Rhesus haem dis.   75 80   0 0 
G6PDd kernicterus   75 80   0 0 
Note. Figures for mean life expectancy with optimal care are for the situation in the absence of preventive 
interventions (e.g. prenatal diagnosis). Since prenatal diagnosis leads to termination of pregnancy of the most 
severely affected fetuses, it tends to increase the observed survival of life-born affected infants. 
Disability and cure with optimal care, and with none 
Definitive cure of conditions currently included in the Global Database is limited to 




































disorders live some disability. This can range from well on care42 (e.g. congenital 
hypothyroidism with regular replacement treatment) to the very severe (e.g. associated 
severe physical and mental disability). Because of this diversity, in the Global Database 
quantification of physical disability is limited to estimates of the proportion of survivors at age 
five with severe disability (including shortened life expectancy), mild to moderate disability 
(with less or no effect on life expectancy), well on treatment (a near-normal life expectancy 
with no physical or mental disability)43 and effectively cured. 
Table 2.14 shows the estimated proportion of each outcome by disorder group as used in 
the current database. However it is hard to obtain the desired rates from the literature (oro-
facial clefts are an exception) and they need much improvement. In the current Global 
Database they are used mainly as place-holders. 
Table 2.14. Provisional estimates of disability with optimal care and no care used in the Global Database 
Disorder group 















Down syndrome     100   100 
Other autosomal     100   100 
Turner syndrome    100  100  
Kleinfelter syndrome    100  100  
Spina bifida and e'cele 0   0 100 0 100 
Oro-facial clefts 80  20 0 0 100 
Congenital heart disease 80  12 8 80 20 
CNS not NTD 0  30 70 0 100 
Eye 50  50 0 0 100 
Ear, face, neck 60  40 0 0 100 
Respiratory 90  10 0 0 100 
Digestive 90  10 0 0 100 
Abdominal wall 95  5 0 0 100 
Urinary 95  5 0 50 50 
Multiple malformations 5  25 70 0 100 
Genital 95  5 0 100 0 
Limb 95  5 0 90 10 
Congenital hypothyroidism 0 100 0 0 0 100 
PDA assoc w prematurity 100  0 0 80 20 
Pyloric stenosis 100   0 0 lethal lethal 
Dominant    20 80 20 80 
X-linked    25 75 25 75 
Recessive (not 
consanguinity-associated  
  2 10 88 10 90 
Consanguinity-associated   2 10 88 10 90 
Sickle cell disorders    50 50 10 90 
Thalassaemias   30 60 10 10 90 
Rhesus haemolytic disease 100       50 50 
G6PDd kernicterus 100    50 50 
Outputs of the Method 
The Global Database generates the following outputs, designed to meet the needs of policy-
makers. As with inputs, they are divided into outputs at age 5 and long-term outputs. 
Outputs to age 5: 
 Baseline affected birth prevalence (scale of the problem) 
 Potential outcomes in the absence of intervention (the no-care situation) 
                                               
42 Normal life expectancy and quality of life as long as treatment is maintained. 
43 Not included in the 2015 version of the Global Database: to be included in the 2016 version. 
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 Effects of interventions before birth 
 Actual birth prevalence and birth outcomes 
 Effects of interventions after birth on survival and disability 
 Actual outcomes for live born: early deaths, disability, cure 
Long-term outputs: 
 Estimated years of life lost, lived with disability or lived cured. 
 Estimated number and age distribution of living affected individuals. 
 Future projections: potential effects of present policies, and of changes in policy on 
numbers and outcomes. 
 Improved assessment of costs and benefits 
Expressing Outputs for Various Audiences 
Though the primary target is those seeking to formulate policy in this area, they are not the 
only people with an interest, and different audiences prefer to use data in different ways. 
Tailoring the presentation of outputs requires several decisions to be made. 
 Rates or numbers? Rates (usually /1,000 births) are best for comparisons between 
countries, regions and time periods. The primary emphasis in these methods articles 
is on rates, to enable comparisons between WHO regions and sub-regions. 
However, for planning purposes policy-makers usually also want numbers. Country-
specific rates and numbers are both available in the online presentation. 
 Rates may be calculated using different denominators. Population number is the 
usual denominator in a public health context (e.g. the incidence of a disorder = new 
cases /100,000 population/year). By contrast, annual births are the usual 
denominator for rates for congenital disorders (e.g. affected births or under-5 deaths 
/1,000 births), and this convention is used throughout the Global Database. 44 
Expression in terms of births /1,000 enables more reliable comparisons between 
countries and regions than rates /100,000 population (See Annex A3: Different ways 
of expressing incidence).  
 When it is desirable to harmonise Global Database rates with major public health 
enterprises such as the Global Burden of Disease (GBD) study, they can be re-
calculated as rates /100,000 population. Alternatively, as the GBD reports numbers 
as well as rates, GBD numbers can be related to WPP annual births to obtain rates 
/1,000 births. This method is used for the comparison between GBD and Global 
Database estimates of early mortality summarised in Annex A1: Comparison of GBD 
and Global Database under-5 mortality estimates. 
 The use of births as a denominator is extended in the Global Database to the 
description of costs and benefits. For example years of life lost, lived with disability or 
lived cured are calculated in terms of average implications for each member of the 
relevant birth cohort. 
 Tables or charts? Tabular data is required for planning purposes, and can be used to 
produce graphical visualisations, but can also lack communicative immediacy for the 
general reader. Charts can convey complex information at a glance and so are best 
for introducing an argument or summarising results. However in this context they can 
                                               
44 Affected birth prevalence is calculated in congenital anomaly registries as rate /10,000 total births (stillbirths and live 
births). For use in the Global Database these are translated to rates /1,000 total births. However the Global Database 
uses WPP birth estimates for calculating affected births, but these apply only for live births. This calculation therefore 
results in modest under-estimation of numbers affected. 
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only be used for comparing rates, because vast differences in population sizes mean 
that large populations dominate any chart showing absolute numbers. Therefore 
when relevant a supporting table is provided in the Table Annexe. 
Outputs to 5 years of age 
This section gives examples of each of the above outputs, charted by WHO region. Rates for 
Western Europe are included as the global reference region for assessing effects of 
interventions. See the Table Annexe for supporting data. All rates shown are for 2005-09, 
calculated using WPP 2012 revision.45 
Baseline birth prevalence and no-care birth outcomes  
Figure 2.2 shows estimated baseline birth prevalence by WHO region and main disorder 
group. Despite inter-country differences baseline birth prevalence is relatively constant for 
any given country, and provides an objective measure of the scale of the problem. All 
outcomes, whether with no care or optimal care, must fit into the “envelope” it provides. The 
charts that follow demonstrate this central role of baseline birth prevalence.  
Figure 2.5 shows the distribution of fetal death/stillbirth, under-5 death, and survival with 
disability by 5 years of age in the no-care situation, and Figure 2.6 shows estimated actual 
outcomes in 2010-14. 
Though errors are likely in estimating outcomes, an error in one compartment simply shifts 
numbers into other compartments without altering the total envelope. For example, under-
estimation of mortality increases estimated numbers living with disability (or cured) and vice 
versa. 
 
Figure 2.5. Total congenital disorders. Estimated outcomes at 5 years of age in the absence of intervention per 
1,000 live births. World by WHO region, ranked in descending order of total baseline birth prevalence. 
The total height of the columns shows baseline (potential) birth prevalence. All outcomes fit within the 
envelope this provides. 
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Figure 2.6. Total constitutional congenital disorders. Estimated actual outcomes. World by WHO region, ranked in 
descending order of total baseline birth prevalence. (TOP = termination of pregnancy for fetal 
impairment.) 
Effect of interventions before birth 
Figure 2.7 shows estimated reduction in total affected birth prevalence due to pre-birth 
intervention in 2010, by type of intervention. Globally, the largest contributions were from 
anti-D for rhesus negative mothers and termination of pregnancy for fetal impairment. The 
contribution of folic acid food fortification was relatively small because it only began to be 
implemented on a large scale around 2007. The effect of genetic risk detection and 
counselling is relatively small because in most cases risk is only detected retrospectively, i.e. 
after the diagnosis of an affected child. 
 
Figure 2.7. Estimated reduction in affected births /1,000 due to interventions before birth, 2010-14. WHO regions 
ranked in descending order of total reduction. 
Actual birth outcomes: fetal death /stillbirth 
This outcome is covered fully here because it is not addressed elsewhere in this series. 
The strong association between congenital disorders and stillbirth (see Table 2.10) means 
that congenital disorders contribute disproportionately to stillbirths: globally in 2005-09 they 
represented 3.9% of total births (range 2.6% in Asia Pacific HI region to 5.8% in the Gulf 
States), but over 14% of stillbirths (range 10.5% in South East Asia to 52% in the Gulf 
States) (Table 2.15). The main potential contributors to fetal death are chromosomal 
disorders, neural tube defects, single gene disorders and rhesus haemolytic disease. Pre-
birth interventions have most effect on these disorders and so are particularly effective in 
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fetal death/stillbirths due to congenital disorders were avoided by interventions before birth 
(range 11.1% in AFR to 27.5% in Western Europe). 
However the uncertain definition of stillbirths affects all estimates. For example the 
contribution of congenital disorders to stillbirth may be over-estimated in the Global 
Database because EUROCAT fetal death rates (defined as death in utero after 20 weeks’ 
gestation) are used as a proxy for stillbirths, while rates from Cousens, Blencowe et al. 
(2011) – stillbirth defined as death in utero after 28 completed weeks’ gestation – are used 
as denominator. 
Table 2.15. Estimates of annual stillbirths and proportion associated with congenital anomalies and congenital 
disorders. Rates in 2005-09. Stillbirth rates from Stanton, Lawn et al. (2006) and Cousens, Blencowe 






















Algeria, W Sahara 830 1.13 9,464 2.7 14.2 4.1 32.2 
Sub-Saharan Africa 28,338 2.89 842,250 2.5 4.6 4.9 10.8 
Southern Africa 1,720 1.99 34,851 2.4 5.6 3.5 12.1 
AFR 30,888 2.79 886,565 2.5 4.8 4.8 11.1 
North America 4,631 0.30 14,004 2.7 29.7 3.2 38.1 
Caribbean 730 1.24 9,196 2.4 8.3 3.5 14.7 
Central America 4,942 0.81 40,482 2.6 12 3.3 21.3 
South America 4,476 1.05 47,539 2.8 13.5 3.6 23 
S America HI 988 0.61 6,045 2.8 20.7 3.3 26.1 
AMR 15,767 0.74 117,265 2.7 14.9 3.4 23.7 
Gulf states 824 0.69 5,758 2.7 18.7 5.8 52.9 
N Africa /Middle East 8,240 1.55 129,767 2.6 8.8 4.6 26.3 
Afghanistan /Pakistan 5,712 4.11 244,770 2.8 4.6 6.1 15.3 
Somalia, Djibouti, S Sudan 441 2.94 13,370 2.5 4.6 3.9 11.1 
EMR 15,217 2.52 393,666 2.7 6.2 5.2 19.3 
Western Europe 4,526 0.31 14,019 2.5 19 3.0 27.5 
Central Europe 1,223 0.39 4,829 2.5 14.8 3.0 20.5 
Eastern Europe 2,334 0.88 20,788 2.6 9.7 3.0 12.2 
Turkey 1,297 1.16 15,178 2.3 7.6 3.6 20.7 
Central Asia 1,671 0.88 14,831 2.6 15.1 4.0 36.7 
EUR 11,051 0.63 69,646 2.5 12.6 3.2 22.9 
South Asia 29,608 2.34 708,193 2.7 7.8 4.0 13.6 
Southeast Asia 7,029 1.44 102,363 2.4 8.4 3.3 12 
SEAR 36,637 2.16 810,556 2.6 7.9 3.8 13.4 
East Asia 17,889 0.90 162,519 2.3 12.8 2.9 17.2 
Southeast Asia 4,810 1.44 70,329 2.5 8.4 3.2 10.5 
Asia Pacific HI 1,854 0.30 5,563 2.1 18.3 2.6 27.2 
Oceania 260 1.45 3,824 2.5 9.5 3.4 16.4 
Australasia 351 0.29 1,025 2.5 18 3.0 25.1 
WPR 25,164 0.96 243,260 2.4 11.6 3.0 15.5 
World 134,724 1.84 2,520,958 2.6 7.3 3.94 14.5 
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Table 2.16. Estimated no-care (potential) and actual fetal deaths due to constitutional congenital disorders /1,000 















deaths, % of 
total 
stillbirths 
AFR 29.4 2.9 2.7 0.2 5 9.4 
AMR 7.3 2.3 1.5 0.8 35 20.4 
EMR 26.4 5.1 4.2 0.9 18 16.0 
EUR 5.9 2.4 1.2 1.2 48 21.1 
SEAR 22.3 2.8 2.6 0.2 7 11.9 
WPR 8.2 1.7 1.0 0.7 42 12.4 
World 19.1 2.8 2.3 0.5 16 12.3 
W Europe 3.3 2.2 0.7 1.5 67 22.3 
Figures 2.8 and 2.9 show no-care (potential) and estimated actual fetal deaths /1,000, by 
cause and WHO region. The largest reduction is in fetal deaths attributable to rhesus 
haemolytic disease. 
 
Figure 2.8. Estimated no-care (potential) fetal deaths due to constitutional congenital disorders /1,000 births. WHO 
regions ranked in descending order of total baseline rate. 
 
Figure 2.9. Estimated actual fetal deaths due to constitutional congenital disorders /1,000 births. WHO regions 
ranked by baseline rate. 
Figure 2.10 shows reduction in fetal deaths /1,000 births by type of intervention. 
Interventions with most effect were anti-D for rhesus negative mothers, and termination of 
pregnancies likely to end in stillbirth. As with total affected births, genetic risk detection and 

































































Figure 2.10. Estimated reduction in fetal death/stillbirths due to congenital disorders /1,000 births in 2010-14 by type 
of intervention. WHO regions in descending order of total estimated reduction. 
Actual birth outcomes: affected live births 
Figure 2.11 shows estimated actual live births /1,000 in 2005-09 by WHO region and 
disorder group. Total live births provide the envelope for assessing the effects of diagnosis 
and care. 
 
Figure 2.11. Estimated actual live births congenital disorders /1,000 by main group, 2010-14. WHO region in 
descending order of total affected birth prevalence. (Compare with Figure 2.2). 
Early mortality 
The discussion of early mortality is limited to under-5 mortality for the sake of brevity, and 
because it is the chosen indicator for progress towards the 4th Millennium Development 
Goal. Figures 2.12 and 2.13 show estimated potential and actual under-5 mortality due to 





































































Figure 2.12. no-care (potential) under-5 deaths due to congenital disorders /1,000 births, by disorder type and WHO 
region. 
 
Figure 2.13. Estimated actual under-5 deaths due to congenital disorders /1,000 births 2010-14, by disorder type 
and WHO region. 
Table 2.17 shows estimated per cent reduction in under-5 mortality by disorder group and 
WHO region in 2010-14. Estimates for Western Europe are included, as an indicator of the 
power of available interventions when fully deployed at the population level. 
Table 2.17. Estimated % reduction in under-5 mortality due to congenital disorders by disorder group and WHO 
region, 2010-14. 


























EMR 20 7 25 15 42 7 59 19 22 
AFR 5 2 9 6 6 2 7 5 7 
SEAR 12 4 15 10 27 4 10 14 13 
AMR 47 15 53 29 52 16 61 54 49 
EUR 74 24 74 38 72 15 84 75 67 
WPR 48 17 69 26 75 16 62 38 58 
World 27 9 34 17 12 6 29 19 26 
W Europe 91 30 84 46 99 32 100 100 80 
In Western Europe current interventions are estimated to have reduced baseline early 
mortality by around 80%. The reduction is greatest for chromosomal disorders, congenital 
malformations, haemoglobin disorders and the two genetic risk factors. The reduction in 
mortality due to other single gene disorders is far smaller. Consequently the total power of 







































































Figure 2.14 shows estimated effective cure for around 5/1,000 children world-wide, and 
around 14/1,000 in high income settings. The most striking finding is that access to 
paediatric surgery can restore a normal life to around 14 otherwise severely affected children 
/1,000 births. 
 
Figure 2.14. Estimated effective cure for congenital disorders /1,000 births, 2010-14, by cause and WHO region. 
Regions ranked in ascending order of cure /1,000 births. Cure for neonatal jaundice is due to early 
diagnosis and medical care. Cure for congenital malformations is almost entirely attributable to 
paediatric surgery.  
Actual and perceived outcomes 
Figure 2.6 summarises the distribution of actual outcomes in 2010, within the envelope of 
baseline birth prevalence, taking account of all interventions. 
However the prevalence of congenital disorders tends to be perceived through their 
contribution to early death and disability. Termination of pregnancy, fetal and under-5 death 
and cure all remove cases and so reduce visibility. This leaves survival with disability as the 
primary perceived indicator of prevalence. Figure 2.15 shows that perceived burden may be 
reduced by as much as two-thirds when all available interventions are deployed. Reduced 
visibility may partly explain the low priority assigned to congenital disorders in most high 
income settings. 
 
Figure 2.15. Estimated actual survivors with disability at 5 years /1,000 births, 2010-14, by WHO region, ranked in 
descending order of disability /1,000 births. 
Table 2.18 shows the estimated total per cent reduction in adverse outcomes due to 
interventions at 5 years of age, in 2010-14. The greatest proportionate reduction is in under-






















































Table 2.18. Per cent reduction in unfavourable outcomes below baseline rates due to interventions, by WHO 
region, 2010-14 
WHO region Fetal deaths Under-5 deaths Disability at 5 yr Total adverse outcomes 
EUR 48 67 30 53 
WPR 42 58 31 47 
AMR 35 49 19 38 
EMR 18 22 3 15 
SEAR 7 13 5 10 
AFR 5 7 -2 4 
World 16 26 10 20 
W Europe 67 80 39 65 
 
Discussion 
Completeness of coverage  
Ideally the Global Database would include all congenital disorders, as defined by WHO. 
However the range that can be included is limited because the modelling method used starts 
from baseline birth prevalence, i.e. births /1,000 in the absence of any intervention. At 
present the Global Database is limited to severe early-onset constitutional congenital 
disorders, because their baseline birth prevalence is known or can be estimated for most 
countries. 
In future it is hoped to include adult-onset single gene disorders (e.g. familial cancers, 
familial hypercholesterolaemia, neurodegenerative disorders), bicuspid aortic valve46, and 
disorders due to genetic risk factors (e.g. haemochromatosis). Their inclusion would greatly 
increase the estimated burden of congenital disorders. 
Environmental congenital disorders are not currently included. This is because maternal 
exposure to risk varies with place, time and level of development of health services, and 
insufficient country-specific surveillance data is available to define baseline birth 
prevalences, or to quantify the effects of interventions. Table 2.19 shows the results of an 
attempt to provide at least provisional estimates at the request of WHO EMRO. Sufficient 
global data were available to make approximate estimates for the commonest congenital 
infections (rubella, toxoplasmosis, cytomegalovirus, syphilis, AIDS), but not for effects of 
other infections, other harmful exposures or nutritional deficiencies. Therefore in Table 2.19 
estimates for congenital infections are doubled to obtain a general indication of the likely 
contribution of environmental disorders in 2010-14. This results in a global average baseline 
birth prevalence of around 13/1,000 - 25% of total early-onset congenital disorders. (The 
estimate of 20/1,000 for the African region reflects high estimates for syphilis and AIDS.)  
Table 2.19. Estimated contribution of environmental congenital disorders to baseline birth prevalence of total 
early-onset congenital disorders, 2010-14 
WHO 
region 
Baseline affected births /1,000 births 
Environ-mental 









AFR 46.8 10.0 20.0 66.9 30 
SEAR 37.3 8.7 17.4 54.6 32 
AMR 33.8 5.9 11.8 45.6 26 
EMR 52.1 4.4 8.8 60.9 14 
WPR 30.8 2.9 5.7 36.6 16 
EUR 34.5 2.8 5.7 40.2 14 
World 39.5 6.7 13.4 52.9 25 
W Europe 33.7 2.4 4.8 38.4 12 
                                               
46 Bicuspid aortic valve is a congenital cardiac defect, probably dominantly inherited, that affects 1-2% of most 
populations and is one of the main causes of adult-onset aortic valve disease and/or aortic aneurysm. 
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Coverage of early-onset constitutional congenital disorders 
Coverage differs according to disorder group as indicated in Table 2.20. 
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The table shows that most estimates of baseline birth prevalence are acceptably reliable, but 
may be under-estimates for some disorder groups. 
Most estimates of outcomes are evidence-based, but may be less reliable than baseline birth 
prevalences due to the limitations of available observational data. 
Estimates for survival in a no-care situation are based on historical reports from high income 
countries, supplemented by expert opinion. A full table of estimates is included in Annex F3: 
Estimating survival with congenital malformations in the absence of diagnosis and care. 
Probability of over- or under-estimation 
Great care has been taken to exclude over-estimation (for example, see the method used to 
avoid double counting in Article 7: Congenital malformations: birth prevalence and birth 
outcomes), but there is a high probability of under-estimation. 
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1. Affected birth prevalence is calculated in congenital anomaly registries on the basis 
of total births (still births and live births). These are related to WPP live birth rates to 
obtain estimated affected birth prevalence: this leads to modest under-estimation. 
2. The EUROCAT average rates used to calculate birth prevalences and outcomes are 
low estimates because there is demonstrable under-ascertainment in some 
participating registries. 
3. Adjustment for uneven country contributions leads to an 8% increase in average 
EUROCAT rates. However no attempt has been made to adjust for this limitation, in 
order to remain as close as possible to the source data. 
4. There is internal evidence in of selective under-ascertainment of terminations of 
pregnancy and fetal deaths in some countries. 
5. Congenital disorders increase susceptibility to infection and other causes of early 
death. Since the ultimate cause of death is defined as the underlying cause, this 
manoeuvre probably leads to under-estimation of deaths due to congenital disorders. 
6. Nevertheless, estimated early deaths are adjusted to “attributable” early deaths by 
subtracting deaths from other causes, calculated using local early mortality rates. 
Possible future change in inputs 
Table 2.21 shows that inputs least likely to change are birth prevalences of chromosomal 
disorders and congenital malformations. Inputs most likely to change are: 
 Most recent (past 10 years) WPP demographic estimates  
 Most recent EUROCAT (5 years) rates for fetal death and termination of pregnancy 
 Birth prevalence of rare single gene disorders 
Table 2.21. Likelihood of future change in inputs 
Input Likelihood of change 
For every country 
WPP demographic data 
There may be significant differences between WPP estimates and country 
observational data. 
There may be quite marked changes in estimates for the most recent 10 
years. 
Estimated access to services Can be updated if any change in IMR, e.g. using country observations.  
For every disorder group 
Baseline birth prevalence Relatively constant 
Intervention before 
pregnancy 
Increase in genetic risk identification 
Policy change re anti-D, & folic acid food fortification 
Termination of pregnancy Policy change re TOP for fetal impairment 
Fetal deaths Rate falls with TOP for fetal impairment 
Survival, if no care Relatively constant 
Survival, optimal care 
Steady improvement for many conditions: evidence-based estimates may fall 
behind reality. 
Adults: % living 
independently 
More data is needed. 
adults: reproductive success 
Increases as total fertility rate falls, because it is expressed as a % of the 
population norm. 
We conclude that as long as they are viewed as ball-park estimates intended to provide a 
broad general picture, the current estimates have reasonable long-term validity. 
The importance of baseline birth prevalences 
Specific features that justify a special epidemiological approach to constitutional congenital 
disorders are (a) the relative stability of their baseline birth prevalence in any given 
population, and (b) the fact that in the absence of intervention they cause early death or life-
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long disability (i.e. there is no remission). Thus their baseline birth prevalence provides a 
solid foundation for estimating the effects of interventions that is not available for most other 
groups of medical conditions. 
The relative stability of baseline birth prevalence also provides opportunities for some ways 
of expressing rates and outcomes that are uniquely applicable for congenital disorders. For 
example: 
 Incidence is expressed as birth prevalence – affected births /1,000 total or live births 
– rather than in terms of new cases /100,000 population (as used e.g. by the Global 
Burden of Disease study). 
 The fact that all outcomes must fit within the “envelope” provided by baseline birth 
prevalence is very helpful in evaluating rates for e.g. mortality, disability and cure. 
 Burden can be expressed in years (or months) of life affected by congenital disorders 
per person in the relevant birth cohort (by contrast with e.g. number (or proportion) of 
years of life lost or lived with disability in the population).  
Expressing burden in terms of years /person in the birth cohort 
This is the preferred method used for describing burden in the Global Database because (a) 
annual births provides a more stable denominator than e.g. population number and (b) 
expressing outcomes in terms of months or years affected per person born facilitates 
intuitive grasp the burden of a disorder. 
Figure 2.16 illustrates these points by comparing different ways of expressing the estimated 
impact of congenital anomalies. It is shown above that their baseline birth prevalence does 
not differ greatly between populations.  
 The green columns in the chart show average years affected by congenital 
anomalies per person born. The differences between WHO regions are largely due to 
differences in local life expectancy.  
 The brown columns show average years affected per 1,000 population (a form of 
expression commonly used in public health epidemiology). Because baseline birth 
prevalence is relatively constant, years affected /1,000 population are highest when 
life expectancy is short and fall as life expectancy increases. This somewhat counter-
intuitive effect can complicate comparisons between populations and over time, and 
the estimated effect of interventions. 
 
Figure 2.16. Different ways of expressing the potential life-time impact of total congenital anomalies. The estimates 




































Bundling of outputs for different purposes 
The way that outputs are bundled for presentation is determined by the object of the 
exercise. Outputs from the Global Database can be presented differently to suit different 
objectives. 
The current purpose is to estimate numbers of individuals born annually with congenital 
disorders, and outcomes for these individuals, in the context of the administrative structure 
of the WHO. Therefore outputs are bundled by WHO region and notional sub-region. 
However if required they can also be bundled by e.g. GBD region. In addition congenital 
malformations are presented in terms of individuals with malformations (isolated or multiple) 
rather than numbers of congenital malformations. However if required (e.g. to calculate the 
need for clinical interventions) the Database can also generate numbers of congenital 
malformations  
Comparison of under-5 mortality estimates with GBD 
This topic is covered in Article 1: Introduction: scope and general overview. 
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Article 3: Methods for generating long-term estimates 
Abstract 
Decision-makers ideally need (1) an estimate of current patient numbers and age 
distribution; (2) projections of the effects of any policy change on patient numbers, and (3) 
an assessment of costs and benefits of different policy decisions. This article describes the 
additional inputs and methods required to generate such long-term estimates for 
constitutional congenital disorders, and gives some examples of outputs. All calculations 
start from estimated affected live births. 
The following additional inputs are required: 
 data on population number and age distribution from UN World Population Prospects 
(WPP); 
 life-time survival curves obtained when necessary by extending existing survival 
data; 
 mean life expectancy with no care and with optimal care, calculated from the life-time 
survival curves. 
The above estimates are prospective. They predict future survival, and so long-term age 
distribution, of the cohort of patients born in a particular year. To calculate current patient 
number and age distribution, it is necessary to create retrospective survival curves that take 
account of the services available at the time each age group was born. The article includes 
the method used for generating these curves. 
With these additional inputs, the estimates in Article 2: Core methods for estimates to five 
years of age can be extended to generate the following outputs: (1) estimated number and 
age distribution of living patients (treated and untreated); (2) calculation of average years of 
life affected by congenital disorders, and years lost, lived with disability or cured; (3) future 
projections of effect of policy change on these outputs. 
Years of life lost, lived cured, or with disability due to congenital disorders are described in 
terms of average years affected per person in the relevant birth cohort, i.e. per person born 
in any given year. The application of this method indicates that: (a) current interventions 
reduce average loss of life due to constitutional congenital disorders per person born by 
7.5% in AFR, 28% globally and 75% in Western Europe; (b) interventions that reduce 
mortality may increase numbers living with disability; (c) in high income settings such as 
Western Europe treatment (mainly paediatric surgery) adds at least 1.29 years of healthy life 
per person born. 
We emphasise the need for improved quantitative methods for assessing disability, and the 
human costs and benefits of services for prevention and care of congenital disorders. 
Introduction 
Among the most important pieces of information sought by decision-makers seeking to plan 
services and policies for the future are: 
 an estimate of current patient numbers and age distribution 
 projections of the effects of any policy change on patient numbers 
 an assessment of costs and benefits of different policy decisions. 
The Global Database is capable of generating most of these estimates. The calculation 
starts from estimated live birth prevalence and available survival data (described in Article 2: 
Core methods for estimates to five years of age). It requires the following additional inputs: 
 population number and age distribution 
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 life-time survival curves for each disorder group 
 retrospective survival curves, taking account of the evolution of care over the past 70 
years or so. 
This article gives details of these additional inputs, and some examples of outputs. 
Population number and age distribution 
This data is required for calculating potential and actual patient numbers and age 
distribution. Estimates are available from WPP by 5-year intervals from 1950 to 2100 (see 
Article 4: Uses of demographic and geographic data). As an example, Figure 3.1 shows the 
change in population age distribution in Europe between 1950 and 2015. 
 
Figure 3.1. Population age distribution in Europe, 1950 and 2015. WPP estimates. Europe refers to the 
geographical region, not WHO EUR. Age distribution in 1950 is heavily weighted towards younger age 
groups. The striking deficiency in the 30-34 age group is due to the Second World War. 
Figures 3.2 and 3.3 show estimated age distribution in 1950, and projected to 2050, for the 
world and Western Europe. Figures 3.4 and 3.5 show the corresponding change in 
proportion of the population under 12 and over 50 years of age. The comparison illustrates 
the changing pattern of need for medical services: the proportion under 12 years of age is 
the indicator of need for paediatric services: the proportion over 50 is the indicator of need 
for services for later-onset disorders of adult life (mainly non-communicable diseases). 
 
Figure 3.2. Age distribution of the world population in 1950, and projected for 2050. The 1950 distribution is typical 
for most populations in the past. Numbers were heavily weighted towards younger age groups, and 
total over 80 less than those aged 75-79. The projected distribution for 2050 shows typical future age 

























































































































































































Figure 3.3. Age distribution of the population of Europe in 1950, and projected for 2050, illustrates the likely future 
increase in proportion of the population in the oldest age groups. 
 
Figure 3.4. Proportion of the world population under 12 and aged 50 years or more, 1950-2050 (WPP estimates) 
 
Figure 3.5. Proportion of the world population under 12 and aged 50 years or more, 1950-2050 (WPP estimates) 
Obtaining life-time survival curves 
Sources for survival estimates used in the Global Database are given in Table 2.12 of Article 
2: Core methods for estimates to five years of age. 
Life-time survival curves with optimal care are available for Down syndrome, spina bifida, 
oro-facial clefts and sickle cell disorders.47 For most other disorders observational data are 
                                               
47 Some of these curves may be out of date because they were collected over many years, and new interventions may 








































































only available to age 20 or 30. Survival curves for these disorder groups are completed by 
extrapolating the observed rate of attrition in the last full 5-year interval, to 80 years of age. 
All survival curves used in the Global Database are adjusted in two ways: (a) for background 
under-5 mortality at the time and place the data were collected, to produce curves that 
represent mortality in the absence of any other cause of death48, and (b) for the estimated 
effects of termination of pregnancy49. Since this option is not available in all countries, curves 
for global use must start from estimated survival in the absence of this service. The 
estimated effect of termination of pregnancy is added at a later stage in the calculation. 
In high income settings normal survival is expected for curable congenital malformations, the 
additional conditions, and the two disorders due to genetic risk factors presently included. 
The following figures show the resulting long-term survival curves for the main groups of 
congenital disorder, in the absence of care and with optimal care. 
 
Figure 3.6. Chromosomal disorders. Estimated % survival with no care. 
                                               
48 Since most survival data, including that for the no-care situation, was collected in high income settings with low early 
mortality, this adjustment makes relatively little difference for most disorder groups. 



















UK population 2003 Down before 1950
Other trisomies no care Rare chromosomal  no care
Turner no care Klinefelter no care
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Figure 3.8. Congenital malformations by major severity group. Estimated survival if no care. 
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Down opt care from 1990
Rare chromosomal opt care
Other trisomies opt care
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Figure 3.9. Congenital malformations by major severity group. Estimated survival with optimal care 
 
Figure 3.10. Single gene disorders. Estimated % survival with no care. SCD = sickle cell disorder. B thal major = 
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UK population 2003 OC albinism no care
Mild SCD no care X-linked no care
Recesssive no care Severe SCD no care
B thal major no care Dom < 1yr no care
Alpha thal hydrops no care
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Figure 3.11. Single gene disorders. Estimated survival with optimal care 
The above survival curves are prospective. They predict future survival, and so long-term 
age distribution, of the cohort of patients born in a particular year. They do not show patients’ 
current expected age distribution. 
Prospective survival curves are used in the following ways for calculating long-term 
outcomes. 
 To estimate disorder-specific mean life expectancy (mean age at death), with no care 
and optimal care. These are then combined with estimated access to care to 
calculate disorder- and country- specific mean life expectancy. This in turn is used to 
calculate years of life lost, lived cured, or lived with disability. 
 For constructing retrospective survival curves to use in calculating the number and 
age distribution of patients living at any given time. For this purpose, estimates for 
each age group must be adjusted according to the services available at the time they 
were born. Retrospective survival curves are derived from prospective curves, taking 
account of the historical evolution of services outlined in Table 3.1.50 
 For projecting the likely future evolution of patient number and age distribution (a) 
assuming no policy change and (b) with adoption of specific polices. 
                                               
50 Global Database numbers of living patients are calculated from survival with no care and with optimal care, and 
estimated access to services. Survival with no care does not change over time and access to care is allowed for in all 
calculations. Therefore the only additional requirement is for estimates of retrospective survival with optimal care, 



























































































UK population 2003 Dom < 1yr opt care
X-linked opt care Recessive opt care
Consang-assoc opt care OC albinism opt care
Severe SCD opt care Mild SCD opt care
B thal major opt care Alpha thal hydrops opt care
Hb H disease opt care
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Table 3.1. Evolution over time of optimal care for congenital disorders, based on Table 2.11 of Article 2: Core 
methods for estimates to five years of age. 
 
Calculation of mean life expectancy 
Table 3.2 shows disorder-specific mean life expectancy with no care and optimal care 
calculated from the full survival curves. The difference between life expectancy with no care 
and with optimal care measures the survival benefit of care. 
Mean life expectancy is used in the Global Database to calculate costs of the disorder, and 
benefits of interventions, in terms of years of life lost, lived with disability or lived cured. 
The rates in Table 3.2 represent life expectancy with the disorder in the absence of any 
other cause of death. In the Global Database, these “ideal” rates are adjusted by multiplying 
by local life expectancy divided by a notional optimal life expectancy of 80 years. 
Intervention 1940s 1950s 1960s 1970s 1980s 1990s 2000s 2010 -
Chromosomal  disorders Mandatory care Repair of CHD
NTD (spina bi fida) Selective closure routine closure
Oro-facia l  clefts Surgica l  repair
Pyloric s tenos is Surgica l  repair
Congen heart disease Repair PDA
Repair "less  
severe" defects




Other congen malfns NN exam: surgica l  repair
Improved surgica l  
techniques
Congen hypothyroidism NN screen, Rx
Hb: thalassaemia
Transfus ion, parentera l  Fe chelation Oral  i ron chelation
Hb : s ickle cel l NN screen & care







Table 3.2. Estimates of mean life expectancy by disorder group, with no care and with optimal care 
Main group Disorder group 
Mean life expectancy, years Years gained per 
affected person No care Optimal care 
Chromosomal disorders 
Down syndrome 7.7 50.6 42.9 
Other trisomies 0.1 0.1 0.0 
Other autosomal 6.9 45.6 38.6 
Turner syndrome 56.8 67.8 11.1 
Klinefelter syndrome 66.4 66.4 0.0 
Congenital 
malformations 
Anencephaly 0.0 0.0 0.0 
Spina bifida & e'cele 0.5 41.2 40.7 
Oro-facial clefts 4.4 73.0 68.6 
Very severe CHD 2.0 6.6 4.6 
Severe CHD 15.8 63.6 47.9 
CNS not NTD 0.5 42.5 42.0 
Eye 39.6 74.7 35.0 
Ear, face, neck 72.2 72.2 0.0 
Respiratory 15.6 44.4 28.8 
Digestive system 3.8 60.7 56.9 
Abdominal wall defects 0.5 62.0 61.5 
Urinary system 10.6 67.5 56.9 
Multiple malformations 0.5 29.8 29.3 
Genital system 76.7 76.7 0.0 
Limb 69.8 74.2 4.4 
Additional conditions 
Congenital hypothyroidism 11.5 80.0 68.5 
Prematurity-associated PDA 30.5 80.0 49.5 
Pyloric stenosis 0.5 80.0 79.5 
Rare single gene 
Dominant 1.3 17.6 16.3 
X-linked 12.1 39.4 27.3 
Recessive 6.7 28.1 21.4 
Consanguinity Consanguinity-associated 6.7 28.1 21.4 
Haemoglobin disorders 
Sickle cell disease 3.0 41.5 38.5 
Beta thalassaemia 2.4 65.1 62.7 
Genetic risk factors 
Rhesus haem disease 1.9 80.0 78.1 
G6PDd kernicterus 1.9 80.0 78.1 
Calculation of years of life lost, lived with disability or lived cured 
Mean life expectancy for the congenital disorder under consideration can be used to assess 
the life-time impact of the disorder in terms of years of life lost, and the proportionate 
outcomes in Table 2.14 of Article 2: Core methods for estimates to five years of age can be 
used to estimate years lived with disability or lived cured. However two values are available 
for mean life expectancy – “ideal” mean life expectancy in the absence of any other cause of 
death (see Table 3.2), or life expectancy adjusted for local life expectancy. The Global 
Database can generate either output. For this presentation mean life expectancy is adjusted 
for local life expectancy. 
The steps in the calculation are then as follows. 
1. Calculation of years lost, lived with disability or lived cured, per affected birth. The 
denominator for these calculations is population mean life expectancy. 
2. Years of life lost per affected birth are multiplied by annual affected births to obtain 
implications for the community in terms of total years of life lost, lived with disability or 
lived cured. 
3. These can then be converted to rates using different denominators. For example the 
GBD calculates years of life lost /year /100,000 population. 
4. In the Global Database total years of life affected, years lost, years lived with 
disability and years lived cured are expressed as years per individual in the relevant 
birth cohort. The method has the advantage of being intuitively accessible to a 
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general audience (it relates the effect of an intervention to the group that was eligible 
to receive it), and of having a stable denominator. 
All the above calculations are prospective, i.e. predict future losses and gains for the 
relevant birth cohort. 
Construction of retrospective survival curves 
Curves are constructed in four steps. 
1. Define the timing of advances in care for the disorder group under consideration (see 
table 3.1). 
2. Select the “anchor” years from which one wants to look back to estimate the likely 
number of living patients in that year. 
3. Obtain survival data for each phase in the evolution of care. For instance, taking the 
example of spina bifida, Figure 3.12 shows survival with supportive care only 
(Laurence and Tew 1971), selective closure for around 30% less severe cases 
(Lorber and Salfield 1981), and non-selective closure (Mason and Meyers (1986), 
Oakeshott and Hunt (2003)). 
 
Figure 3.12. Prospective “optimal” survival curves for spina bifida, based on observations at three different periods in 
the evolution of patient care. The curves show that since non-selective closure only became policy in 
the later 1970s relatively few survivors over the age of 45 would be expected in 2010, but numbers of 
older patients are likely to continue rising until 2050. (The number of younger survivors also depends on 
local policy with respect to prenatal diagnosis (since 1980) and folic acid food fortification (since around 
2000)). 
4. Construct retrospective survival curves by shifting back sequentially through the 
prospective curves, as shown in Table 3.3. The first set of columns show prospective 
survival colour-coded by period. The next six columns show curves for six anchor 
years spaced at 20 year intervals from 1950 to 2050. This initial calculation assumes 
abrupt changes in interventions and produces curves with sharp discontinuities. In 
the last six columns the initial curves are smoothed to allow for the fact that it usually 
takes 15-20 years for improvements in care to diffuse through an entire health 
system. (See Annex A5: Creating retrospective survival curves for the full 
calculation.) 
Figure 3.13 shows the smoothed retrospective survival curves. Each curve represents the 
outcome of “best available care” over the 70 years preceding the anchor year, in terms of the 
proportion of potential patients in each 5-year age group who are likely to be alive in the 
anchor year. For example in 2010 one would not expect there to be many survivors with 



























1975, and that numbers of older survivors, and service needs, are likely to continue to rise 
until around 2050 even in settings where prenatal diagnosis is available. 


























Birth 100 100 100 100 100 100 100 100 100 
1 yr 24.1 39.3 74.7 24.1 39.3 74.7 74.7 74.7 74.7 
5 yr 21.0 34.8 67.0 21.0 30.7 69.1 69.1 69.1 69.1 
5-9 18.0 32.3 65.7 18.0 22.6 65.5 65.5 65.5 65.5 
10-14 15.0 29.6 63.7 15.0 15.0 51.8 62.8 62.8 62.8 
15-19 12.0 26.1 59.0 12.7 12.7 38.3 60.0 60.0 60.0 
20-24 11.1 25.0 57.3 11.1 11.1 20.4 57.3 57.3 57.3 
25-29 10.2 23.8 55.6 10.2 10.2 14.8 55.5 55.5 55.5 
30-34 9.1 22.5 53.7 9.1 9.1 9.1 43.4 53.6 53.6 
35-39 7.9 21.0 51.6 7.7 7.7 7.7 31.2 51.5 51.5 
40-44 6.1 19.0 49.1 5.9 5.9 5.9 14.5 48.8 48.8 
45-49 3.6 16.2 45.7 3.6 3.6 3.6 3.6 45.3 45.3 
50-54   12.3 41.1         32.5 40.6 
55-59   10.5 34.9         19.8 33.9 
60-64   7.7 25.7         7.7 24.5 
65-69   3.9 12.9           12.9 
70-74                   
75-79                   
 
 
Figure 3.13. Retrospective survival curves for spina bifida, looking back from “anchor years” at 20-year intervals 
from 1950 to 2050, based on the three curves in Figure 3.7. The curves are smoothed (15-yr rolling 
averages). Retrospective survival becomes progressively shorter as the anchor year moves back in 
time. 
Calculation of present patient number and age distribution 
In order to plan for service needs, policy-makers need to know the approximate numbers 
presently living with specific disorders. This information can only be reliably obtained using a 
patient register. However few such registers exist even in high income settings and even for 
disorders such as Down syndrome, largely because of difficulty in obtaining the necessary 
long-term (though relatively modest) funding. Therefore, for most countries, it is necessary to 
devise a method for estimating present patient numbers and age distribution. In the Global 
Database this is achieved for each disorder group using the following steps. 
1. Obtain data on the number and age distribution of the relevant population in the year 


























intervals. World Population Prospects51 (WPP) provides country-specific estimates by 
5-year interval from 1950-2100. 
2. Apply the baseline live birth prevalence of the disorder to calculate the number of 
patients who would be living in the year of interest by 5-year age intervals, if their 
survival equalled the population norm. 
3. Use available data on the evolution of the effect of interventions before birth by 5-
year age intervals, to calculate (a) the number of affected births avoided and (b) 
potential actual patient number if survival equalled the population norm, in each 5-
year age group. 
4. Calculate estimated access to services by 5-year age group, using WPP historical 
infant mortality rates. 
5. Calculate (a) the number of surviving patients by 5-year age interval, and (b) the 
number in each 5-year age group who died at earlier ages, using disorder-specific 
long-term survival curves with optimal care and no care and estimated access to 
services. 
Note that it is not necessary to adjust any of these estimates for local mortality, because 
when the denominator is number surviving in each age group, all-cause death is already 
taken into account. 
Estimation of past and future patient numbers 
Thanks to the availability of WPP demographic data, the same method can be used to 
estimate the number and age distribution of living patients at different periods in the past 
from 1950 onwards. It can also be used project patient numbers and age distribution by 5 
year intervals up to 2050. 
Future projections of the likely effects of implementing interventions such as folic acid food 
fortification or prenatal diagnosis with the option of termination of pregnancy are of particular 
interest to policy-makers. They can be calculated (a) assuming no change in present 
policies, and (b) assuming world-wide spread of available interventions. In the Global 
Database all future projections allow for changes in estimated access to services. 
Long-term outputs 
Long-term outputs from the Global Database include (1) Estimated years of life lost, lived 
with disability or lived cured. (2) Estimated number and age distribution of living affected 
individuals. (2) Projected future effects on numbers and outcomes, of present policies, and 
potential policy changes. (3) Improved assessment of long-term costs and benefits. 
Estimated years of life lost, lived with disability or cured 
An initial approach to quantifying the burden of a disorder is calculation of years of life lost or 
lived with disability due to the disorder, as used in the Global Burden of Disease Study 
(GBD). In addition, the Global Database includes calculation of years of life gained and/or 
lived cured due to interventions. 
Years affected per person born is the same as local mean life expectancy. This provides the 
envelope for all estimates of outcomes. Figure 3.14 shows Global Database estimates for 
total months affected by constitutional congenital disorders per person in the 2010-14 birth 
cohort, with outcomes in the absence of intervention. The world average is more than 27 
                                               
51 http://esa.un.org/unpd/wpp  
87 
months affected per person born. In the absence of intervention these disorders would be 
responsible for loss of 20 months of life per person born. 
 
Figure 3.14. Total constitutional congenital disorders: live births only. Estimated baseline months affected /person 
born, by WHO region ranked in descending order of total months affected. The column heights show 
baseline months affected per individual in the birth cohort, adjusted to local life expectancy. 
Figure 3.15 shows estimated actual outcomes in 2020-14, in terms of months of life lost, 
lived with disability or lived cured per person born. The striking reduction in death and 
disability in Western Europe demonstrates the potential of global implementation of 
interventions for congenital disorders. 
 
Figure 3.15. Total constitutional congenital disorders, live births only. Estimated actual outcomes 2010-14, 
expressed as years of life lost, lived with disability or lived cured per person in the relevant birth cohort, 
by WHO region. 
Table 3.4 shows the proportionate change in outcomes by WHO region. The row for 
Western Europe shows the maximum present effect of interventions (except folic acid food 
fortification). It shows nearly 50% of years affected are lived cured, 11% lived with disability, 
and around 20% of affected years lost, and 21% reduction in years actually affected due to 





















































Table 3.4. Estimated years per person born affected by congenital disorders, and proportion with different 






Outcomes, % of years affected /person 
No care (baseline) Estimated actual outcomes 2005-09 
Potential 
yrs life lost 










AFR 2.45 81.2 18.8 1.6 75.1 21.6 1.6 
AMR 2.49 79.1 20.9 10.4 40.2 20.5 28.9 
EMR 3.27 82.9 17.1 4.0 66.7 21.4 8.3 
EUR 2.5 79.6 20.4 16.0 29.6 16.0 38.4 
SEAR 2.36 78.4 22.0 2.5 66.9 23.7 6.8 
WPR 2.21 75.6 24.4 7.2 44.3 20.8 27.6 
World 2.52 79.0 21.0 5.2 57.1 24.6 13.1 
W. Europe 2.68 79.9 19.8 21.3 19.8 10.8 48.1 
Estimated number and age distribution of living patients 
Since WPP provides age distribution data from 1950 onwards, it is possible to generate 
estimates of the number and age distribution of patients living in any year from 1950 to 2015 
in any country. The method generates the following estimates for each disorder, and 
provides a comprehensive picture of the history of the selected disorder up to the chosen 
year. 
 Potential number and age distribution if survival equalled the population norm 
 Affected births avoided by interventions 
 Deaths due to lack of access to care available at the time 
 “Unavoidable deaths” that would have occurred with best available care 
 Number and age distribution of patients living with disability or effectively cured. 
 Annual deaths due to the disorder, and their age distribution (by applying prospective 
survival curves to estimated living patients).  
Since the data is complex it is best presented in charts. As an example, Figure 3.16 shows 
global estimates for spina bifida by 5-year age intervals in 2010. 
 
Figure 3.16. World 2010. Estimated distribution of outcomes for spina bifida in 2010. The total outline represents the 


















































































In Figure 3.16 (world estimates for spina bifida): 
 The total outline shows the number of individuals who would be living with spina 
bifida if survival equalled the population norm, according to age in 2010 (6.98 
million). The outline reflects the age distribution of the world population in 2010. 
 The green fill shows cases avoided by folic acid food fortification (only 56 thousand in 
2010 because fortification only started to become policy in the late 1990s). 
 The orange fill shows cases avoided by termination of pregnancy (196 thousand in 
2010). 
 The grey fill shows deaths that would have occurred even with best care available 
when the affected person was born (unavoidable deaths). The great majority of 
deaths occurred soon after birth, but they appear in all age groups because the chart 
shows all outcomes. The black fill shows numbers of deaths that occurred because 
of lack of access to available care (avoidable deaths). (Total losses from the current 
world population due to spina bifida = 6.35 million). 
 The blue fill shows estimated numbers living with spina bifida in 2010 (399 
thousand). 
Future projections 
Figures 3.17 and 3.18 show global projections for spina bifida in 2050 with two extreme 
policy assumptions: (a) no change in present policies on folic acid food fortification and 
abortion for fetal impairment, and (b) both global spread of folic acid food fortification and 
unrestricted access to prenatal diagnosis with the option of termination of pregnancy for 
those with access to services from the year 2010.  
 
Figure 3.17. World 2050. Estimated distribution of outcomes for potential spina bifida if no change in present 
policies. Estimated total unaffected due to folic acid food fortification = 714 thousand; total avoided due 





















































































Figure 3.18. World 2050. Estimated distribution of outcomes of potential spina bifida, if global FA food fortification 
and global legalisation of termination of pregnancy for fetal impairment, from 2010. Estimated total 
unaffected due to folic acid food fortification = 3.12 million; total avoided due to termination of pregnancy 
= 442 thousand. Total deaths 5.22 million. Total living with spina bifida = 268 thousand. 
Table 3.5 summarises the estimated long-term effects of different policy decisions for spina 
bifida at a global level. All the estimates take account of change in access to care in the time 
period involved. 
Table 3.5. World picture of spina bifida: past, and potential future numbers with different future scenarios 
Estimate 
Past history 
Future: from 2010 
no policy change 
global FA 
fortification 
global FA and 
TOP legal 
1950 1970 1990 2010 2030 2050 2030 2050 2030 2050 
Potential if no intervention 2,532 3,614 5,231 6,977 8,324 8,324 8,324 9,062 9,062 9,062 
Unaffected due to FA 0 0 0 56 370 714 1,839 3,123 1,839 3,123 
Termination of pregnancy 0 0 28 196 476 832 294 442 393 629 
Potential with interventions 2,532 3,614 5,203 6,725 7,477 7,516 6,190 5,496 6,091 5,310 
Total deaths 2,486 3,490 4,989 6,347 7,085 7,224 5,946 5,412 5,858 5,218 
Living with NTD 47 124 207 399 545 696 327 324 297 268 
% of potential unaffected due 
to FA 
   0.8 4.5 7.9 22.1 34.5 22.1 34.5 
% of potential avoided by TOP   0.5 2.8 5.7 9.2 3.5 4.9 4.7 6.9 
% of potential living with NTD 1.8 3.4 4.0 5.9 7.3 9.3 5.3 5.9 4.9 5.1 
Discussion 
Additional inputs and stages 
Extending survival curves 
For long-term estimates it is necessary to extend the existing observation-based optimal 
survival curves 
Life-time data on survival with congenital disorders is necessary to generate long-term 
estimates, but most existing data only applies for survival to 20-30 years of age. This is 
because many of the interventions that increase survival were introduced between 1950 and 
1980, and follow-up observation for at least 50 years would be required to evaluate their full 
effect. Therefore in many cases it is necessary to extrapolate from existing survival data to 
obtain a full life-time curve. In the Global Database this is done in two ways, (a) based on the 
observed excess attrition in the oldest surviving group plus the population rate, and (b) 
assuming the population rate for all survivors after 20 years of age. 
In fact, because the highest loss of life is in the first five years, uncertainty in extrapolation to 

















































































therefore has relatively little effect on most estimates of years of life lost due to congenital 
disorders. 
Table 3.6. Comparison of mean life expectancy calculated based on survival curves to 20 years extrapolated in 
two ways. Calculations based on Tennant, Pearce et al. (2010) adjusted for effect of TOP 
Disorder group 
Disorder-specific attrition rate 
plus population rate 




Neural tube defects  41.2 47.3 6.2 
CNS not NTD 42.5 48.2 5.7 
Multiple malformations 29.8 33.8 4.1 
Cardiovascular system  65.8 68.6 2.7 
Digestive system  60.7 63.1 2.4 
Eye  74.7 74.7 0 
Ear, face, and neck  72.2 72.2 0 
Respiratory  44.4 44.4 0 
Orofacial clefts  75.6 75.6 0 
Abdominal wall  62 62 0 
Urinary  67.5 67.5 0 
Genital 76.7 76.7 0 
Limb  74.2 74.2 0 
UK population 2003 76.7 76.7 0 
Calculating number and age distribution of surviving patients 
The Global Database uses current population age distribution as the basis for calculating the 
“baseline” (potential) number of living patients, i.e. the number who would be alive if their 
survival had equalled the population norm. Since the number of in each 5-year group of the 
general population is the product of births in that interval minus all antecedent deaths from 
all causes, it is not necessary to seek other information on numbers of births or survival. 
Retrospective survival curves are then applied, to estimate the number of patients actually 
surviving in each age group. There are several sources of uncertainty in the calculation and 
application of the retrospective curves (see Article 6: Chromosomal disorders: calculating 
birth prevalence, survival and patient numbers for an example). Firstly, observational data on 
survival in high income settings before 1970 is scanty. Secondly, the curves currently used 
assume prompt and equitable implementation of advances as they became available, but 
this is unlikely to have been the case: it usually takes 10-20 years for validated interventions 
to penetrate an entire health system. Therefore in some cases numbers of older survivors 
may be over-estimated. 
Calculating age distribution at death 
Mean life expectancy enables calculation of years of life lost, but does not give any 
information on distribution of age at death. This can only be calculated from estimated 
patient number and age distribution. Distribution of age at death is important, because it 
enables informative comparison with age at death estimates produced by the Global Burden 
of Disease study. 
Previous studies 
The only previous study explicitly designed to assess burden of congenital anomalies 
remains that of Czeizel and Sankaranarayanan (1984), who not only recorded birth 
prevalence but also collected follow-up data on infant mortality and survival to 20 years of 
age, categorised types of disability in survivors, and expressed results in terms of years of 
life lost, lived with disability or lived effectively cured. The published results are summarised 
in Table 3.7. This remarkable study passed almost unnoticed internationally because its 
global relevance was not recognised. 
In Hungary mean life expectancy was 70 years when Czeizel and Sankaranarayanan (1984) 
made their classical estimates of burden. Their estimates would need to be adjusted to 
contemporary mean life expectancy for comparison with Global Database estimates. 
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Later reports from Skjaerven, Wilcox et al. (1999) and Lie, Wilcox et al. (2001), who 
collected data on Swedish people born with congenital anomalies in order to assess their 
genetic contribution to subsequent generations, have added valuable diagnostic-group-
specific data on long-term survival and reproductive success. 
Table 3.7. Czeizel and Sankaranarayanan (1984) estimates of average years of life affected per person in the 



















Central nervous system 2.17 0.152 0.119 0.029 0.004 
Eye 0.32 0.022 0.004 0.010 0.008 
Ear, face, neck 0.46 0.032 0.000 0.010 0.023 
Cardiovascular system 7.92 0.554 0.184 0.098 0.274 
Respiratory system 0.28 0.020 0.007 0.007 0.006 
Cleft palate, or lip & palate 1.42 0.099 0.003 0.022 0.076 
Alimentary system 2.78 0.195 0.043 0.007 0.144 
Urinary system 1.57 0.110 0.021 0.040 0.049 
Skeletal system 2.07 0.145 0.027 0.027 0.091 
Miscellaneous including multiple 2.74 0.192 0.043 0.039 0.109 
Total potentially lethal 21.73 1.52 0.45 0.29 0.78 
Musculo-skeletal system 5.43 0.380 0.000 0.012 0.513 
Genital organs 7.52 0.526 0.000 0.072 0.454 
Total not usually lethal 12.95 0.91 0.00 0.08 0.97 
Total non-chromosomal 34.68 2.43 0.45 0.37 1.75 
Total chromosomal  1.26 0.088 0.031 0.056 0.001 
Total 35.94 2.66 0.48 0.43 1.75 
Musculo-skeletal system: Western European rate for congenital dislocation of the hip are used, instead of the 
unusually high Hungarian rate. 
Improving the assessment of costs and benefits 
For a more general discussion of this topic, and the limitations of present methods, see 
Annex A7: Assessing costs and benefits. 
In their classical study of the burden of congenital anomalies Czeizel and Sankaranarayanan 
(1984) recognised the limitations of an approach limited to assessing death, disability and 
cure. As a step towards a more refined quantification of disability they initiated a 
classification of types of disability. However they made no attempt at quantification in view of 
the following serious limitations. 
1. The examples considered apply only for congenital anomalies. To extend the 
approach to other congenital disorders it would be necessary to create many new 
categories, in combinations specific to each diagnosis.52. Furthermore, differences 
between the implications of different clinical problems makes it almost impossible to 
derive a meaningful total score for comparative purposes.53 
2. The approach focuses almost entirely on physical disability. However the 
predominant challenge in the unfolding life of people born with a congenital disorder 
is social - the possibility of integration into society. 
3. There is no allowance for effects on the family. For example, rhesus haemolytic 
disease and alpha thalassaemia hydrops fetalis involve a serious risk to the life of the 
mother: most single gene disorders have a high recurrence risk and so reduce the 
                                               
52 For example, kernicterus due to G6PD deficiency or rhesus incompatibility, functional disability due to neuro-
degenerative disorders, anaemia and pain due to haemoglobin disorders. 
53 The Global Burden of Disease study tries to overcome this problem by using rating panels to assign relative disability 
weights, and thus to calculate disability-adjusted life years (DALYs) for each clinical picture. 
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parents’ reproductive success, and entrain a quantifiable risk for relatives of having 
similarly-affected children. 
Developing a truly sensitive approach for the full range of congenital disorders, though 
worthwhile, would take considerable time and effort, starting with agreement on common 
quantitative methods. 
As an interim step towards improving the assessment of disability, a generic approach that 
can be applied to any childhood-onset disorder might be developed by shifting the primary 
focus from clinical measures to factors affecting social integration (see Annex A6: The need 
for better quantitative methods for assessing the burden of congenital disorders). The social 
approach would take account of an affected individual’s ability to reach adulthood and 
achieve normal life-time goals such as ability to live independently, sexual development and 
functioning, and ability to build a family. In the Global Database success in building a family 
– reproductive success – is taken as the single most important quantifiable indicator of the 
ultimate effectiveness of current interventions.54 Interestingly, reproductive success is the 
same as genetic fitness55 as defined in classical population genetics – the ability of an 
individual to pass their genes on to the next generation, relative to the population norm 
(Harris (1970), Bodmer and Cavalli-Sforza (1976)). 
Reproductive success has the advantage of being measurable. In a study designed to 
assess the extent to which improving the care of individuals with congenital anomalies 
affects the human gene pool, Skjaerven, Wilcox et al. (1999) and Lie, Wilcox et al. (2001) 
documented survival and reproduction to age 30 of affected individuals born in Norway in 
1967-1982 (see Annex A6: The need for better quantitative methods for assessing the 
burden of congenital disorders for fuller description). Table 3.8 shows estimates of the 
proportion of infants with the disabilities included in the Global Database expected to reach 
20 years of age at the present time, and the per cent of these survivors expected to be able 
to build a family with no care and with optimal care. The table combines the estimates of 
Skjaerevan and Lie for congenital anomalies56, with additional data from the literature or 
based on the clinical picture of each disorder. The table incidentally underlines the 
inadequacy of a purely physical approach by demonstrating the difference between survival 
and ability to build a family. 
Note: The current Global Database does not produce estimates for reproductive success, 
however we anticipate that this will be included in the next version of the Global Database. 
                                               
54 This means that the ultimate aim of treatment is to restore genetic fitness to patients – a point for discussion. 
55 The term reproductive success, which has the same meaning, is preferable for a general audience. 
56 For this table, an attempt is made to allow for the fact that Skjaerevan and Lie did not provide estimates for all 
disorder groups, their observations apply only for a high income setting, and some rates are now probably under-
estimates because their data applies for individuals born between 1967 and 1982, but treatment, public attitudes to 
disability, and availability of social support have all improved subsequently. 
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Table 3.8. Estimated proportion of survivors to adult life able to achieve main life objectives 
Main group Disorder group 
Potential) live 
births /1,000 
No care Optimal care 
% surviving 
@ 20 yr 
Ability of 
survivors to 
build a family, 
% of pop 
norm 
% surviving 








Down syndrome (+21) 1.59 18.5 0 91 0 
Other trisomies (+13, +18) 0.311 0 0 0 0 
Other autosomal 0.55 10 0 49 0 
Turner syndrome (XO) 0.175 94 0 97 19 




Anencephaly 0.51 0 0 0 0 
Spina bifida & e’cele 1.02 0 0 57 31 
Oro-facial clefts 0.91 2.5 13 98 71 
Very severe CHD 0.38 3.1 0 13 31 
Severe CHD 1.13 39.6 0 76 31 
Less severe CHD 1.79 26.1 15 98 100 
CNS not NTD 0.84 0 0 61 14 
Eye 0.27 56.2 25 96 77 
Ear, face, neck 0.27 93.1 25 93 68 
Respiratory system 0.46 23.8 25 57 65 
Digestive system 0.95 4.3 25 81 64 
Abdominal wall defects 0.33 0 0 80 57 
Urinary system 2.56 16.5 45 87 84 
Multiple malformations 1.33 0 0 43 23 
Genital system 1.76 98.8 25 100 56 
Limb 3.39 91.2 50 96 66 
Additional 
conditions 
Congenital hypothyroidism 0.21 0 0 100 100 
PDA assoc w prematurity 0.3 12 0 100 100 
Pyloric stenosis 0.87 0 0 100 100 
Single gene 
disorders 
Dominant (onset <1 yr) 1.4 0 0 35 15 
X-linked 0.05 10 13 57 12 
Recessive (baseline) 1.66 7 3 42 13 
Consang-assoc recessives 4.31 7 3 42 13 
Severe SCD 2.09 0 0 84 40 
Mild SCD 0.72 60.7 61 92 46 
Transfusion-dependent b thal 0.23 0 0 91 45 
Milder b thal & Hb H disease 0.16 60.7 61 99 49 
Apha thal hydrops fetalis 0.016 0 0 0 0 
Genetic risk 
factors 
Rhesus haem disease 0.9 0 0 100 100 
G6PDd kernicterus 1.3 0 0 100 100 
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Article 4: Uses of demographic and geographic data 
Abstract 
Demographic data provides an essential background for Community Genetics. It is not only 
essential for epidemiological estimates, but also provides an overall picture of the evolution 
of the health status of a population. This article amplifies the summary of demographic data 
given in Article 2: Core methods for estimates to five years of age. 
Demographic data used in the Global Database is obtained from the following sources. 
1. Basic demographic data from UN World Population Prospects 2015 revision: country 
estimates from 1950-2015, and median projections from 2015-2050, for: total 
population; annual live births; infant mortality; under-5 mortality; mean life expectancy 
(both sexes); total fertility rate; sex ratio at birth; per cent of births to mothers aged 35 
plus; and population age and sex distribution. 
2. Stillbirths: from the systematic review of Cousens et al. 2011. 
3. Neonatal mortality: from www.childmortality.org 
4. Coefficient of consanguinity: from publications by and personal communications with 
A. Bittles, and www.consang.net 
5. Early mortality due to HIV/AIDS, from IHME-GBD 2013 
Charts are included to illustrate the evolution of each demographic indicator from 1950 to 
2015, and median projections to 2050. 
The article comments on the general relevance of each indicator, points out potential pitfalls 
in its direct application to the epidemiology of congenital disorders, and details the way it is 
applied in the Global Database. 
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Article 5: Estimating access to services 
Abstract 
This article gives details of the method for estimating access to services outlined in Article 2: 
Core methods for estimates to five years of age. 
The two General Method articles show that enough information exists to enable country-
specific estimates of the baseline birth prevalence of constitutional congenital disorders 
country, and outcomes in the absence of care and with optimal care. Therefore if the 
proportion of the population with access to optimal care is known, it is possible to construct a 
provisional picture of annual affected births and outcomes. However there is no single 
readily-available source of global information on access to care, so was necessary to 
develop a general method for estimating access. 
A first step towards a general method was taken when the WHO Child Health Epidemiology 
Reference Group (CHERG) defined five levels of access based on neonatal mortality rate. 
This article describes how this initial step was built on to develop an equation for estimating 
the proportion of a population with access to optimal care, based on infant mortality (IMR). 
Proportion with access = (1-BETADIST(LN(IMR-10),2.5,5.5,0,LN(1000))) 
However a problem of circularity arises with use of this equation because early-onset 
congenital disorders themselves contribute significantly to infant mortality. Therefore before 
being used as a basis for estimating access, infant mortality should be adjusted for mortality 
due to congenital disorders whose baseline birth prevalence differs substantially between 
populations. Accordingly in the Global Database access is estimated on the basis of infant 
mortality minus estimated mortality due to consanguinity-related disorders and AIDS. 
Adjustment for mortality due to haemoglobin disorders was also considered, but not 
implemented for reasons given in the article. 
The article also describes how estimates for termination of pregnancy are adjusted 
according to the local legality or otherwise of abortion for fetal impairment. 
The article emphasises the provisional nature of all estimates of access. Ideally an 
alternative method of estimating access in the case of constitutional congenital disorders, 
may be by comparing Global Database estimates of actual live birth prevalence with the 
recorded number of cases treated, or with utilisation of essentials including blood, blood 
products, and pharmaceuticals. 
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Part II. Congenital anomalies 
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Article 6: Chromosomal disorders: calculating birth prevalence, 
survival and patient numbers 
Abstract 
This article gives details of the methods used to obtain the estimates of birth prevalence and 
outcomes for chromosomal disorders presented in the General Method articles. 
Chromosomal disorders have two characteristics that are particularly helpful in estimating 
their global epidemiology. Firstly, the baseline birth prevalence of Down syndrome and other 
trisomies can be calculated from maternal age distribution, providing independent estimates 
that can be compared with registry data. Secondly, full life-time survival data is available for 
the major groups of chromosomal disorder. 
Additional input data needed for estimates of chromosomal disorders are: (1) UN World 
Population Prospects (WPP) estimates of maternal age distribution from 1950-2015, and 
median projections to 2050; (2) UN Demographic Yearbook data on accuracy of age 
reporting and “age heaping”; (3) EUROCAT and ICBDSR data on reported birth prevalence 
of chromosomal disorders, and pregnancy outcomes; (4) updated estimates of maternal-
age-related Down syndrome birth prevalence, and birth prevalence of other chromosomal 
disorders. 
Calculation of Down syndrome birth prevalence using demographic data required the 
following steps. 
(1) Calculation of Down syndrome live birth prevalence by 5-year maternal age intervals, to 
match the age intervals used in demographic databases. 
(2) Application of these rates to WPP maternal age distributions: this gave improbably high 
rates for many lower-income countries, almost certainly due to inaccuracy of age data as 
shown by UN data on “age heaping”. 
(3) It was observed that when only maternal age data from countries with demonstrably 
reliable age reporting is used, there is a linear relationship between estimate Down 
syndrome live birth rate based on the full range of maternal age, and the per cent of mothers 
35 plus, described by the following simple equation. 
Down potential live births /1,000 = 0.834 + (% of mothers 35plus x 0.067) +/- 4.2%. 
In the Global Database (a) this equation is used to calculate Down syndrome live birth 
prevalence; (b) the baseline live birth prevalence of “other trisomies” (Edwards syndrome 
plus Patau syndrome) is calculated as 19.5% of Down syndrome; (c) The baseline live birth 
prevalences of other chromosomal disorders are considered to be constant and unrelated to 
maternal age; (d) total affected birth prevalences (stillbirths plus live births) are calculated 
from live birth prevalences by adding known (or estimated) rates for fetal death/stillbirth. 
A detailed comparison with Down syndrome birth prevalences and pregnancy outcomes in 
the EUROCAT and ICBDSR “umbrella” congenital anomaly registries supports the general 
applicability of the simplified maternal-age-based estimates. 
These inputs are used to estimate early mortality, mean life expectancy, number of affected 
individuals living at any one time, and years of life affected, and lost or lived with disability 
due to chromosomal disorders. The following tables give an overall summary to 5 years of 
age for total chromosomal disorders in 2010 by WHO region, including estimates of the per 
cent decrease in pathological outcomes due to current interventions. A negative value in the 
final column indicates an increase in survivors with disability at age 5. Table 6.3 shows long-
term estimates in terms of the number of months affected by chromosomal disorders per 
person born in 2010. 
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Table 6.1. Total chromosomal disorders. Estimated potential and actual stillbirths by WHO region. 
WHO 
region 
Potential total SB 








% of stillbirths 
avoided by TOP 
AFR  4.40 0.76 0.02 0.74 3.2 
AMR  4.11 0.70 0.12 0.58 17.8 
EMR  4.33 0.75 0.06 0.68 8.4 
EUR  4.31 0.74 0.37 0.37 49.8 
SEAR  3.70 0.62 0.05 0.58 7.5 
WPR  3.66 0.62 0.19 0.42 31.3 
World 4.02 0.69 0.11 0.58 15.4 
W Europe 5.05 0.89 0.61 0.28 68.8 
Table 6.2. Total chromosomal disorders. Estimated potential and actual affected live birth prevalence and 





















































at 5 yr 
AFR  3.64 1.99 1.38 0.7 3.62 5.6 1.86 1.44 6.6 -4.4 
AMR  3.40 1.88 1.48 10.1 3.06 59.4 0.96 2.04 48.7 -37.8 
EMR  3.59 1.99 1.47 3.4 3.46 25.4 1.57 1.73 20.9 -17.7 
EUR  3.57 2.00 1.53 32.4 2.41 79.8 0.51 1.87 74.6 -21.8 
SEAR  3.08 1.62 1.35 2.9 2.99 14.7 1.39 1.47 14.3 -8.6 
WPR  3.04 1.61 1.39 17.1 2.52 50.6 0.83 1.64 48.4 -18.1 
World 3.34 1.80 1.41 8.2 3.06 28.5 1.29 1.62 28.5 -15.3 
W Europe 4.16 2.45 1.70 49.9 2.09 100.0 0.17 1.90 92.9 -11.8 
Table 6.3. Total chromosomal disorders: live births. Estimated potential and actual months affected by 
chromosomal disorders per person born 
WHO region 
Potential, if no intervention 
Actual with current 
interventions 




























AFR 2.39 1.70 0.68 0.02 1.52 0.85 0.7 10.5 -23.8 
AMR 3.10 2.25 0.85 0.42 1.50 1.27 10.4 33.3 -50.7 
EMR 2.90 2.11 0.79 0.15 1.45 1.35 3.6 31.3 -70.5 
EUR 3.25 2.40 0.85 1.44 1.20 0.96 33.8 50.1 -12.0 
SEAR 2.48 1.73 0.75 0.10 1.05 1.36 3.0 39.5 -82.0 
WPR 2.74 1.93 0.81 0.65 0.93 1.32 17.7 51.7 -63.2 
World 2.69 1.92 0.77 0.34 1.25 1.19 9.4 35.1 -54.8 
W Europe 4.07 3.12 0.95 2.61 1.09 0.95 49.9 65.1 0.2 
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Article 7: Congenital malformations: birth prevalence and birth 
outcomes 
Abstract 
This article gives details of the methods used to obtain the estimates of birth prevalence and 
outcomes to age five for congenital malformations shown in the General Method articles. To 
simplify presentation the topic is sub-divided into a main article describing the general 
method used for congenital malformations, and four subsidiary articles describing how 
estimates are obtained for neural tube defects, oro-facial clefts, congenital heart disease, 
and three additional conditions not usually included in congenital anomaly registries. This 
summary covers all except the last of these articles. 
EUROCAT and ICBDSR umbrella registry data on congenital malformations is used in the 
Global Database for three main purposes. 
1. To enter reported baseline (potential) birth prevalences in participating countries. 
2. To follow changes with time in the distribution of birth outcomes (termination of 
pregnancy for fetal impairment, fetal death/stillbirth, live birth) in participating 
countries. 
3. To obtain average European rates for birth prevalences and outcomes that can be 
used for generating estimates for countries with little or no observational data. 
Both ICBDSR and EUROCAT data are used for the first two purposes, but only the 
comprehensive EUROCAT data can be used to derive average European rates for the full 
range of congenital malformations. The article includes close examination of the strengths 
and limitations of EUROCAT data. 
Next it shows how EUROCAT data for non-syndromic congenital malformations are adjusted 
for associations to obtain rates for isolated malformations by system group, and for multiple 
malformations. The adjustment needed for rates for outcomes differ by malformation group. 
Then there are separate sections on individual malformation groups 
 Neural tube defects: country and regional differences in baseline birth prevalence, 
calculation of rates for termination of pregnancy, effects of folic acid food fortification. 
 Oro-facial clefts. Variation in birth prevalence - ? role of under-ascertainment. 
 Congenital heart disease. The distinction between congenital heart defects (6-
8/1,000 births) and congenital heart disease. No evidence of major differences 
between populations though there may be a consanguinity-related increase. Bundled 
into 3 (or two?) main groups. Effect of PND on birth prevalence of most severe and 
lethal disorders. 
The following tables give an overall summary of prevalence and outcomes to 5 years of age 
for total congenital malformations in 2010 by WHO region. The tables include estimates of 
the per cent reduction of pathological outcomes due to current interventions. A negative 
value indicates an increase in survivors with disability at age 5. 
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Stillbirths /1,000 avoided 




% of stillbirths avoided 
by FAFF & TOP 
AFR  18.42 0.65 0.02 0.63 3.7 
AMR  19.43 0.71 0.18 0.53 25.2 
EMR  20.32 1.04 0.12 0.92 11.2 
EUR  18.97 0.68 0.26 0.42 37.9 
SEAR  20.84 1.27 0.10 1.17 8.2 
WPR  20.21 1.00 0.31 0.70 30.8 
World 19.79 0.94 0.15 0.79 15.6 
W 
Europe 
18.60 0.55 0.24 0.31 43.7 
Table 7.2. Total congenital malformations. Estimated potential and actual affected live birth prevalence and 
outcomes in 2010 by WHO region 
WHO 
region 


























































l. at 5 
yr 
AFR  17.8 7.9 8.4 0.5 17.7 3.9 6.5 8.5 0.7 17.7 -0.6 3.7 
AMR  18.7 8.9 9.6 5.0 17.8 42.3 3.8 7.0 8.0 56.7 27.0 45.0 
EMR  19.3 9.4 9.2 2.3 18.8 18.4 5.8 8.4 3.3 38.5 8.1 17.8 
EUR  18.3 8.5 9.6 8.5 16.7 56.3 2.4 5.1 10.6 71.7 46.8 63.0 
SEAR  19.6 9.6 9.2 1.5 19.3 10.4 6.3 9.3 2.1 34.3 -1.1 11.0 
WPR  19.2 9.3 9.6 5.7 18.1 37.0 3.8 7.6 7.4 59.0 20.9 41.1 
World 18.9 9.0 9.2 3.1 18.3 21.9 5.2 8.1 4.3 41.7 11.8 23.5 
W Europe 18.0 8.3 9.7 9.3 16.4 69.0 1.5 4.1 12.9 82.2 57.3 78.9 
 
7.1 Neural tube defects 
This content is in preparation. 
7.2 Oro-facial clefts 
This content is in preparation. 
7.3 Congenital heart disease 
This content is in preparation. 
7.4 Additional conditions 
This content is in preparation. 
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Article 8: Congenital malformations: estimating outcomes of live 
births 
Abstract 
This article describes how available data on survival are used for creating life-time survival 
curves for different groups of congenital malformation, with optimal care and in the absence 
of care. The curves are then used to calculate the following by malformation group: (a) mean 
life expectancy; (b) years of life lost for the current birth cohort due to congenital 
malformation; (c) number and age distribution of survivors, living cured or with disability; (d) 
projected effects of future policy change on number and age distribution of survivors living 
cured or with disability. 
Estimates for survival in the absence of care are based on reports from the older literature 
on survival before the introduction of current interventions, supplemented by expert opinion. 
Estimates of survival with optimal care are based on Tennant et al. (2010), adjusted for the 
effect of selective termination of more severely-affected pregnancies. In addition, in view of 
evidence of improved survival with congenital heart disease since 2000, mortality estimates 
are reduced by 20% for the years from 2000 onwards.  
These survival curves are prospective, i.e. predict the future implications for affected 
individuals born in a given year. They are used to calculate mean life expectancy. This is 
then used (together with estimates for each malformation group of actual birth prevalence 
and proportion of correctable by paediatric surgery), to estimate total years of life affected, 
and years of life lost, or lived with disability or lived cured, per individual in the relevant birth 
cohort. 
As an example of long-term outputs, Table 8.1 shows estimated years potentially and 
actually affected by congenital malformations per person in the 2010 birth cohort, together 
with estimated outcomes in terms of years of average years of life lost, lived with disability or 
cured per person in that birth cohort. 
Table 8.1. Total congenital malformations: live births. Estimated potential and actual years affected, and 
outcomes per person born 
WHO 
region 











Outcomes with current 
interventions 
































AFR 1.02 0.69 0.33 0.0 1.01 0.63 0.35 0.04 8.7 -6.1 3.9 
AMR 1.59 1.14 0.45 4.4 1.52 0.56 0.24 0.72 50.9 46.7 45.3 
EMR 1.38 0.97 0.4 2.2 1.35 0.74 0.36 0.25 23.7 10.0 18.1 
EUR 1.55 1.11 0.44 7.7 1.43 0.35 0.13 0.95 68.5 70.5 61.3 
SEAR 1.37 0.97 0.4 1.5 1.35 0.81 0.39 0.15 16.5 2.5 10.9 
WPR 1.49 1.05 0.44 5.4 1.41 0.55 0.27 0.59 47.6 38.6 39.6 
World 1.35 0.94 0.4 3.0 1.31 0.65 0.34 0.32 30.9 15.0 23.7 
W. Eur 1.69 1.21 0.48 7.7 1.55 0.23 0.04 1.27 81.0 91.7 75.1 
The article also shows how the number and age distribution of living survivors is calculated 
for any given year, using population age distribution in the chosen year, and retrospective 
survival curves created taking account of services available at the time of birth of each 5-
year age group. 
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Part III. Genetic disorders 
104 
Article 9: Haemoglobin disorders: a model for single gene 
disorders 
Abstract 
This content is in preparation. 
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Article 10: Single gene disorders 
Abstract 




Article 11: Gene clustering and parental consanguinity 
Abstract 




Article 12: Disorders due to genetic risk factors: rhesus 
haemolytic disease 
Abstract 




Article 13: Disorders due to genetic risk factors: G6PD 
deficiency 
Abstract 






Annexes A: General Method 
Annex A1: Comparison of GBD and Global Database under-5 mortality 
estimates 
This content is in preparation. 
Annex A2: Environmental disorders 
This content is in preparation. 
Annex A3: Different ways of expressing incidence 
This content is in preparation. 
Annex A4: Calculation of attributable early mortality 
This content is in preparation. 
Annex A5: Creating retrospective survival curves 
This content is in preparation. 
Annex A6: The need for better quantitative methods for assessing the 
burden of congenital disorders 
This content is in preparation. 
Annex A7: Assessing costs and benefits 
This content is in preparation. 
Annex A8: Evolution of infant mortality in Western Europe 
This content is in preparation. 
Annex A9: Bundling of countries /territories 
This content is in preparation. 
Annex A10: Comparison of estimates in March of Dimes 2006 report 
with Global Database estimates for 2010.  
This content is in preparation. 
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Annexes B: Use of demographic data 
Annex B1: Comparison of estimates from sequential WPP revisions 
This content is in preparation. 
Annex B2: Reason for limiting projections to 2050 (instead of 2100) 
This content is in preparation. 
Annex B3: Birth rate and infant mortality- the global development curve 
This content is in preparation. 
Annex B4: Charts illustrating use of sex ratios 
This content is in preparation. 
Annex B5: Relation between infant and under-5 mortality  
This content is in preparation. 
Annex B6: Effect of the HIV/AIDS epidemic in Southern Africa 
This content is in preparation. 
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Annexes C: Calculating access to services 
Annex C1: Correlation of potential indicators with IMR 
This content is in preparation. 
Annex C2: Adjustment of IMR for effects of parental consanguinity 
This content is in preparation. 
Annex C3: Adjustment of IMR for AIDS-related mortality 
This content is in preparation. 
Annex C4: Policies on prenatal diagnosis in 11 EUROCAT countries in 
2005 
This content is in preparation. 
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Annexes D: Chromosomal disorders 
Annex D1: Clinical pictures 
This content is in preparation. 
Annex D2: Disability with chromosomal disorders 
This content is in preparation. 
Annex D3: Calculation of birth prevalence  
This content is in preparation. 
Annex D4: Adjustment for gestation at prenatal diagnosis 
This content is in preparation. 
Annex D5: Miscarriage, stillbirth and prematurity 
This content is in preparation. 
Annex D6: Rare chromosomal abnormalities 
This content is in preparation. 
Annex D7: Gestation at prenatal diagnosis (EUROCAT data) 
This content is in preparation. 
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Annexes E: Congenital malformations 1 (birth prevalence) 
Annex E1: Main groups of congenital anomalies 
This content is in preparation. 
Annex E2: “Other syndromes” 
This content is in preparation. 
Annex E3: Comparison of congenital malformation groups reported by 
EUROCAT and ICBDMR 
This content is in preparation. 
Annex E4: The problem of ascertainment 
This content is in preparation. 
Annex E5: Prematurity 
This content is in preparation. 
Annex E6: Age cut-off in EUROCAT registries (in 2010) 
This content is in preparation. 
Annex E7: Conversion of non-syndromic to isolated congenital 
malformations 
This content is in preparation. 
Annex E8: Fetal deaths 
This content is in preparation. 
Annex E9: Tables 
This content is in preparation. 
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Annexes F: Congenital malformations 2 (survival) 
Annex F1: Sources for survival data for congenital disorders 
This content is in preparation. 
Annex F2: Adjusting Tennant survival data for effect of termination of 
pregnancy 
This content is in preparation. 
Annex F3: Estimating survival with congenital malformations in the 
absence of diagnosis and care 
This content is in preparation. 
Annex F4: Estimating survival with untreated oro-facial cleft 
This content is in preparation. 
Annex F5: Calculating mean age at death 
This content is in preparation. 
Annex F6: Calculating years of life lost due to congenital disorders 
This content is in preparation. 
Annex F7: Grading disability 
This content is in preparation. 
Annex F8: Changes with time in interventions for live-born children with 
congenital disorders 
This content is in preparation. 
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Table Annexe 
For ease of use, the table annexe containing supplementary data is provided in machine 
readable format in the following files associated with this document online in UCL Discovery. 
TA01-Bottom-Line-WHO-2017-04.xlsx 
Contents: 
 Datasheet 1: Grand Total by WHO region 
TOTAL constitutional congenital disorders /1,000 births, and av. annual numbers 
2010-14, by WHO region and sub-region 
 Datasheet 2: Grand Total by country 
TOTAL constitutional congenital disorders /1,000 births, and av. annual numbers 
2010-14, by country, WHO sub-region and WHO region 
 Datasheet 3: Main group totals 
Six groups of constitutional congenital disorders /1,000 births and av. annual 
numbers 2010-14, by country, WHO sub-region & region 
TA02-Chromosomal-Disorders-WHO-2017-04.xlsx 
Contents: 
 Grand Total by WHO region 
TOTAL chromosomal disorders /1,000 births, and average annual numbers 2010-14, 
by WHO region and sub-region 
 Grand Total by country 
3 groups of chromosomal disorders (Down syndrome, other autosomal, sex 
chromosomal) /1,000 births, and av. annual numbers 2010-14, by WHO region and 
sub-region  
 Main group totals 
TOTAL chromosomal disorders /1,000 births and av. annual numbers 2010-14, by 
country, WHO sub-region & region 
TA03-Congenital-Malformations-WHO-2017-04.xlsx 
Contents: 
 WHO regions Grand Total 
TOTAL congenital malformations /1,000 births, and av. annual numbers 2010-14, by 
WHO region and sub-region 
 WHO regions sub-groups 
5 sub-groups of congenital malformations (NTDs, OFCs, CHD, other potentially 
lethal, other sub-lethal) /1,000 births, and av. annual numbers 2010-14, by WHO 
region and sub-region  
 Country Grand Total 
TOTAL congenital malformations /1,000 births and av. annual numbers 2010-14, by 
country, WHO sub-region & region 
 Country sub-group rates 
5 sub-groups of congenital malformations (NTDs, OFCs, CHD, other potentially 
lethal, other sub-lethal) /1,000 births, by country, WHO sub-region & region 
 Country sub-groups numbers 
5 sub-groups of congenital malformations (NTDs, OFCs, CHD, other potentially 
lethal, other sub-lethal): average annual numbers, by country, WHO sub-region & 
region 
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 Selected outputs April 2017 
All the above estimates in one spreadsheet 
TA04-Rare-single-gene-WHO-2017-04.xlsx 
Contents: 
 WHO regions Grand Total 
TOTAL rare single gene disorders /1,000 births, and average annual numbers 2010-
14, by WHO region and sub-region 
 WHO regions Sub-groups 
2 groups of rare single gene disorders (basic and consanguinity-associated) /1,000 
births, and average annual numbers 2010-14, by WHO region and sub-region  
 Country Grand Total 
TOTAL rare single gene disorders /1,000 births and average annual numbers 2010-
14, by country, WHO sub-region & region 
 Country sub-group rates 
2 groups of rare single gene disorders (basic and consanguinity-associated) /1,000 
births, by country, WHO sub-region & region 
 Country sub-groups numbers 
2 groups of rare single gene disorders (basic and consanguinity-associated): average 
annual numbers, by country, WHO sub-region & region 
 Selected outputs April 2017 
All the above estimates in one spreadsheet 
TA05-Hb-Disorders-WHO-2017-04.xlsx 
Contents: 
 WHO regions Grand Total 
TOTAL haemoglobin disorders /1,000 births, and av. annual numbers 2010-14, by 
WHO region and sub-region 
 WHO regions Sub-groups 
3 groups of haemoglobin disorders (sickle cell disorders, beta thalassaemias, alpha 
thalassaemias) /1,000 births, and av. annual numbers 2010-14, by WHO region and 
sub-region  
 Country Grand Total 
TOTAL haemoglobin disorders /1,000 births and av. annual numbers 2010-14, by 
country, WHO sub-region & region 
 Country sub-group rates 
3 groups of haemoglobin disorders (sickle cell disorders, beta thalassaemias, alpha 
thalassaemias) /1,000 births, by country, WHO sub-region & region 
 Country sub-groups numbers 
3 groups of haemoglobin disorders (sickle cell disorders, beta thalassaemias, alpha 
thalassaemias): average annual numbers, by country, WHO sub-region & region 
 Bundled outputs April 2017 
All the above estimates in one spreadsheet 
 Detailed outputs, April 2017 
6 groups of haemoglobin disorders classified clinically (Severe SCD, less severe 
SCD, Transfusion-dependent beta thalassaemia, less severe beta thalassaemia, 
lethal alpha thalassaemia, less severe alpha thalassaemia). This sheet also includes 
estimates of annual numbers of affected births, under-5 deaths and survivors at 5 




 WHO regions Grand Total 
Total Rhesus haemolytic disease: rate /1,000 births, and average annual numbers 
2010-14, by WHO region and sub-region 
 Country rates per 1,000 
Estimated Rhesus haemolytic disease /1,000 by country, WHO sub-region & region 
 Country annual numbers 
Estimated annual Rhesus haemolytic disease by country, WHO sub-region & region, 
2010-14 
 Selected outputs April 2017 
Estimates downloaded, including all the above in one spreadsheet 
TA07-G6PDd-NNJ-WHO-2017-04.xlsx 
Contents: 
 WHO regions Grand Total 
Total estimated G6PD deficiency neonatal jaundice: rate /1,000 births, and average 
annual numbers 2010-14, by WHO region and sub-region 
 Country rates per 1,000 
Estimated G6PD deficiency neonatal jaundice /1,000 by country, WHO sub-region & 
region 
 Country annual numbers 
Estimated annual G6PD deficiency neonatal jaundice by country, WHO sub-region & 
region, 2010-14 
 Selected outputs April 2017 
Estimates downloaded, including all the above in one spreadsheet 
TA08-Three-additional-conditions-WHO-2017-04.xlsx 
Contents: 
 WHO regions Grand Total 
TOTAL additional conditions /1,000 births, and average annual numbers 2010-14, by 
WHO region and sub-region 
 Diagnoses by WHO region 
The three additional conditions /1,000 births, and average annual numbers 2010-14, 
by WHO region and sub-region  
 Country Grand Total 
TOTAL additional conditions /1,000 births and average annual numbers 2010-14, by 
country, WHO sub-region & region 
 Country rates /1,000 
Three additional conditions /1,000 births, by country, WHO sub-region & region 
 Country annual numbers 
Three additional conditions: average annual numbers, by country, WHO sub-region & 
region 
 Selected outputs April 2017 




 Comp GBD MGDb 2012 country 
Global Database estimates of baseline birth prevalence of congenital ANOMALIES 
and outcomes in 2010: comparison of GBD and Global Database estimates of 
attributable under-5 mortality by country, WHO region and sub-region 
 Comp by WHO region 
Global Database estimates of baseline birth prevalence of congenital ANOMALIES 
and outcomes in 2010: comparison of GBD and Global Database estimates of 
attributable under-5 mortality by WHO region and sub-region 
 Selected charts 




Method by which these calculations are made 
 Total months life WHO region 
Total constitutional congenital disorders: months affected /person born 2010-14, by 
WHO region and sub-region 
 Total months life country 
Total constitutional congenital disorders: months affected /person born 2010-14, by 
country, WHO sub-region and WHO region 
 Months life by Main Groups 
Total constitutional congenital disorders: months affected /person born for six groups 
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